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Summary 
Breast cancer risk is a common indication for referral to clinical genetics. National Institute 
of Health and Care Excellence (NICE) guidelines use family history to stratify patients by 10-
year risk of breast cancer from the ages 40-49. Patients are divided into low (10-year risk 
<3%), moderate (3-8%) and high risk (>8%). Those with a BRCA mutation are considered to 
be very high risk. Women at moderate or high risk are offered screening from age 40. This 
study aimed to assess the effectiveness of NICE risk categorisation at identifying women at 
risk of early onset breast cancer.  
Family history data was obtained for unaffected women with a family history of 
breast cancer, aged <50 years, referred to Tayside clinical genetics from 2000-2010. Patients 
were risk stratified de novo by NICE criteria. Those who went on to develop breast cancer 
were identified.  
1,409 women were included in the cohort, with a total of 15,414 patient-years of 
follow up. Of these patients, 35.84% were NICE low risk, 37.04% moderate risk and 27.11% 
were high risk. 22 BRCA mutation carriers were identified.  
30 invasive breast cancers developed, 13 in moderate and 13 in high risk women. 
Kaplan-Meier analysis demonstrated no significant difference in cancer rates between low 
and moderate risk women from ages 40-49 (Log rank p=0.431). There was a significant 
difference from 40-49 years between low and high risk women (p=0.036), but not on 
exclusion of BRCA carriers (p=0.136). The 10-year absolute risk from 40-49 years was 0.82% 
(95% CI, 0.72-0.94%) for low risk, 1.68% (1.53-1.83%) for moderate risk, and 3.56% (3.34-
3.80%) for high risk women. NICE absolute 10-year risk thresholds for screening were not 
met in any group.  
This study provides some evidence that screening prior to age 50 in those without a 
BRCA mutation may be unnecessary. In the study cohort, NICE family history criteria identify 
women at increased risk of breast cancer, but not at the absolute risk thresholds suggested 
for screening. There is a need for further evaluation of NICE criteria. 
  
ix 
 
 
 
List of Abbreviations 
ANOVA, analysis of variance; 
AUROC, area under the receiver operating curve; 
BCAC, Breast Cancer Association Consortium; 
BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm; 
CBC, contralateral breast cancer; 
CI, confidence interval; 
COCP, combined oral contraceptive pill; 
DCIS, ductal carcinoma in situ; 
ER, oestrogen receptor; 
FDR, first degree relative; 
FGFR2, fibroblast growth factor receptor 2;  
FH, family history; 
GWAS, genome-wide association study; 
HER2, human epidermal growth factor 2; 
HRR, homologous recombination repair; 
HR, hormone receptor; 
HRT, hormone replacement therapy; 
ICER, incremental cost-effectiveness ratio; 
IR, ionising radiation; 
KM, Kaplan-Meier; 
LCIS, lobular carcinoma in situ; 
LD, linkage disequilibrium; 
MAF, minor allele frequency; 
MD, mammographic density; 
MMSS, modified Manchester scoring system; 
MMS, modified Manchester score; 
MSS, Manchester scoring system; 
NBSP, National Health Service breast screening programme; 
NHEJ, non-homologous end-joining; 
OR, odds ratio; 
PR, progestogen receptor; 
ROC, receiver operating curve; 
RR, relative risk; 
SD, standard deviation; 
SDR, second degree relative; 
TERT, telomerase reverse transcriptase; 
TF, transcription factor; 
TNBC, triple negative breast cancer. 
x 
 
 
 
List of Figures 
Figure 1. Breast cancer trends over time for UK females. Data from cancerresearchuk.org (1) ........... 2 
Figure 2. Nomogram developed by Gore and Altman for sample size calculation (224) Image from an 
article by Jones, Carley and Harrison (222) ................................................................................ 69 
Figure 3. Boxplot of MMS by NICE risk category, with significant outliers shown. .............................. 81 
Figure 4. Ages of in situ carcinoma diagnosis by NICE risk group ........................................................ 85 
Figure 5. Consort diagram overviewing data collection and final cohort ............................................ 87 
Figure 6. Boxplot of age of invasive cancer diagnosis by NICE risk category ....................................... 88 
Figure 7. ROC for invasive cancer diagnosis over total patient follow up time, comparing the 
combined NICE moderate and high risk group (including BRCA carriers) to the NICE low risk 
group (AUROC=0.615 (0.526-0.704), p=0.031) ........................................................................... 98 
Figure 8. ROC for invasive cancer diagnosis over total patient follow up time, comparing the NICE 
high risk group (BRCA carriers included) to the NICE low risk group (AUROC=0.670 (0.549-
0.791) (p=0.016) ......................................................................................................................... 98 
Figure 9. KM analysis of invasive breast cancer in the low and moderate NICE risk categories across 
total patient follow up time. Log-Rank p=0.048. ...................................................................... 100 
Figure 10. KM analysis of invasive breast cancer in the low and moderate NICE risk categories 
between ages 50-59. Log-Rank p=0.037 ................................................................................... 100 
Figure 11. KM analysis of invasive breast cancer in the low and high NICE risk categories (BRCA 
carriers included) across total patient follow up time. Log-Rank p=0.003. .............................. 102 
Figure 12. KM analysis of invasive breast cancer in the low and high NICE risk categories (BRCA 
carriers included) between ages 40-49 years. Log-Rank p=0.036. ........................................... 102 
Figure 13. KM analysis of invasive breast cancer in the low and high NICE risk categories (BRCA 
carriers excluded) across total patient follow up time. Log-Rank p=0.019. ............................. 104 
Figure 14. KM analysis of invasive breast cancer in the moderate and high NICE risk categories (BRCA 
carriers included) across total patient follow up time. Log-Rank p=0.274. .............................. 106 
Figure 15. KM analysis of invasive breast cancer in the moderate and high NICE risk categories (BRCA 
carriers excluded) across total patient follow up time. Log-Rank p=0.644. ............................. 108 
Figure 16. KM analysis of invasive breast cancer in the low and moderate or high NICE risk categories 
(BRCA carriers included) across total patient follow up time. Log-Rank p=0.011. ................... 110 
Figure 17. KM analysis of invasive breast cancer in the low and moderate or high NICE risk categories 
(BRCA carriers included) from age 50-59. Log-Rank p=0.050 ................................................... 110 
Figure 18. KM analysis of invasive breast cancer in the low and moderate or high NICE risk categories 
(BRCA carriers excluded) across total patient follow up time. Log-Rank p=0.024 ................... 112 
Figure 19. KM analysis of invasive breast cancer in the low and moderate or high NICE risk categories 
(BRCA carriers excluded) from age 50-59 years. Log-Rank p=0.049. ........................................ 112 
Figure 20. KM survival curve showing invasive breast cancer rates for the low, moderate and high 
NICE risk groups across total patient follow up time (BRCA carriers included) ........................ 114 
Figure 21. KM survival curve showing invasive breast cancer rates for the low, moderate and high 
NICE risk groups across total patient follow up time (BRCA carriers excluded) ....................... 114 
Figure 22. Boxplot comparing age at breast cancer diagnosis between women seen in clinical 
genetics prior to diagnosis and women not seen prior (p=0.598) ............................................ 117 
  
xi 
 
 
 
List of Tables 
Table 1. UK incidence and mortality data by age range. Absolute number and incidence rates for 
2013, mortality rates based on data from 2009-2014. Data obtained from cancerresearch.org 
(1) .................................................................................................................................................. 2 
Table 2 . Intrinsic breast cancer subtypes - adapted from Dai X et al. (15)............................................ 5 
Table 3 Intermediate risk genes and their associated RR/OR .............................................................. 28 
Table 4. RR associated with different family histories according to meta-analysis by Pharoah et al. 
(149) ............................................................................................................................................ 35 
Table 5. RR associated with risk factors identified by Gail et al. 1989 (156) ........................................ 39 
Table 6. Correlation coefficients of BOADICEA, BRCAPRO and Claus .................................................. 45 
Table 7. Original MSS. Adapted from Evans et al. 2004 (206). ............................................................. 50 
Table 8. ICR MSS. Scoring system is combined for BRCA1 and BRCA2. ................................................ 52 
Table 9. Breast cancer risk category by lifetime risk and risk between ages 40-50. (Adapted from 
NICE guideline CG164 (79)) ......................................................................................................... 54 
Table 10. Criteria for categorisation into moderate or high risk category by FH alone according to 
NICE CG164 (79).......................................................................................................................... 55 
Table 11. Recommended screening and intervention by risk category according to NICE CG164 
(79). ............................................................................................................................................. 57 
Table 12. Categorical and continuous variables selected for statistical analysis ................................. 65 
Table 13. Information regarding number of relatives within families in the cohort............................ 74 
Table 14. An overview of the reported cancer incidence in relatives of those within the cohort ....... 75 
Table 15. Number of specific relatives diagnosed with cancer ............................................................ 76 
Table 16. Average ages of cancer diagnosis within family members of the entire cohort .................. 77 
Table 17. NICE risk categories and specific criteria assigned to the cohort (before BRCA mutation 
results) ........................................................................................................................................ 79 
Table 18. Original and final risk categorisation .................................................................................... 82 
Table 19. Fischer’s exact test, sensitivity, specificity and AUROC for MMS ≥17 and carrying a BRCA 
mutation ..................................................................................................................................... 83 
Table 20. Number of women years of follow up for each age range and NICE risk category. ............. 84 
Table 21. Age of invasive cancer diagnosis statistics by NICE category (years) ................................... 88 
Table 22. Results of independent t-test analysis of continuous variables with breast cancer 
development............................................................................................................................... 90 
Table 23. Results of Pearson Chi-square/Fischer’s exact test of categorical variables with breast 
cancer development ................................................................................................................... 91 
Table 24. Mean MMS and AUROC for invasive breast cancer overall and by age range. .................... 92 
Table 25. Cancer diagnosis by age range and NICE category. % 10-year risk calculated based on 
number of women years of follow up, shown in Table 21. ........................................................ 93 
Table 26. RR and OR for NICE risk categories ....................................................................................... 94 
Table 27. Sensitivity, specificity, PPV and NPV for NICE risk categories as compared with the low risk 
group. ......................................................................................................................................... 95 
Table 28. AUROC for varying age ranges and NICE risk categories. ..................................................... 97 
Table 29. Summary of KM survival results comparing rates of invasive breast cancer between 
different NICE risk categories. .................................................................................................. 113 
Table 30. Summary data for NICE risk categories A) BRCA mutation carriers analysed separately B) 
BRCA mutation carrier analysed within high risk group ........................................................... 115 
Table 31. Breakdown of women who were/were not seen in clinical genetics who developed breast 
cancer under the age of 50 in Tayside from 2000-2010 ........................................................... 116 
Table 32. KM survival analysis data summary .................................................................................... 134 
 
 
1 
 
 
 
1. Introduction 
1.1. Overview of breast cancer 
1.1.1. Breast cancer epidemiology and population screening 
In the UK, breast cancer is one of the most common cancers in females, affecting up 
to 1 in 8 women in their lifetime (1).  Risk is dependent on age, environmental and 
non-modifiable risk factors. Fortunately, treatment outcomes remain largely positive 
due to advances in the understanding of breast cancer, and population screening, 
with survival rates of >90% for women aged 40-69 (2). Over the last 20 years, rates 
of both invasive and in situ breast cancer have been increasing, however mortality 
rates continue to improve (see Figure 1). Detailed age dependent UK incidence and 
outcome data for breast cancer can be seen in Table 1. This demonstrates a peak 
incidence rate of invasive breast cancer in the older age group, however it is worth 
noting that the largest number of breast cancers occur in the middle age ranges. 
Therefore, the bulk of the UK breast cancer burden comes from women in their 
middle age, with peak numbers diagnosed between the ages of 60-69. In males, 
breast cancer still remains very uncommon with just 340 cases diagnosed in the UK 
in 2013 (1).  
UK population screening programmes have been in place for breast cancer since 
1988. Women between the ages of 50-70 are invited for mammographic screening 
every 3 years as part of the National Health Service Breast Screening Programme 
(NBSP), although studies are ongoing investigating the possibility of extending this to 
ages 47-73 (3). A comprehensive review by the Independent UK Panel on Breast 
Cancer Screening found that it has resulted in a 20% relative risk (RR) reduction in 
breast cancer mortality in the screened population (4). They also identified issues 
around over-diagnosis, however deemed that any harm this may cause to individual 
women through investigations and treatment, is largely outweighed by the 1,300 
breast cancer deaths probably prevented every year (4). Despite the success of the 
NBSP, evidence for its cost effectiveness is less clear. A study which followed up 
364,500 women for 35 years found a cost of £20,800 per quality adjusted life year 
gained associated with screening, slightly higher than the guidance threshold of 
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£20,000 set by NICE (5). The authors concluded only a moderate cost effectiveness 
of the screening programme. Despite this, the NBSP may be partly accountable for 
the both the increasing incidence and decreasing mortality seen in the UK population 
since the late 1980s.  
 
 
Table 1. UK incidence and mortality data by age range. Absolute number and incidence 
rates for 2013, mortality rates based on data from 2009-2014. Data obtained from 
cancerresearch.org (1) 
Age Range 
(years) 
Average number of 
cases per year 
Rate per 100,000 (UK population) 
Invasive breast 
cancer incidence 
In Situ breast 
cancer incidence 
Breast cancer 
mortality 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85-89 
>90 
34 
206 
586 
1,277 
2,804 
5,189 
5,934 
5,101 
6,541 
6,951 
4,513 
4,405 
3,800 
2,683 
1,662 
1.6 
9.5 
27.5 
62.7 
121.4 
219.1 
277.6 
273.3 
351.2 
409.3 
343.8 
393.0 
425.1 
453.8 
450.5 
0.1 
0.7 
1.8 
4.9 
11.7 
32.5 
61.9 
47.2 
56.1 
62.7 
37.3 
24.5 
17.4 
14.6 
10.2 
0.1 
0.9 
3.1 
7.2 
14.9 
24.4 
35.1 
44.6 
55.5 
66.5 
84.5 
115.2 
160.0 
222.8 
345.2 
Overall 51,691 159.6 20.2 35.2 
Figure 1. Breast cancer trends over time for UK females. Data from cancerresearchuk.org (1) 
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1.1.2. Pathology  
Breast cancer is categorised broadly according to site of origin. This splits the disease 
into ductal carcinoma, occurring in the mammary ducts, and lobular carcinoma, 
occurring in the breast lobular tissue i.e. the milk producing tissue of the breast. In 
addition, this is further sub-categorised into ductal/lobular carcinoma in situ 
(DCIS/LCIS) and invasive cancers, dependent on whether or not the tumour has 
invaded into the surrounding structures. Lobular carcinoma is thought to account for 
approximately 10% of invasive breast cancers, and be more strongly associated with 
exposure to female hormones (discussed later), than ductal carcinoma (6, 7). 
Although both cancers seem to be somewhat linked with a familial predisposition, 
lobular carcinoma has been found to be less prevalent in groups of people with 
certain high risk mutations i.e. BRCA1 and TP53 (discussed later), which cause a 
genetic predisposition to breast cancer (7). Although this broad classification is still 
used clinically, many other ways of classifying breast cancer pathologically have been 
developed, and have found to be relevant to both the treatment and aetiology of 
breast cancer.  
Immunohistochemistry allows for the identification of subtypes of breast cancer 
based on receptor expression. This includes oestrogen receptors (ER), progestogen 
receptors (PR) and human epidermal growth factor 2 receptors (HER2). The ER and 
PR are often grouped together as ‘hormone receptors’ (HR), as PR expression is 
considered to be an indicator of ER signalling (8). However, it has been suggested 
that absence of PR expression may be a useful prognostic indicator, shown to 
influence recurrence free and overall survival (9, 10). ER positivity has been found to 
be present in approximately 75% of breast cancers, and is more common in post-
menopausal breast cancer (11). However, in individuals with highly deleterious 
mutations in BRCA1, a breast cancer predisposition gene, around 75% of tumours are 
found to be ER negative (12).  Like the general population, 75% of tumours in those 
with a mutation in BRCA2 (discussed later) are found to be ER positive (12). ER 
receptor status also has implications for treatment, as these tumours are sensitive to 
treatment with anti-oestrogens, such as tamoxifen which is (primarily) an oestrogen 
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antagonist, and aromatase inhibitors which prevent the synthesis of oestrogen 
peripherally (11). Approximately 20% of breast tumours are HER2 positive, and 
expression of this receptor was originally linked to more aggressive tumours (13). 
However, since the advent of therapies which target the HER2 receptor specifically, 
the prognosis for this subtype has improved. Trastuzumab (Herceptin) is a HER2 
specific receptor modulator which prevents it’s downstream signalling to oncogenic 
proteins (8). HER2 positivity has been found to be very rare in BRCA mutation 
carriers, with just 2.1% of women with BRCA1 and 6.8% of BRCA2 related breast 
tumours being positive (14).  Another subgroup are ‘triple negative’ breast cancers 
(TNBC) which express neither HR nor HER2. They are seen more often in younger 
women and are associated with a more aggressive phenotype, with no targeted 
therapies like those available for HR or HER2 positive breast cancer (15). 65-80% of 
breast cancers in BRCA1 mutation carriers have been found to be TNBC and both 
BRCA1 and BRCA2 mutation carriers have been found to present with more advanced 
TNBC than non-carriers (15).  
The above classifications are used clinically as they have the ability to inform 
treatment. However, another classification system known as the ‘intrinsic subtype’, 
which is not currently being used clinically, is being extensively investigated. These 
subtypes which were identified through unique gene-expression profiles are 
intrinsically linked to receptor status, but have been found to better differentiate 
survival outcomes, and may potentially lead to differing therapeutic strategies (16). 
The names and some of the features of the five intrinsic subtypes are outlined in 
Table 2. As well as different gene-expression and prognostic outcome, it has been 
possible to differentiate levels of genomic instability, ploidy, methylation profiles and 
protein expression between the groups. For example, the DNA of basal-like tumours 
tends to be hypo-methylated, whereas luminal B tumours are hyper-methylated; 
Luminal A tumours are mainly diploid with little genomic instability, compared to 
mainly aneuploid, highly genomically unstable HER2 and basal-like tumours (17). In 
general the tumours have also been mapped to an immunohistochemical profile. The 
exceptions are the normal-like tumour (which is similar to luminal A), and luminal B 
which seems to present as either HER2 positive or negative (16). Family history (FH) 
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of breast cancer in a first degree relative (FDR) has found to be linked to luminal A, 
luminal B and HER2-overexpressing breast cancers (18). In addition, reduced 
expression of BRCA1 was found to be linked to basal-like breast cancer. This is 
perhaps unsurprising, as it has a TNBC expression profile, seen more commonly in 
individuals with BRCA1 mutations (19). Research in the field of gene-expression 
classification is extensive and it is clear that it may greatly impact clinical care in the 
future. However, as yet current practise uses an immunohistochemical-based 
classification.  
 
 
Table 2 . Intrinsic breast cancer subtypes - adapted from Dai X et al. (15). 
Intrinsic Subtype 
Immunohistochemistry profile 
Outcome Prevalence 
ER PR HER 
Luminal A 
Luminal B 
 
HER2 over-
expression 
Basal 
Normal-like 
+ 
+ 
 
- 
- 
+ 
+ 
+ 
 
- 
- 
+ 
- 
+ 
- 
+ 
- 
- 
Good 
Intermediate 
Poor 
Poor 
Poor 
Intermediate 
23.7% 
38.8% 
14% 
11.2% 
12.3% 
7.8% 
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1.2. Breast Cancer Risk Factors 
1.2.1. Socioeconomic status and ethnicity 
As opposed to many cancers, breast cancer is widely considered to be a disease 
primarily affecting socioeconomically affluent populations, with consistently 
reported increased incidence in higher social groups (20). However, despite this, a 
study of a Scottish population from 1994 demonstrated that mortality was greater in 
lower social groups, with 66% 5-year survival in the most affluent group and 55% 5-
year survival in the least affluent groups, despite no significant differences in tumour 
biomarkers (21). This is a trend which has been replicated in more recent studies, 
and in those of different study populations. Additionally, the evidence is growing that 
women of lower socioeconomic status are more likely to have breast cancers with a 
poorer prognosis and which present at a later stage (20, 22, 23). Literature reviews 
have noted the strongest associations between social status and breast cancer 
incidence appear to apply to post-menopausal women. This is thought to reflect the 
fact that post-menopausal breast cancers, in general, may be more likely to be 
associated with the cumulative effect of specific lifestyle factors, whilst younger 
breast cancers may be more tied to genetics and less reliant on factors such as social 
class (20). Most studies investigating socioeconomic status and breast cancer have 
been based on the assumption that social class itself is unlikely to have a direct effect 
on breast carcinogenesis, and that it is instead a marker for a sum of behaviours and 
exposures which encompass a profile of risk. However, it is becoming more evident 
that the discrepancy is difficult to explain by this model, and thus, the effect is 
established but as of yet poorly understood (20).  
Much of the work concerning race and breast cancer has been carried out in 
populations from the USA, however the results have been more or less consistent. It 
is well recognised that breast cancer as a whole tends to affect white women more 
so than other racial groups (24, 25). However, there appears to be crossover, with 
rates higher in black women than white women at age <40 years – one study 
demonstrated incidence rates of 16.8/100,000 and 15.1/100,000 for black and white 
women respectively, aged <40 years (26). Racial group also has a significant impact 
on breast cancer survival outcomes. Figures from the USA have shown a 5-year 
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survival of 91.4% for Asian women, 88.6% for non-Hispanic white women, 87% for 
Hispanic/Latina women, 85.4% for Native American women and 78.9% for African 
American women (27). African American women have also been consistently shown 
to present with more aggressive breast cancer of ER-ve/PR-ve and TNBC subtypes, 
which have fewer treatment options and a poorer prognosis (24, 26). It has been 
suggested that the poorer survival outcomes in ethnic minority groups may be linked 
to poorer access to healthcare and less screening. African American women have for 
some time been screened at least as often as white women in the USA, with no 
change in prognosis, however it is suggested that there may be significant over-
reporting of mammography attendance in this group (24, 28). There is increasing 
evidence that tumour behaviour and biology may vary by ethnicity, meaning that the 
observed differences in prognosis may be explained by biological mechanisms – 
further research into these differences is needed to improve understanding and 
treatment of breast cancers in different ethnic groups (24, 29). 
1.2.2. Hormonal and reproductive factors 
Steroid hormones, more specifically sex hormones such as oestrogen are known to 
have significant effects on growth, differentiation and functioning of the breast, and 
are major promoters of proliferation in both normal and neoplastic breast tissue (30, 
31). It is therefore somewhat unsurprising that both exogenous and endogenous 
hormonal factors have been shown to have an association with breast cancer 
pathogenesis. These factors are largely linked to oestrogen exposure, which is 
considered to be the main modifiable risk factor for breast cancer (1). 
Endogenous 
Breast cancer has been found to be more common in women who have never breast 
fed, those with early age at menarche and later menopause, and nulliparous women 
(32). An earlier age at menarche and later menopause is thought to contribute to 
breast cancer risk due to prolonged exposure of the breast epithelium to sex 
hormones, such as oestrogen and progestogen. This is due to an increased number 
of ovulatory cycles throughout life (33). Accordingly, breast cancer risk has been 
shown to increase by 17% for every 5-year increase in the age at menopause (34). 
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Similarly, the decrease in breast cancer risk associated with increased duration of 
breast feeding is thought to be linked to the reduced hormone exposure resulting 
from breast-feeding, which prolongs the anovulatory period following childbirth (33). 
What is less clear is the cause of the association between breast cancer and parity. 
Later age at first full-term pregnancy and lower/nulli-parity are both well-established 
factors which increase breast cancer risk. However, interestingly, it has been shown 
that uniparous women (particularly those aged 30 or more) have an elevated risk of 
breast cancer soon after delivery compared to nulliparous women - this declines 
some years later (35). Generally, circulating sex hormones are likely to be higher in 
pregnancy. Therefore, it is hypothesized that risk decrease may be due to the altered 
hormonal environment specific to pregnancy, maturation of breast tissue in response 
to pregnancy (resulting in a greater degree of differentiation), an effect on mammary 
stem cells, or changes in oestrogen responses of the mammary gland (35). The 
mechanism is poorly understood however it is clear that the protective effect of 
parity is complicated and dependent on several additional factors.  
As with many other cancers, increased age is also an established breast cancer 
risk factor, and it is thought one reason for this is the effect of endogenous hormones. 
Although the levels of circulating oestrogens in post-menopausal women are greatly 
decreased compared to pre-menopausal women, the difference in the composition 
of breast tissue may contribute to increased risk with age. Breast stromal cells and 
specifically adipocytes in breast tissue contain aromatase enzymes which convert 
circulating cholesterol to oestradiol (32), a potent naturally occurring oestrogen. In 
post-menopausal women, the proportion of breast tissue made up of adipocytes as 
opposed to fibrous tissue is much greater than in pre-menopausal women. Due to 
this, it is recognised that oestradiol levels in the breast tissue of post-menopausal 
women are much greater than plasma levels (36).  
Exogenous 
Long term hormone replacement therapy (HRT) with oestrogen-containing 
preparations is also thought to contribute significantly to the increased risk of breast 
cancer in post-menopausal women. There is a reported RR of 1.43 for post-
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menopausal women who have ever used HRT, and 1.66 among current users, 
increasing with total duration of use (37). UK guidelines suggest that HRT is 
inappropriate for women who have breast cancer, or who are at high risk due to a 
strong FH, and alternatives for managing menopausal symptoms should be sought 
(38). If symptoms are unmanageable and the patient is informed of the risk, HRT 
should be used at as low a dose for as little a time as possible, and these women 
should be preferentially given oestrogen-only preparations.  The increased risk is of 
course applicable to any woman taking HRT, and it comes with other risks such as 
increased incidence of venous thrombo-embolism. However, HRT is an effective 
treatment for menopausal symptoms such as vasomotor flushing, mood disturbance 
and sexual dysfunction, as well as longer term benefits including improved bone mass 
density, and decreased risk of fragility fractures and coronary heart disease (38). 
Therefore, whilst the increased risk of breast cancer associated with HRT is not 
insignificant, as with any treatment intervention the risks and benefits to the 
individual patient should be assessed.  
Perhaps more relevant to pre-menopausal women is the impact of oestrogen-
containing contraceptive preparations such as the combined oral contraceptive pill 
(COCP). A review and analysis of forty-four studies evaluating COCP use and breast 
cancer incidence found that having ever used a COCP, versus having never used one, 
had a significant impact on risk of breast cancer (odds ratio (OR) =1.08 (95% 
confidence interval (CI), 1.00-1.17)). Risk was further increased for current users, or 
those with a shorter time since last use, however no relationship was found with total 
duration of use (39). As with HRT, the COCP is contraindicated in women with breast 
cancer, history of breast cancer or at high risk of breast cancer according to UK 
guidelines (40). An interesting caveat is that having ever used the COCP is associated 
with a 30% reduction in the risk of ovarian cancer in the general population, and has 
also been found to reduce ovarian cancer risk in women who carry BRCA mutations 
(41), which hugely increase lifetime risk of developing breast and ovarian cancer. 
Meta-analysis has shown an inverse relationship between ovarian cancer and COCP 
use in BRCA mutation carriers, and a modest but not statistically significant increase 
in breast cancer risk in this group (though absolute risk would remain much greater 
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than the general population) (41). It is therefore suggested that use of the COCP in 
this specific high risk population, may not be contraindicated due to the net benefit 
of reduced risk of ovarian cancer; this helps avoids definitive surgery such as 
oophorectomy in women who have not yet completed their family.  
Overall, HRT and the COCP use is not recommended in women with breast cancer 
or with an increased risk. Any woman seeking these treatments should be made 
aware of the potential risks, benefits and counselled accordingly, though for most, 
the increased risk of breast cancer is not a contraindication.  
Reproductive and hormonal risk factors and triple negative breast cancer 
Although the hormonal risk factors discussed above are well established for breast 
cancer overall, the effect of these differs when looking at different breast cancer 
subtypes. Evidence for associations with reproductive risk factors has been found to 
be most consistent for tumours which are ER +ve and/or PR +ve. Associations are less 
convincing for TNBC, a subtype which accounts for 10-20% of diagnosis (42). Since 
oestrogen is a major promoter of proliferation in neoplastic breast tissue, it is 
unsurprising that ER +ve tumours may proliferate in response to oestrogen exposure 
– for TNBC however, the picture is less clear. It has been shown that reproductive 
risk factors are more strongly associated with HR +ve tumours than with ER-ve and 
PR-ve tumours (31, 43), although this is poorly understood. HER2 status appears to 
be less of a discriminator when it comes to risk factors (31). It has been suggested 
that TNBC may represent a distinct subtype of breast cancer epidemiologically. 
Differences that have been established include an association between increased 
parity and increased TNBC risk and increased age at first pregnancy and decreased 
TNBC risk, quite contrary to traditional perceptions of breast cancer risk factors (42).  
TNBC also has a tendency to affect women of a younger age, and is more common in 
black women compared to HR +ve cancer (31).  The epidemiology of TNBC specifically 
is poorly understood, and further work is required to establish the relevance of 
traditional breast cancer risk factors in this subtype.  
  
11 
 
 
 
1.2.3. Modifiable Lifestyle Factors 
There is well-established evidence that modifiable factors contribute to the 
pathogenesis of multiple cancers, including breast cancer, although the biological 
mechanisms are not always well described. Nonetheless, the factors discussed below 
have been associated with breast cancer, and therefore represent potential lifestyle 
changes that may confer a modest reduction in breast cancer risk. 
Obesity, diet and physical activity 
Obesity has been found to increase breast cancer risk in post-menopausal women. 
In a case-control study from the USA, there was an increased risk of 8% for every 5kg 
heavier a woman is compared to her lowest adult weight (44). However, for younger 
women the relationship is less clear, with some suggesting that obesity pre-
menopause may in fact decrease the risk of getting breast cancer pre-menopause, or 
at least have negligible effect (45, 46). It is speculated that this may be as a result of 
the anovulatory state that can occur in obese pre-menopausal women, resulting in 
less endogenous oestrogen exposure.  
 Under normal physiological circumstances, circulating sex hormones in post-
menopausal women would be expected to be lower than that of pre-menopausal 
women, which would be expected to have a risk-lowering effect. However, in obesity 
there is an increase in peripheral adipose tissue which express aromatase enzymes 
responsible for production of oestradiol. Additionally, it has been demonstrated that 
levels of CYP19A1 mRNA (which encodes aromatase) levels are 2-4 times higher in 
fat from the buttocks, thighs and abdomen of post-menopausal women compared to 
young women (47). Therefore, the increased risk associated with obesity may in part 
be due to higher circulating oestrogens in obese post-menopausal women (48). 
Another causal link may be due to a metabolic state which often arises to some 
degree in obesity known as ‘metabolic syndrome’. This involves insulin resistance, 
dysglycaemia or hyperglycaemia, dyslipidaemia, hypertension and an overall chronic 
inflammatory response, which together is thought to produce a pro-carcinogenic 
state. This may link obesity to breast cancer, as well as other cancers (48). 
Accordingly, weight loss of 5% has been shown to reduce breast cancer risk by as 
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much as 25-40%, and is of probable benefit in all overweight women regardless of 
the presence of other risk factors (49).  
 Since, in basic terms, weight is dependent on net calories consumed vs 
calories used, it is intrinsically linked to both diet and exercise. Whilst weight loss 
generally has been linked to a decreased risk of breast cancer, evidence is less certain 
when it comes to the specifics of either diet, or physical activity in particular. 
Research has been carried out regarding dietary composition and its effect on breast 
cancer risk. Specific dietary components have been linked to breast cancer, for 
example, as with many cancers, increased fruit and vegetable intake decreases risk 
(33). There has been shown to be a 5% decrease in risk for every additional 10g of 
fibre consumed per day, particularly soluble fibres (50). High fat intake, particularly 
from unsaturated fat has been linked to breast cancer risk, and one study 
demonstrated that a reduced fat diet significantly improves relapse free survival in 
breast cancer patients (48, 51). This was not however replicated in further studies 
(52), so the evidence remains uncertain. Consumption of ‘well-done’ red meat, and 
processed meat has also been linked to a significantly increased risk of breast cancer, 
although it is unclear as to whether or not this is due to the fat content of meat, 
chemical exposure from processing or if this is just a marker of unhealthy lifestyle 
generally (33, 49). Much hype surrounded the possibility of dairy products as a 
contributor to breast cancer, as it was hypothesized that oestrogen consumption 
from this source would increase risk. However, this has been dispelled and in fact it 
has been shown that that there is a decreased rate of breast cancer in those who 
consume more dairy products (49). Products derived from soya have also caused 
controversy, as they are high in isoflavones which have been shown to have both 
weak oestrogenic and anti-oestrogenic effects as well as inhibiting cancer growth in 
laboratory conditions (49). Despite the weak oestrogenic effect, intake of 5g of soya 
protein/day is associated with a reduction in breast cancer risk in Asian populations, 
although it is thought that this impact may be as a result of effects on the developing 
breast in which case intake of soya products as a child/adolescent may be more 
important (49, 53). 
13 
 
 
 
Although physical activity will contribute to weight loss, it is less clear whether or 
not it itself reduces risk of breast cancer. Physical activity is associated with a 
reduction in endogenous sex hormones, reduction in insulin resistance and reduction 
in chronic inflammatory processes, which overall could contribute to reduced risk 
(49). It has been shown to reduce risk in both pre- and post-menopausal women, 
however the effect was limited in women who were overweight or obese (54). This 
finding possibly gives strength to the assertion that the main benefit of exercise in 
the reduction of breast cancer risk is by decreasing total body weight rather than a 
direct effect of exercise itself. Overall, maintaining a healthy weight, or losing weight 
through exercise or a calorie-reduced diet reduces the risk of breast cancer, 
particularly in post-menopausal women. However, the evidence so far is limited as 
to whether there are any diet-specific or exercise-specific risk-reducing measures 
which are beneficial.  
Alcohol 
Alcohol consumption has been consistently associated with an increased risk of 
developing breast cancer in both pre- and post-menopausal women, with an overall 
RR of 1.6 (33). For every 10g/day increase in alcohol consumption there has been 
found to be a 7-10% increase in risk of breast cancer, with 4-10% of breast cancer 
diagnosed in the USA attributable to alcohol consumption (55). There has been 
speculation as to the biological link between the two. Despite alcohol being largely 
metabolised by the liver, it is known that human breast tissue has a modest capacity 
to do so, and it may be that metabolites resulting from this have a direct carcinogenic 
effect. Acetaldehyde and reactive oxygen species, both products of alcohol 
metabolism are known to cause DNA point mutations, crosslinks, chromosomal 
aberrations and strand breaks (55). Accumulation of these abnormalities with 
continued exposure could contribute to neoplastic change within breast tissue. 
Additionally, another effect of alcohol is to increase circulating levels of oestrogen, 
which is thought to contribute to propagation of breast cancer rather than neoplastic 
change itself. In a study in which 30g/day of ethanol was consumed by women age 
21-40 years for 3 menstrual cycles, it was shown that there was a 28% increase and 
21% increase in plasma oestradiol and oestrone (endogenous oestrogens) 
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respectively (56) - an increase in oestrogens has also been demonstrated in post-
menopausal women after alcohol consumption (57). It is thought that this may 
contribute to proliferation of already neoplastic breast tissue, especially given that 
ethanol has been shown, by some mechanism, to cause proliferation of ER+ve but 
not ER-ve breast cancer cell lines (58). 
Smoking 
Tobacco smoking has been indicated as cause or risk factor for the development of 
several human cancers including cancer of the upper airways, oral cavity, 
oesophagus, liver, pancreas, and bladder, with the highest RR for current smokers 
being that of lung cancer (RR=8.96) (59). The link with breast cancer however is less 
clear. The role of smoking in breast cancer seems to be of particular relevance for ER 
+ve breast cancers in people with specific polymorphisms in the NAT2 gene, involved 
in the metabolism of tobacco products (60). Additionally, the risk appears to be 
greater for those who began smoking in adolescence, with an OR of 1.5 (95% CI, 0.9-
2.5) for women who started smoking between ages 10-14 years compared to 1.2 (0.8-
1.5) for those who began aged >20 years (61). Overall, the evidence would suggest 
that tobacco smoking is associated with a modest increase in risk of pre-menopausal 
breast cancer with some reports of an association with post-menopausal breast 
cancer as well (48, 49). 
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1.2.4. Mammographic Density 
Mammographic Density (MD) refers to the component of tissue on breast 
mammography which appears radio-dense. Radio-dense tissue represents 
fibroglandular components of the breast, and radio-transparent areas represent 
fatty tissue. An increased MD has been consistently linked to an increased risk of 
breast cancer in both pre- and post-menopausal women. Studies investigating the 
relationship between MD and breast cancer risk have taken several approaches, 
including measuring absolute dense area, percentage dense area and absolute non-
dense area as measurements of MD. In a meta-analysis (62), the age-adjusted OR in 
pre-menopausal women, for one standard deviation increment in absolute dense 
area was 1.38 (95% CI, 1.3-1.49), for percentage dense area OR=1.45 (1.35-1.55) and 
for absolute non-dense area 0.78 (0.69-0.89). For post-menopausal women, the 
same figures were 1.37 (1.33-1.40), 1.53 (1.44-1.64) and 0.79 (0.73-0.85) respectively 
(62). For post-menopausal women, percentage dense area and absolute non-dense 
area were corrected for BMI and parity, however the same correction did not 
significantly affect absolute dense area or the figures quoted for pre-menopausal 
women. The authors of this meta-analysis concluded that absolute and percentage 
dense area were both strong risk factors for breast cancer, with percentage dense 
area being the stronger of the two risk factors. Evidence for the value of absolute 
non-dense area as a risk determinant was deemed inconclusive. Greater associations 
have been drawn when comparing the extremes of MD, with one meta-analysis 
quoting a RR of breast cancer of 4.64 (95% CI 3.64-5.91) for dense area >75%, 
compared to <5% (63). The confounding effect of BMI in post-menopausal women is 
an interesting component of analysis of MD and breast cancer risk. As discussed 
previously, higher BMI is known to increase breast cancer risk in post-menopausal 
women, partly due to increased adipose tissue both peripherally and in the breast, 
contributing to increased aromatisation of sex hormone precursors. However, 
increased MD, supposedly representing decreased breast adiposity, is also linked to 
an increased breast cancer risk. An explanation which has been suggested for this 
discrepancy is that it is largely primary stromal preadipocytes which have aromatase 
activity. This activity may diminish as they differentiate into mature adipocytes (64), 
which may be present in fatty radiotranslucent breast tissue.   
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The biological mechanisms behind increased breast cancer risk and increased 
MD are unclear, although several hypotheses exist. The most simple of these 
suggests that it is merely due to a larger amount of fibroglandular tissue at risk of 
malignant transformation. However, this is less able to explain the stronger 
association with percentage dense area compared to absolute dense area (62). It has 
also been proposed that tissue stiffness and structural changes of stromal collagen 
may explain this association better (65). Other proposed mechanisms include 
hormonal factors and altered genetic profile of dense breast tissue (65). Fibroblasts 
derived from dense and non-dense breast tissue have demonstrated marked 
differences in gene expression profiles, with several signalling pathways that are 
known therapeutic targets in cancer being upregulated in dense tissue (66). Attempts 
to identify genetic associations which increase MD in the population have identified 
a few polymorphisms which may contribute (67). 
Although increased MD appears to be a well-established risk factor, some 
controversy exists concerning its clinical utility and the reliability of the evidence that 
it is a risk factor. There have been claims that there are several weaknesses in studies 
of MD and breast cancer. This includes a lack of standardised definition of high MD 
(ranging from 25% in some studies to 75% in others) and inappropriate comparisons 
of the extremes of MD whilst ignoring the majority, weakening the strength of 
evidence (68). Other issues include the limited impact incorporation of MD has had 
on the predictive power of risk prediction models (69, 70). Additionally, using MD as 
a means to assess breast composition may not be reliable, as much of the result relies 
on thickness of the breast, position and other confounders such as water content of 
the breast (68). However, research is underway to identify methods of assessing 
breast density and volume of dense and non-dense tissue which is more accurate 
(66). Should this be successful and a standardised approach developed, it may be 
possible to incorporate breast density as a modest predictor of breast cancer risk, 
alongside other cumulative risk factors.  
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1.2.5. Ionising Radiation 
Ionising radiation (IR) encompasses all X-rays used in diagnostic radiation and 
radiotherapy. It is known to cause indirect DNA damage to cells by production of free 
radicals as well as through direct damage via single-stranded or double-stranded 
DNA breaks. Single-stranded DNA breaks are, more often than not, successfully 
repaired by base-excision repair mechanisms, however double-stranded breaks are 
more complex and require repair by homologous recombination repair (HRR) (71). 
Cumulative DNA damage leaves the cell vulnerable to mutagenesis and cell death. 
This is taken advantage of in the treatment of various cancers including breast cancer 
by radiotherapy, where the increased cellular proliferation rates and defective DNA 
repair mechanisms make the cancerous cells particularly vulnerable to the damage 
induced by IR. Radiotherapy for breast cancer is known to reduce the risk of local 
recurrence and improve overall survival (72). However, any radiation exposure also 
affects normal tissue, which is left vulnerable to bystander DNA damage and in itself 
may result in mutations which drive cancer development (71).  
Research into the effects of IR on breast cancer risks have focussed on specific 
groups of patients, including those exposed to radiation from nuclear weapons, those 
treated with IR for Hodgkin’s lymphoma, people with scoliosis and tuberculosis 
monitored with X-rays, and people treated with IR for haemangiomas in childhood. 
A study into solid cancer incidence was carried out looking at 65,525 female members 
of a cohort who were resident in Hiroshima and Nagasaki and survived nuclear 
weapon attacks. The group was stratified by distance from the site of impact at the 
time of bombing. Excess RR for women over 50 years was 5.3 (95% CI, 2.5-8.6) per 
Gy unit of exposure (73). Studies of women treated with IR for Hodgkin’s lymphoma 
have shown an overall RR of breast cancer in this group of 5.0 (95% CI, 4.5-5.5), with 
a tendency to increased risk at younger age of exposure (74). Studies into patients 
with scoliosis and those treated for haemangioma have shown similar patterns, and 
risk has been shown to be linearly correlated with dose – there has however been no 
dose threshold identified, suggesting that any IR exposure may increase risk to some 
degree (71, 75, 76). 
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Perhaps of greater significance to the general population who develop breast 
cancer is the risk of contralateral breast cancer (CBC) after treatment of a primary 
breast cancer with IR. The evidence for whether or not treatment with radiotherapy 
increases risk of a subsequent breast cancer is mixed. One study of 134,501 patients 
with locally invasive or intraductal breast cancer reported a documented CBC in 4.2%. 
Overall, the risk of CBC was not significantly associated with radiotherapy (RR=1.04, 
95%CI, 0.97-1.1) until 5 years after exposure, when radiotherapy was associated with 
a 14% increase in CBC risk (RR=1.14, 95% CI=1.03-1.26), most pronounced in patients 
<45 years at initial cancer diagnosis (77). Although inconclusive, this study suggested 
a trend towards increased risk of a subsequent cancer with a greater effect at 
younger age of exposure, although other studies of a similar nature have also yielded 
inconclusive evidence (71). It is plausible that CBCs occurring in those with radiation 
exposure are just a manifestation of increased genetic risk and other risk factors. In 
addition, the benefits of radiotherapy at reducing recurrence risk of the breast cancer 
being treated, probably outweigh the radiation exposure risk; a large meta-analysis 
of 10,801 women identified an absolute risk reduction of 15.7% for 10-year 
recurrence (p=<0.0001) (78).  
Another group of interest is that of BRCA mutation carriers whose substantially 
increased breast cancer risk is due to a genetic defect in proteins required for DNA 
double-strand break repair by HRR, which may lead to repair by non-homologous end 
joining (NHEJ), a less reliable method of repair. Since IR is known to induce DNA 
double-strand breaks, it is reasonable to hypothesize that this group may be more 
susceptible to the deleterious effects of IR. This is especially relevant since 
mammography is a suggested means of screening women with known BRCA 
mutations (79). One of the most comprehensive studies into IR exposure and BRCA 
mutation carriers was a retrospective cohort study of 1,993 mutation carriers. They 
found that any exposure to radiation before the age of 30 was associated with an 
increased risk of breast cancer (RR=1.90, 95% CI, 1.2-3.0), with risk increasing with 
dose (80). Levels of dose which had an effect on risk in this cohort was much lower 
than has been reported in non-BRCA mutation carriers, suggesting an increased 
susceptibility.  
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Overall, IR is a risk factor for developing breast cancer, with reported RR as high 
as 4.5 for women exposed to high dose radiation at a young age (71). In specific 
populations exposed to IR, it may be appropriate for clinicians to have a high index 
of suspicion for breast cancer. For patients who develop sporadic breast cancer and 
are treated with radiotherapy at an older age, the risk of developing another cancer 
attributable to therapeutic IR radiation exposure is probably negligible, however the 
significance in younger women and BRCA mutation carriers is less clear.  
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1.3. Familial predisposition to breast cancer 
Although breast cancer is a common sporadic cancer, up to 20% of cases of breast 
cancer arise in familial clustering (81, 82), being up to twice as common in a woman 
with an affected FDR (83). The relationship between FH and breast cancer has long 
been recognised, despite all the factors contributing to this being unclear. Shared 
environmental factors are thought to influence risk, however genetic predisposition 
is thought to be the major factor (84). Some high and intermediate risk genes have 
been identified, however the mechanisms behind clustering in many families remains 
unexplained. The genetic risk factors for breast cancer, including known risk genes 
and FH, are discussed below.   
1.3.1. High-risk, high-penetrance genes 
Four genes have been identified in which mutations are of high-penetrance and 
convey a greatly increased risk of breast cancer – these are BRCA1, BRCA2, TP53 and 
PTEN.  
BRCA1 and BRCA2 
BRCA1 was first mapped to chromosome 17q21 in 1990 by linkage analysis of 23 
families with younger age at cancer onset, bilateral disease and male breast cancer 
(85). The gene itself was later identified by positional cloning (86). The same 
techniques led to the identification of BRCA2 thereafter (87), allowing investigation 
of both genes roles in development of breast and ovarian cancer. Both BRCA1 and 
BRCA2 are known to be tumour suppressor genes which facilitate the repair of 
double-stranded DNA breaks (83). DNA double-strand breaks can be repaired by 
NHEJ or HRR. NHEJ involves the formation of large multiprotein complexes at the site 
of double-strand breaks and repair of the broken ends via DNA ligases. This is thought 
to be an error-prone means of DNA repair, however recently a more precise sub-
pathway of NHEJ has been identified (88). HRR, or more specifically, gene conversion, 
involves invasion of the damaged DNA by a strand from the homologous 
chromosome to act as a template for repair mechanisms. This mechanism is 
dependent on the DNA recombinase enzyme RAD51, which facilitates invasion of the 
homologous sequence. Both BRCA1 and BRCA2 proteins are known to aid double-
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strand break repair by RAD51 dependent mechanisms through interaction with the 
RAD51 protein (89, 90). Additionally, both BRCA1 and BRCA2 have been found to be 
involved in other DNA repair complexes, including BRCA1-Containing Complex, and 
have roles in cell cycle progression and checkpoint control (91). These functions may 
be reflected in the genetic instability of tumours with BRCA abnormalities, explaining 
why mutations in the BRCA genes increase the probability of carcinogenesis (92).  
Disease-causing mutations in the BRCA genes have been found to result in the 
formation of truncated proteins. Most of these are individually rare, however there 
are known founder mutations in Ashkenazi Jewish and Icelandic populations (83) 
amongst others. Interestingly, sites of mutation have been found to be linked to the 
phenotype expressed; mutations in the central portion of both genes have been 
found to increase the ratio of ovarian to breast cancers within families compared to 
mutations at the 5’ or 3’ end (83). The prevalence of BRCA1 mutations in the UK 
population is estimated to be at around 0.07-0.09% and for BRCA2, 0.14-0.22%, 
meaning that overall, they contribute to a small fraction of the total breast cancer 
burden, given that it is such a common disease (93). However women who do carry 
a BRCA1 mutation have a 65% and 39% risk by age 70 of breast and ovarian cancer 
respectively. The corresponding risk for BRCA2 mutation carriers is 45% and 11% (94). 
BRCA1 tumours are more likely to be high grade, ductal carcinomas with a TNBC 
receptor profile (95). Men who carry a BRCA mutation are also at an increased risk of 
breast cancer, and BRCA mutations have been linked to both pancreatic and prostate 
cancer.  Given their role as tumour suppressors, it is unsurprising that homozygosity 
for mutations in either of the BRCA genes is detrimental. There are no reports of 
homozygous BRCA1 mutations and it presumed to be embryonically lethal. Those 
homozygous for a BRCA2 are known to have Fanconi anaemia, a highly penetrant 
cancer predisposition syndrome and cause of significant physical abnormalities (83).  
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TP53 
TP53 encodes a transcription factor (TF), p53, which becomes activated in response 
to cellular stress such as DNA damage, oncogene activation, and hypoxia. Its 
activation results in downstream activation of tumour suppressor genes involved in 
DNA repair and cell cycle control. MDM2, an inhibitor of p53 activity is negatively 
regulated by cellular stress, and the balance between activity of these proteins helps 
to regulate cellular damage (96). Ultimately, p53 can induce cell cycle arrest by 
various mechanisms, including at the G1/2 checkpoint by promoting activity of cyclin 
dependent kinase inhibitor p21 (97). Mutations in TP53 that disrupt it’s function can 
be found in up to 50% of human cancers (96). However, as well as loss of function, 
mutations in p53 can result in dominant-negative and gain of function effects (97). Li 
Fraumeni syndrome is a cancer predisposition syndrome resulting from inherited 
TP53 mutations. Women with Li Fraumeni syndrome have a greatly increased 
lifetime risk of cancer, and carcinoma of the breast has been found to be the most 
frequent cancer in females of this group (98). Breast cancers occurring in women with 
a germline TP53 mutation are significantly more likely to be HER2 amplified tumours 
(83% compared to 19% of controls, p=1.2x10-6) (99). However, Li Fraumeni syndrome 
is rare, so while the risk to women with the condition is significant, it’s contribution 
to inherited breast cancer is small.  
PTEN 
Cytogenetic analysis of a variety of human cancers, followed later by more detailed 
mapping, identified a tumour suppressor gene at chromosome 10q23.3, called PTEN. 
It was found to be mutated in gliomas, prostate cancer and breast cancer (100-102). 
Early studies identified loss of heterozygosity at the region containing PTEN in around 
50% of 32 primary invasive breast cancers (102). In addition, a small study of 5 
families meeting diagnostic criteria for Cowden disease, an autosomal dominant, 
multiple benign hamartoma syndrome, identified a number of PTEN point mutations 
in 4 of 5 families (103). As well as benign hamartomas, individuals with Cowden 
disease can present with developmental delay and malignant tumours (104). The 
evidence for PTEN as a tumour suppressor was strengthened by the discovery that 
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heterozygous PTEN null mice develop a variety of cancers including breast, thyroid, 
endometrial and prostate cancer (105). The gene product, PTEN, normally acts to 
dephosphorylate phosphatidylinositol-3,4,5-trisphosphate, which is an upstream 
activator of AKT; AKT is a driver of cell proliferation and angiogenesis, and is anti-
apoptotic. Therefore, dysregulation of AKT has oncogenic effects (106). Mutations 
which affect the phosphatase activity of PTEN are therefore thought to cause de-
repression of AKT and contribute to tumour development. However, mutations out-
with the catalytic domain of PTEN, which disrupt regulatory features rather than 
function, have been shown to cause far more diverse phenotypes (for example, 
autistic spectrum disorder and developmental delay with macrocephaly) (100).   The 
understanding of genotype-phenotype correlations in PTEN germline mutation 
carriers is still developing. However, it has been broadly determined that mutations 
causing loss of function of the catalytic domain are more likely to cause tumour 
predisposition phenotypes, and mutations which still confer partial function are 
more closely linked to autism and developmental delay (100). Studies have 
determined the lifetime breast cancer risk in patients with a germline PTEN mutation 
to be significantly raised. One study of 3,366 female patients, 295 of which had a 
PTEN mutation estimated the breast cancer risk to rise sharply from age 30 years for 
those with a mutation, with an approximately 35% penetrance by age 50 years and 
85.2% (71.4-99.1%) penetrance by age 70 years. Another study of 154 patients found 
similar results, with breast cancer risk rising sharply after age 30 years and reaching 
a 77% (59-91%) risk by age 70 years. Although these studies had limited numbers of 
patients with a constitutional PTEN mutation, they both demonstrate a significantly 
increased lifetime risk of breast cancer for these patients. Clinically in the UK, women 
with a PTEN mutation are treated as high risk and offered screening at an early age 
(79). Despite this, PTEN mutations are thought to contribute to <1% of breast cancer 
cases (107). 
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Although a mutation in one of the highly penetrant genes conveys a significantly 
increased risk of breast cancer for that individual, mutations in BRCA1 and BRCA2 are 
known to contribute to just 15-20% of the excess familial risk of breast cancer (83). 
The remaining risk has yet to be explained by shared environmental factors and this 
explanation for familial clustering has been deemed unlikely. Extensive population 
studies have added weight to a polygenic model of multiple genetic factors acting 
independently. A low-penetrance, polygenic risk model has been found to be the 
best fit for data on women who have had breast cancer, and for multiple-case 
families not due to BRCA mutations. It is unclear whether this polygenic effect would 
be multiplicative or additive (108). This has been widely accepted as an explanation 
for the remaining familial breast cancer risk (83). Efforts have therefore been made 
to identify risk alleles that are of lower penetrance than the genes described above.  
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1.3.2. Intermediate-risk genes 
Several intermediate risk genes have been identified which each confer 
approximately a 2 fold risk of breast cancer to those with a constitutional mutations 
in these genes. Some of the genes which have been identified as having a convincing 
role in breast cancer risk work in DNA repair pathways. CHEK2, ATM, BRIP1 and 
RAD50 are intermediate risk genes which code for proteins which work alongside 
BRCA1. The RR/OR found to be associated with the intermediate risk genes, 
discussed below, are shown in Table 3. Despite their effect on breast cancer risk, 
current UK guidance does not suggest screening for mutations in these genes in 
women with a FH of breast cancer.  
CHEK2 and ATM 
Among other roles, CHEK2 and ATM are both known to phosphorylate and activate 
both BRCA1 and p53 in response to DNA damage. CHEK2 itself is also a direct 
substrate of ATM (109, 110). In activating these proteins, they contribute to BRCA1-
mediated double strand break repair as well as cell cycle arrest. A biallelic mutation 
in ATM is known to cause ataxia-telangiectasia, an autosomal recessive condition 
which predisposes to cancer as well as conferring phenotypic features such as ataxia, 
telangiectasia and neurodegeneration (110). In a study of individuals with familial 
breast cancer not found to be caused by mutations in BRCA1 or BRCA2, a 
heterozygous mutation, CHEK2*1100delC, was found in 5.1% of breast cancer cases 
compared to a frequency of 1.1% in healthy individuals (p=3x10-7) (109). Observation 
of an increased breast cancer incidence in family members of those with ataxia-
telangiectasia lead to a similar study looking at ATM, which identified mutations in 
12/443 affected individuals and 2/521 controls (p=0.0047) (111). These mutations 
were the same as those known to cause ataxia-telangiectasia, but were present as 
heterozygous mutations.  
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BRIP1 
BRIP1 encodes BRCA1-associated C-terminal helicase, a protein which interacts 
directly with BRCA1. It has been found to aid BRCA1 localisation to double-strand 
breaks through its helicase activity, and be involved in maintaining BRCA1 at double-
strand breaks after localisation. Consequently, BRIP1 deficient cells have been found 
to have delayed double-strand break repair (112). Biallelic mutations in BRIP1 have 
been found to cause Fanconi anaemia subtype FA-J (113). Monoallelic mutations in 
BRIP1 were identified in 9/1212 individuals with breast cancer from BRCA mutation 
negative families and only 2/2081 controls (p=0.0030) in a British cohort (114). 
However, several studies from outside the UK have failed to identify an association 
between BRIP1 mutations and breast cancer (115). Although BRIP1 is available in 
some countries for genetic testing related to breast and ovarian cancer, it has been 
suggested that the breast cancer risk is in fact negligible, and that BRIP1 should be 
considered more of an ovarian cancer risk gene (116). 
RAD50 
RAD50 constitutes part of the MRN complex (MRE11, RAD50, and NBS1). The MRN 
complex is phosphorylated and activated by ATM, and interacts directly with BRCA1 
in a cell-cycle dependent manner. The complex formed aids in the identification of 
double-strand breaks and downstream signalling to DNA repair mechanisms (117, 
118). Identification of a RAD50*687delT mutation has been identified in a Finnish 
population, where it was found to be significantly more frequent in individuals 
affected with breast cancer (8/317) compared to matched controls (6/1000) 
(p=0.0004) (119). However, as with BRIP1 the relevance of this is contentious, as 
RAD50 mutations associated with breast cancer have not been linked to breast 
cancer outwith this study population. Indeed, in a study involving a UK cohort, only 
1 of 435 breast cancer cases was found to have a constitutional RAD50 mutation 
(120).  
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PALB2 
PALB2 encodes a tumour suppressor protein which is recruited to DNA double-strand 
breaks in a BRCA1-dependent fashion. Although its recruitment is BRCA1-dependent, 
the most well documented role of PALB2 is as a partner protein of BRCA2, by 
facilitating BRCA2 recruitment and stabilisation at double-strand breaks, as well as 
assisting assembly of RAD51 foci (121). Perhaps unsurprisingly, given its partnership 
with BRCA2, the PALB2 gene has been found to cause Fanconi anaemia subtype FA-
D1 and FA-N when mutated biallelically, which are both associated with a markedly 
increased incidence of childhood cancers (83, 122, 123). Monoallelic mutations in 
PALB2 have been found to increase susceptibility to breast cancer. A large case-
control study found PALB2 mutations in 10/923 cases of familial breast cancer 
compared to 0/1,084 control (p=0.0004), a significant finding which has been 
replicated in other populations (124, 125). Estimates of cumulative risk have been 
carried out, looking at population specific mutations, including studies in Finnish 
(126) and Australian (127) populations. These studies found a cumulative breast 
cancer risk to age 70 years of 40% and 91% respectively. This risk would appear 
strikingly high, however the analysis in the studies were based on 17 PALB2 mutation 
carriers in a cohort of 1,918 breast cancer cases in the Finnish study, and 17 mutation 
carriers in 1,403 in the Australian study. Perhaps with larger cohorts of mutation 
carriers, these risks could be further refined. 
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These intermediate risk mutations are present in genes which encode proteins in the 
same pathways as BRCA1 and BRCA2. This would suggest that the pathways behind 
BRCA-related breast cancers are also aberrant in these families, but with a different 
underlying mechanism. It is less clear is why these intermediate-risk mutations 
should be less penetrant than BRCA mutations despite affecting the same pathways. 
However, there is some debate to be had surrounding this assumption. It has been 
suggested that in women with a strong FH of breast cancer which is not due to a 
BRCA mutation, a mutation in one of these intermediate penetrance genes still 
carries a high absolute risk (128). Additionally, in a large study of 35,409 women with 
a breast cancer diagnosis, 9.3% of women carried a pathogenic variant in a known 
risk gene, of which 51.5% had a mutation in a gene other than BRCA1 or BRCA2 (129). 
Mutation prevalence in the whole cohort was 2.3% for each BRCA gene, and 1% each 
for ATM, CHEK2 and PALB2. The evidence is now reasonably strong that these 
‘intermediate-risk’ mutations contribute to breast cancer. However, the clinical 
interpretation of them is less clear. Despite their link with increased breast cancer 
risk, these genes may account for only 2.3% of familial breast cancer risk (83), and do 
not explain the entirety of familial breast cancer which is not BRCA related, 
suggesting there are other factors at play. 
 
 
Table 3 Intermediate risk genes and their associated RR/OR 
 Relative Risk (95% CI) 
Odds ratio (95% 
CI) 
Reference 
CHEK2 
Females 
1.7 (1.32-2.20) 
Males 
10.28 (3.54-29.87) 
2.52 (0.78-8.18) 
The CHEK2-breast 
cancer consortium 
(109) 
ATM 2.37 (1.51-3.78) - 
Renwick et al. 
(111) 
BRIP1 2.0 (1.2-3.2) - Seal S (114) 
RAD50 - 4.2 (1.5-12.5) Heikkinen (119) 
PALB2 2.3 (1.4-3.9)  Rahman N (124) 
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1.3.3. Common, low-penetrance genetic variants 
It is thought that genetic risk variants which are common in the population and have 
a low-penetrance could be responsible for a remaining 28% of familial breast cancer 
(130). Through genome-wide association studies (GWAS), approximately 76 loci for 
common, low-penetrance risk variants have been identified using single nucleotide 
polymorphism (SNP) biomarkers (131). One of the largest studies of this sort in 
familial breast cancer was carried out by the Breast Cancer Association Consortium 
(BCAC), which identified 41 new breast cancer associated SNPs, and confirmed the 
association of 27 previously identified SNPs, having studied women from a 
widespread, mainly European population (132). The SNPs identified individually 
carried between a 1.04-1.40 fold increased risk of breast cancer, with an estimated 
minor allele frequency (MAF) of 10-50%. Overall, they analysed 211,155 SNPs, which 
were selected based on identification in meta-analysis of previous GWAS, need for 
fine-mapping of known susceptibility loci and SNPs related to other cancers, among 
others. 52,675 breast cancer cases and 49,436 controls were then genotyped for 
these SNPs. Some of the SNPs identified appeared to contribute to breast cancer risk 
as a whole, however some were found to be specific to sub-types, such as ER +ve or 
–ve breast cancer. Other studies have identified risk variants which seem only to 
modify risk in BRCA1 and BRCA2 related breast cancers (130). Described below are 
some of the SNPs identified by the BCAC study which have also been identified in 
other studies, and for which there is a theorised biological basis for pathogenicity.  
A locus identified by the BCAC study, which had been previously reported, 
was SNP rs2981579 (133), which is in linkage disequilibrium (LD) with rs2981582 
(134) identified by Easton et al. (135). Easton et al carried out a 3-stage GWAS for 
266,722 selected SNPs. In the first stage, these were genotyped in 390 cases selected 
for breast cancer FH (at least 2 female FDRs affected) and 364 controls. Of these, 
12,711 showed a degree of significance. For the second stage of their study, they 
aimed to validate these SNPs in 3,990 invasive breast cancer cases and 3,916 
controls. For the third stage, 30 of the most significant SNPs were investigated in 
21,860 invasive breast cancer cases, 988 breast carcinomas in situ and 22,578 
controls. 6 SNPs were found to be significant after stage 3, one of which was 
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rs2981582. They estimated it to have a MAF of 0.3 and a per-allele OR for breast 
cancer of 1.26 (p=5x10-62 at stage 3). An interesting step that was taken in this study 
was the further analysis of haplotypes associated with the variant using HapMap 
(136). This confirmed that multiple haplotypes carrying the rs2981582 minor allele 
were associated with an increased risk of breast cancer, suggesting that the SNP 
itself, or another variant very strongly associated with it was the driver (135).  The 
SNP lies within intron 2 of the fibroblast growth factor receptor 2 gene (FGFR2), a 
highly conserved region of the genome which contains TF binding sites (135). The 
FGFR protein family are transmembrane tyrosine kinase receptors which have a role 
in cell proliferation, survival and apoptosis pathways. Amplification of one of the 
FGFR genes has been identified in 7.5-17% of all breast cancers (137). SNPs in intron 
2 have been found to be more common in ER +ve breast cancers, and FGFR2 has been 
found to be preferentially amplified in TNBC, with increased expression associated 
with poorer overall and disease-free survival (137). It was hypothesized that SNPs in 
TF binding sites could lead to increased binding and protein expression, although 
some studies have shown there to be a lack of correlation between genotype and 
cytoplasmic or nuclear protein levels (138). Nonetheless, it is reasonable to speculate 
that polymorphisms in intronic regions could affect the function or stability of the 
protein.  
Another SNP found to be significant in the BCAC study was rs10069690 (139), 
which lies within the telomerase reverse transcriptase (TERT) gene and carries a RR 
of 1.18 (95% CI, 1.13-1.25) (132). It had previously been found to be associated with 
ER -ve breast cancer in an African American population, with a per-allele OR of 1.19 
(1.05-1.36, p=0.007) (140). Functionally, TERT mutations are well-established in 
cancer development. The TERT gene encodes a rate-limiting catalytic subunit of 
telomerase which has a role in maintaining genomic integrity through telomere 
elongation (141). TERT it has been found to be overexpressed in several cancers due 
to promoter mutations, thought to be explained by the immortality associated with 
telomerase deregulation, which occurs in over 90% of human cancers (141). This 
often occurs as a somatic mutation in individuals with a normal germline TERT gene. 
However, highly penetrant germline mutations have been identified in familial 
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melanoma skin cancer (142). Therefore it is possible that less penetrant germline 
TERT mutations in LD or caused by rs10069690 may contribute to familial breast 
cancer.  
Although there is reasonable associative and functional evidence to support 
a number of SNP associations with breast cancer, the relevance of others identified 
by GWAS is less clear. For example, rs1045485 (143) aka CASP8 D302H was only 
found to be of borderline significance in the BCAC study (132), despite having 
previously been identified as associated (135, 144). The caspase 8 (CASP8) gene is an 
important initiator of apoptosis, and interestingly, the minor allele identified was 
deemed to carry decreased risk of breast cancer (per allele OR=0.88 (0.84-0.92) 
(144). Importantly, there was no association of this with FH, meaning its effect may 
only be significant in association with specific other polymorphic loci with 
multiplicative effects. Its role in familial breast cancer is therefore doubtful.   
GWAS studies are typically case-control studies which look to identify 
common variants associated with disease in a population. They are preferred for 
identifying variants with a high MAF and low penetrance. Although a study 
population from a multi-centre study such as in the BCAC (132) should provide 
adequate power, there are several acknowledged limitations of GWAS. The study 
population for the BCAC study was of mainly European descent, which - although 
representative of a wide population - means that distant ancestral variation is 
potentially common to the population. Spurious associations may result given the 
nature of breast cancer as a common malignancy. Replication of the association in 
distinct populations is therefore required for reasonable confirmation of the variant 
with the disease. Several of the 27 previously identified SNPs confirmed in this study 
had been previously reported in African American and Asian populations, however 
the newly identified variants would require replication. Another limitation of this 
study arises from the fact that the cases were unselected for FH of breast cancer. 
Had women with a significant FH specifically been studied, it may be more 
confidently speculated that variant associations were giving rise to a familial risk of 
breast cancer. This is as opposed to being spurious, or due to de novo mutations, 
which is important when considering heritable risk. SNPs are used as genomic 
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markers in these studies and it is often speculated that when a SNP is identified as 
associated with disease, either the SNP itself is pathogenic (less likely), or it is lying in 
LD with a pathogenic variant nearby. Emphasis can therefore be put on fine mapping 
genes within the region that the SNP is carried. However, many SNPs identified by 
GWAS lie in regulatory elements and possibly, trans-regulatory elements which act 
from a remote location to the gene they regulate. Some associated SNPs lie within 
known genes such as BRCA2 and the MYC proto-oncogene (131), however 
establishing the underlying pathogenic mechanism attributable to these variants 
may prove challenging without prior mapping and knowledge of the region in which 
they arise or, alternatively, functional studies.  
The impact of such variants on breast cancer risk remains controversial. 
Estimates for the RR attributable to carrying risk-associated SNPs vary from 33-40 
risk alleles required for 3-fold increased risk of breast cancer (130), to 14 risk alleles 
for a 6-fold increase risk (145). This is dependent on the RR of each SNP, as well as 
the possibility of allelic interactions. However, identification of variants, and multi-
population studies of the risk associated with these variations, is likely to improve 
understanding of how they contribute to disease. Without adequate understanding 
of this, it would be challenging to use them clinically. Pharoah et al. suggest that low-
penetrance, common variants may be of use for risk-stratification in population 
programmes (145). Though individually less useful, they state that a small number of 
susceptibility alleles may be able to discriminate different risk categories. Using 
absolute risk based on 7 known breast cancer susceptibility loci (RR range from 1.07-
1.26), they calculated that women in the 95th risk centile by genotyping would have 
a 10-year risk of 2.3%, which in the UK would not meet criteria for increased 
screening (79). However, the top 0.1% would reach a 10-year breast cancer risk of 
3%, making them eligible for increased breast cancer screening by mammography. 
High risk interventions (10-year risk >8%) would therefore, theoretically, be reserved 
for those most at risk, including BRCA mutation carriers. However, it would be 
reasonable to question the cost-effectiveness of this given the potential need to 
genotype the many women who attend breast cancer clinics with 2 or more FDRs or 
second degree relatives (SDRs) diagnosed with breast cancer. These women are 
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currently considered at 3-8% 10-year risk according to UK guidelines (79). 
Additionally, incorporation of low-penetrance variant information to the Gail model 
(146) for breast cancer risk prediction yielded a minimal improvement (130). Despite 
these reservations, one UK based study assessed a model based on 18 SNPs to 
reclassify risk for non BRCA mutation carriers, and appear to have had some success, 
with an observed risk 96% of expected according to their model, which assumed a 
multiplicative effect of published ORs for each SNP (147). 
The clinical utility of mapping and genotyping common risk variants is still 
controversial. However, the contribution of highly-penetrant mutations to familial 
breast cancer is relatively low, and a proportion of the remaining risk is thought to 
be explained by intermediate and low penetrance genetic variants. Therefore, it is 
widely accepted that polygenic risk is a significant contributor to the patterns of 
breast cancer inheritance seen in some families. With current knowledge, examining 
patterns of family history and inheritance in these ‘non-single gene’ cases, and the 
associated RR of breast cancer, is perhaps more clinically useful than genetic testing. 
This is an approach that has been taken in UK genetics services (79).  
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1.3.4. Family history and relative risk of breast cancer 
Despite several genes linked to an increased risk of breast cancer, more than 70% of 
the genetic predisposition remains unaccounted for (83). It has been suggested that 
the difficulty in identifying predisposing genes may be due to the effect of individually 
rare variants (perhaps ‘family-specific’) contributing to increased risk of a common 
disease. In this case, large population studies may lead to increased difficulty in 
identifying the causative factors (148). With the lack of knowledge of what causes 
such a large proportion of breast cancers in women with a FH, risk assessment cannot 
rely on something as clear cut as genetic testing.  
The RR of developing breast cancer is known to be associated with the type, 
number and age of relatives affected, and so risk calculation can provide a guide as 
to a woman’s risk of developing cancer. A large meta-analysis of 74 studies, which 
included a variety of ethnic populations and age ranges, and looked at the RR 
associated with different breast cancer family histories, was carried out by Pharoah 
et al. in 1997 (149). Using data from 52 case-control and 22 cohort studies, they 
calculated the pooled RR of breast cancer for various family histories. These are 
summarised in Table 4. They also acknowledged that the majority of studies saw the 
RR increase if the relative was diagnosed at <50 years and also in subjects <50 years.  
Another large meta-analysis carried out by the Collaborative Group on 
Hormonal Risk Factors in Breast Cancer also estimated the RR of various family 
histories. They found that the RR of breast cancer increased with an increasing 
number of affected FDRs (p<0.001) with a RR for 1, 2 and 3 affected FDRs of 1.8 (95% 
CI, 1.7-1.91), 2.93 (2.37-3.63) and 3.9 (2.03-7.48) respectively (150). Although they 
did not calculate RR for any history of affected FDR and so are not directly 
comparable with Pharaoh et al. the results of their analysis are broadly similar, 
suggesting an approximate two-fold risk of breast cancer in women with at least 1 
affected FDR, as well as an increase in risk for women with relatives diagnosed at <50 
years (150).  
The Nurses’ Health Study, a prospective cohort study of 121,701 US nurses 
also sought to establish the RR associated with FH, and by age classification of the 
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relative at diagnosis (151). They appeared to find slightly lower RR associated with a 
first degree FH than the previously mentioned studies, identifying a RR of only 1.69 
(95% CI, 1.39-2.05) and 1.37 (1.22-1.53) for a mother diagnosed at <50 years and >50 
years respectively. The corresponding RR for a sister were 1.66 (1.38-1.99) and 1.52 
(1.29-1.77). Although they found a trend towards increased risk for women with a 
FDR diagnosed <50 years, this was not statistically significant (151). They suggest that 
the reason for the difference between their results and that of meta-analyses, is that 
as they undertook a prospective cohort study therefore recall bias which may be 
present in retrospective cohort studies used in meta-analyses is eliminated.  
Although the meta-analyses by Pharoah et al. and the Collaborative Group on 
Hormonal Risk Factors in Breast Cancer carry great statistical power, meta-analyses 
are subject to a great deal of publication bias which may influence results. Despite 
this, it is particularly striking that Pharoah et al. found that having any affected FDR 
carried a RR of 1.9 (1.7-2.0) irrespective of age of the relative at diagnosis (149), since 
as many as 15-30% of women have been found to report a FH of breast cancer (151, 
152).   
 
 
Table 4. RR associated with different family histories according to meta-analysis by Pharoah 
et al. (149) 
Relative Affected RR (95% CI) 
Any relative (unspecified) 1.9 (1.7-2.0) 
FDR (mother, sister or daughter) 2.1 (2.0-2.2) 
Mother 2.0 (1.8-2.1) 
Sister 2.3 (2.1-2.4) 
Daughter 1.8 (1.6-2.0) 
Mother and sister 3.6 (2.5-5.0) 
SDR 1.5 (1.4-1.6) 
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Although a FH of breast cancer carries an increased risk of developing the 
disease, a positive FH has been found to be associated with smaller tumour size. This 
is thought to be due to a higher degree of vigilance and screening uptake in the 
population with a FH. They are therefore are more likely to be diagnosed whilst 
asymptomatic (152). This demonstrates a potential benefit in asymptomatic 
screening, as it allows earlier recognition of cancers in women who are at risk, 
potentially making the tumours more treatable. Since women with a FH are also 
diagnosed at a younger age (152) than those without, early screening in this 
population is likely to be of benefit. One study found no statistically significant 
difference in prognosis between women with and without a FH of breast cancer, 
however it was unclear whether or not the population studied had been screen-
detected or symptomatically detected (153). Mammographic screening in the UK has 
been found to be effective at decreasing the incidence of invasive cancers in those 
who have had DCIS screen detected and treated (154). Additionally, the cost 
effectiveness and incidence of negative effects, such as false positive results, has 
been found to be reduced in screening programmes which alter screening based on 
risk (155). Therefore, in order to achieve early detection of breast cancer in higher 
risk women, whilst avoiding unnecessary cost, identifying an appropriate risk cut off 
and FH that this corresponds to is desirable. 
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1.4. Risk Assessment Models 
1.4.1. Gail 
One of the first widely used models for breast cancer risk prediction using FH, was 
developed by Gail et al. in 1989 (156). They developed their model using case-control 
data from the Breast Cancer Detection Demonstration Project, a multi-centre breast 
cancer screening programme, which enrolled over 280,000 women for annual breast 
screening over a 5-year period (157). Major risk factors predictive of breast cancer 
which they identified in their cohort included late age at first childbirth, multiple 
previous benign breast biopsies, early menarche, and FH of breast cancer in an FDR. 
Gail et al. assumed a proportional hazards model – the addition of each individual 
risk factor has a multiplicative effect on the baseline hazard rate of breast cancer. 
The RR associated with each risk factor was calculated (Table 5), allowing an 
individual’s cumulative RR to be determined by multiplication of their RR for each 
covariate. They then provide a means to convert the individual’s RR, into % projected 
probability of developing breast cancer within the next 10, 20, or 30 years, 
dependent on their initial age at risk calculation. From their model, Gail et al. found 
consistent results with previous studies investigating the probability of developing 
breast cancer in women with a first degree FH (156, 158, 159).  
Validation of the Gail model using the Nurses’ Health Study (160) cohort found that 
overall, by comparing expected to observed breast cancer incidence, the Gail model over 
predicted breast cancer risk in up to 33% of women (161). Similarly, a smaller validation study 
found that the Gail model tended to over predict incidence, particularly in the younger age 
group (162). In their original publication, the authors allude to the possibility of 
overestimation in younger women. They reason that due to their study population 
undergoing annual mammography, the model best applies to this group, in which frequent 
screening identifies early cancers which may otherwise not be apparent until a later date. 
Therefore overestimation may occur in younger unscreened women (146). In agreement 
with this, validation studies which identified overestimation cited this as a possible cause 
(161, 162), and suggested that if this is a valid explanation, cancers in less frequently 
screened women may only be identified at a later disease stage (162). Concern has also been 
raised that the Gail model is limited in its incorporation of FH. Since it only accounts for first 
degree FH, it runs the risk of underestimating risk prediction in those with a FH of bilateral 
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breast cancer, early onset breast cancer, ovarian cancer, a second degree FH etc. A study by 
Euhus et al. compared the suitability of the Gail model compared to other risk prediction 
models in a cohort enriched for those with a FH of breast cancer (163). Of their cohort, 74% 
had a history of risk factors which would be expected to be problematic for the Gail model. 
It was thought to underestimate risk in 13%, due to its inability to account for elements of 
breast cancer FH other than incidence in FDRs (163). However, a systematic review which 
looked at 16 papers validating the Gail model was inconclusive regarding the calibration of 
the Gail model, stating that there was significant heterogeneity between papers and that the 
model did not appear to perform consistently well (164). 
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Table 5. RR associated with risk factors identified by Gail et al. 1989 (156) 
Risk Factor  Associated relative risk* 
Age at menarche (years) 
 
≥14 
12-13 
<12 
 
 
 
1.000 
1.099 
1.207 
Number of previous benign 
biopsies 
 
Age <50 years 
0 
1 
≥2 
 
Age ≥50 years 
0 
1 
≥2 
 
 
 
 
1.000 
1.698 
2.882 
 
 
1.000 
1.273 
1.620 
Age at first live birth 
(years)** 
 
 
<20 
 
 
 
20-24 
 
 
 
25-29 or nulliparous 
 
 
 
≥30 
Number of FDRs with a 
history of breast cancer** 
 
0 
1 
≥2 
 
0 
1 
≥2 
 
0 
1 
≥2 
 
0 
1 
≥2 
 
 
 
1.000 
2.607 
6.798 
 
1.244 
2.681 
5.775 
 
1.548 
2.756 
4.907 
 
1.927 
2.834 
4.169 
*As calculated by Gail et al. **RR for age at first live birth and number of FDRs with a history of breast cancer is expressed as a 
combination of the two factors. 
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1.4.2. Claus 
Another study to investigate risk factors in breast cancer using a proportional hazards 
model was carried out by Claus et al, using 4,730 breast cancer cases and 4,688 
controls from the Cancer and Steroid Hormone Study (165). However, unlike the 
analysis by Gail et al., it focussed on identifying risk factors relevant to women at a 
possible increased risk of breast cancer due to their FH. The risk factors investigated 
were bilaterality, history of benign breast disease, parity, number of livebirths and 
stillbirths, age at first pregnancy, age at onset of breast cancer, age at menarche, 
menopausal status, and age at last menstrual period. Whilst this information was 
gathered on cases and controls, it was incorporated into analysis of risk of breast 
cancer for mothers and sisters of the cases/controls. Also analysed was the age at 
onset of breast cancer for affected relatives. Breast cancer cases were then divided 
into groups, according to the number and type of relatives affected with breast 
cancer. The distribution of risk factors was assessed across varying FH patterns, to 
identify those which could be linked to a genetic predisposition to breast cancer. The 
results of their investigations showed that relatives of cases were more likely to go 
on to develop breast cancer than relatives of controls, with risk increasing as age at 
onset of the case decreased, and with increasing number of affected relatives. 
However, the distribution of the other risk factors investigated showed no relation 
with FH, suggested that they had a less pronounced impact on breast cancer risk in 
families with a possible genetic predisposition (165). Further analysis by goodness-
of-fit tests, to compare the observed age-specific risk with predicted risk under 
genetic models was carried out. They concluded that most of the incidence of breast 
cancer was likely to be due to non-genetic factors. However, a small subset of disease 
may be accounted for by an autosomal dominant allele segregating for increased 
susceptibility to breast cancer, particularly early-onset, for which they proposed 
BRCA1 as a possible candidate (166, 167). With the discovery of new high and 
intermediate risk genes, this single gene dominant model is largely disputed, 
however, this was the premise upon which the Claus model was developed.  
Claus et al. proceeded to use data from their analyses to develop a risk 
prediction tool for clinicians assessing breast cancer risk in a woman with a FH (167). 
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Using the type and number of affected relatives, and age at onset, they produced 
tables which could be used to estimate the age-specific, cumulative probability of 
developing breast cancer for women with a FH. The tables are classified according to 
breast cancer FH, including one FDR affected; one SDR affected; two FDRs affected; 
mother and maternal aunt affected; mother and paternal aunt affected; one 
maternal and one paternal SDR; and two SDRs (both maternal or both paternal) 
affected. All tables are stratified by age of the individual and affected relatives (167). 
In a separate publication, they also evaluated the impact having a first degree FH of 
ovarian cancer had on breast cancer risk under the assumption that transmission of 
both cancers could partly be explained by the same rare autosomal dominant allele. 
As a result, they produced similar cumulative probability tables according to FH. They 
found that a woman with a first-degree FH of ovarian cancer had a 50% greater 
chance of developing breast cancer than a woman with no FH of ovarian cancer (168).  
As with other models, the Claus tables are subject to limitations. They do not 
take into account information on non-hereditary risk factors, and can only 
accommodate for a FH of a maximum of two affected relatives, meaning they may 
underestimate risk in families with a bigger number of affected relatives. 
Additionally, they are based on risk estimates for women in the USA in the 1980s, 
however the incidence rates in North America and in Europe have varied from the 
cohort the tables were based on since their development (169). Indeed, Amir et al. 
found the original data gathered by Claus et al. (on which the tables are based) to 
underestimate breast cancer risk, with an expected to observed (E/O) ratio of 0.56 in 
a screened population with a FH of breast cancer (170). Additionally, another study 
comparing risk models found the Claus tables to estimate a lower risk of breast 
cancer compared to other prediction models. Despite this study comparing risk 
models in a very small number of patients, they concluded that the Claus model is 
likely to underestimate breast cancer risk (171). An extended version of the Claus 
tables, ‘Claus-Extended’ has been developed to incorporate ovarian cancer, bilateral 
breast cancer and multiple cases of breast cancer (172), and the risk estimates 
obtained from this have been found to be more in agreement with more modern risk 
assessment models (171).  
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1.4.3. BRCAPRO 
With the increase in understanding of the importance of BRCA1 and BRCA2 in breast 
cancer pathogenesis, and the identification of the genes themselves, testing women 
for these genes became a possibility in order to identify those at particularly high risk 
(86, 87, 173). In 1998, Parmigiani et al. developed a method for determining the 
probability that an individual carries a germ-line mutation in BRCA1 or BRCA2 on the 
basis of their FH, assuming an autosomal dominant mode of inheritance (174). In 
their model, they use Bayesian methodology to incorporate first and second-degree 
FH of breast and ovarian cancer into a calculation of probability. The prior probability 
of carrying a mutation in either BRCA1 or BRCA2 is determined using published 
mutation frequency and prevalence rates (175, 176). The estimated true probability 
of the individual being a carrier is then inferred. This is done by collecting information 
concerning each family member - whether they have been diagnosed with breast or 
ovarian cancer, the age at diagnosis, or, if cancer free, their current age or age at 
death - using published data by Shattuck-Eidens et al (177). Additionally, they 
incorporate the penetrance of BRCA1  and BRCA2, and allow for uncertainty in carrier 
rates and penetrance functions (174). This model was subsequently incorporated 
into the BRCA1/BRCA2 carrier probability tool ‘BRCAPRO’ (178).  
To assess the validity of BRCAPRO, a retrospective analysis of families in which 
at least one family member had been tested for both BRCA1 and BRCA2 was carried 
out by Berry et al. (179). They concluded BRCAPRO to be a highly sensitive counselling 
tool, with a mean carrier probability of 79% for those who test positive and 39% for 
those who test negative (p=10-10). However, the tool still missed approximately 15% 
of mutations (179). A similar value of 16% of mutations were missed by BRCAPRO in 
a study which used a carrier probability of 10% as a threshold for testing (180). This 
same study compared carrier probability prediction by BRCAPRO to the subjective 
estimates of risk counsellors. It concluded that while BRCAPRO was more specific and 
better able to discriminate between mutation carriers and non-carriers, input from 
risk counsellors was still required due to BRCAPROs incorrect negative assignment of 
mutation-carrying families (180). Another study found that while BRCAPRO 
performed well in ranking individuals by carrier probability, it may over predict 
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mutations, particularly in BRCA1 (181). Some of the inaccuracy of the original 
BRCAPRO model may be due to discrepancies in the published data relied upon to 
build it. Another drawback of the original model is that the authors chose to consider 
BRCA1 and BRCA2 and regard all other breast cancer as being sporadic. However, it 
is accepted that there are families for whom an increased risk of breast cancer is 
apparent, but the risk is not due to BRCA1 or BRCA2. Whilst the purpose of BRCAPRO 
is to estimate carrier probability of mutation in these genes, it is unable to estimate 
the risk of a woman with a FH developing breast cancer, despite carrier status.  
Since its original development, BRCAPRO has undergone several updates. It 
was updated to account for the impact that medical interventions may have on 
carrier probability, specifically the impact of mastectomy and oophorectomy (182, 
183), which minimise the risk of cancer in BRCA mutation carriers (184, 185). This 
was thought to improve accuracy versus other carrier probability prediction models 
that did not account for medical interventions within the family (182).  Additionally, 
breast tumour markers were added to the prediction model. Breast cancer in BRCA1 
carriers are more likely to be TNBCs, whereas BRCA2 carriers and non-carriers are 
more likely to have ER/PR positive breast cancer. HER2 receptor status as been found 
to be similar between BRCA1 and non-carrier breast cancer (186). Addition of these 
markers to BRCAPRO was found to improve discrimination between carriers and non-
carriers as well as between BRCA1 and BRCA2 (187). Various other improvements to 
the programme have been made, including incorporating ethnicity, CBC risk, and the 
ability to account for missing details such as age, with each addition claiming to 
further improve the tools predictive ability (183, 188). BRCAPRO has been 
incorporated into the BayesMendel R statistical package, designed to calculate risk 
prediction for different inherited cancers according to FH. As well as providing 
information on carrier probability, this package also gives as an output the future risk 
of breast and ovarian cancer for individuals (183, 189).  
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1.4.4. BOADICEA 
An analysis on a population derived from the Anglican Breast Cancer Study Group 
(93) with breast cancer onset before age 55 was carried out by Antoniou et al., to 
investigate different genetic models for breast and ovarian cancer, and their use as a 
risk prediction model (190). From the 1,484 breast cancer cases, information was 
gathered regarding FH, and DNA was extracted for analysis of BRCA1 and BRCA2 
mutations. In addition, another group of families were recruited; these contained 
two or more breast cancer cases with one diagnosed under age 50, and at least one 
family member tested for BRCA1 or BRCA2. Using the combined data from these 
groups, the analysis modelled the effects of BRCA1 and BRCA2 alongside either a 
hypothetical major breast cancer susceptibility locus ‘BRCA3’ or a polygenic effect. 
The model of best fit for determining breast cancer susceptibility was found to be the 
BRCA1/BRCA2 mutation, plus a multiplicative polygenetic effect which has the same 
effect regardless of BRCA1/2 mutation status (83).  
They found the risk of breast cancer for non-carriers over all polygenic effects 
to be 4.89%, however by percentile distribution, the lowest and highest percentiles 
had a 1.3% and 17.9% risk respectively. Taking into account superimposed polygenic 
effects, they estimated the cumulative breast cancer risk by age 70 for a BRCA1 
mutation carrier to be 35.26%, and for a BRCA2 mutation carrier 50.26%. On analysis 
of breast cancer risk in smaller age categories they found that the risk of breast 
cancer with a BRCA1 mutation increases till 40-49 years of age and then decreases. 
However, the risk of breast cancer for BRCA2 mutation carriers was found to 
continually increase with age. For ovarian cancer, the risk by age 70 was 26% for 
BRCA1 carriers and 9.1% for BRCA2 carriers, with non-mutation carriers having a 1% 
probability. No polygenic component was applied to ovarian cancer risk prediction 
(190).  
Using the results of their analysis, a model named ‘Breast and Ovarian 
Analysis of Disease Incidence and Carrier Estimation Algorithm’ (BOADICEA) was 
developed to determine mutation carrier probabilities and cancer risks based on FH 
of breast cancer; the model was then validated using the results of epidemiological 
studies (191) and later implemented into a web-based software programme. In 
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agreement with previous studies, BOADICEA shows increasing risk of breast cancer, 
and mutation carrier probability with an increasing number of relatives affected and 
decreasing age at diagnosis. To compare BOADICEA to empirical data, the age specific 
risk of breast cancer for a woman whose mother was affected at the same age was 
calculated. On comparison of the familial RR prediction made by BOADICEA with 
observed values from the meta-analysis by the Collaborative Group in Hormonal 
Factors in Breast Cancer (150), BOADICEA was found to have a correlation coefficient 
of 0.99. Another analysis however did not produce as strong a correlation; the age 
specific annual incidence, according to BOADICEA, in a sister of a breast cancer 
patient was calculated, and compared to an analysis by Peto and Mack (192). The 
correlation coefficient under these circumstances was found only to be 0.36. 
However, in both of these analyses, BOADICEA was found to have as good as, or 
better correlation with observed data than the Claus model or the original BRCAPRO 
model (Table 6) (191). Another study found BOADICEA to outperform BRCAPRO 
when looking at an Ashkenazi Jewish population, whereas the previously mentioned 
study found BRCAPRO to perform marginally better than BOADICEA in a non-
Ashkenazi Jewish population due to it being slightly better at predicting BRCA1/2 
mutations (193). 
 
 
Table 6. Correlation coefficients of BOADICEA, BRCAPRO and Claus 
 Intraclass correlation coefficient between predicted and observed 
dataa 
Age specific risk for a woman 
with a mother affected at her 
current ageb 
Age specific annual incidence for 
a sister of a women affected with 
breast cancerc 
BOADICEA 
BRCAPRO 
Claus 
0.99 
0.35 
0.99 
0.36 
0.07 
0.34 
aas reported by Antoniou et al (94) bObserved data from the Collaborative Group on Hormonal Factors in Breast 
Cancer (150). cObserved data from Peto and Mack (192) 
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BOADICEA has also been validated in international studies. An evaluation of 
BOADICEA in women with a FH of breast cancer in a Swedish population found that 
its ability to discriminate between BRCA mutation carriers and non-carriers was 
measured to an area under the receiver operating curve (AUROC) of 0.83 (194). The 
ratio of observed: expected (O:E) invasive cancer was 1.41, and the ability of the 
model to discriminate between those who developed invasive cancer and those who 
did not had an AUROC of 0.62, slightly better than chance for risk prediction. They 
concluded that, in a Swedish population, BOADICEA could be viably used as a tool for 
mutation carrier probability and lifetime breast cancer risk calculation (194). 
However, BOADIECA performed poorly at predicting the number of BRCA1 or BRCA2 
mutations specifically. This was thought to be due to a high number of BRCA1 
mutations in Sweden, due to a number of founder mutations. This reflects an 
inherent problem with all risk prediction models based on population studies, that 
the model may only be reliable within that population due to genetic, lifestyle and 
cultural differences across societies. Interestingly however, BOADICEA was found to 
fit well to data derived from high risk French-Canadian families, suggesting that the 
allele frequency of BRCA mutations in this group is similar to the UK data the model 
was based on (181). 
BOADICEA claims to be advantageous compared to other risk prediction 
models as it has the ability to include information on all available relatives rather 
than being limited to FDRs or SDRs, unlike other models (191). The nature of the 
model means that the addition of other relevant information is possible. It was 
updated to include the risk of male breast, prostate and pancreatic cancer (195). In 
addition to this, the breast and ovarian cancer incidences in mutation carriers were 
updated to be based on a larger number of families, in order to increase reliability. 
The polygenic component was also altered to be age dependent as opposed to 
constant across all ages (195). Tumour markers including ER, PR and HER2 status have 
also been incorporated (196). Independent validation of the updated model found it 
to be well-calibrated, with an expected to observed number of breast cancers of 0.92 
and an AUROC of 0.7 (197). Criticism of the BOADICEA model has implied that, as well 
as concern that it potentially underestimates the importance of ovarian cancer, the 
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model may be difficult for use by clinicians and therefore not suited for routine 
clinical practise (198). In addition, if polygenic mode of inheritance is assumed in a 
family, inclusion of relatives beyond FDRs and SDRs may be thought to be 
unnecessary due to the rate of decay in shared genetic factors beyond this. Despite 
this, BOADICEA is named as a recommended prediction model by the National 
Institute for Health and Care Excellence (NICE) guidelines on familial breast cancer 
(CG164) (79).  
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1.4.5. Tyrer-Cuzick/ ‘IBIS’ 
Using published data from a number of sources, Tyrer, Duffy and Cuzick developed a 
risk prediction model which incorporates genetic, familial and - like the Gail model - 
personal risk factors to predict absolute risk of breast cancer (199). They use a two 
locus, dominant genetic model, with one locus representative of both BRCA1 and 
BRCA2; the other locus was designed to represent additional unknown ‘low 
penetrance’ susceptibility genes which contribute to the higher risk of breast cancer 
in those with a FH. The probability of a BRCA mutation and subsequent breast cancer 
risk, given FH, was ascertained using data published by Ford et al. (200). The 
additional risk instated by the presence of the low penetrance susceptibility allele, 
was estimated using observed data from Anderson et al. via follow up of women with 
a FH of breast cancer (201). The age specific risk of breast cancer for each genotype 
was calculated, however in addition to this, the personal risk factors were added into 
the calculation. This included age at menarche, parity, age at first childbirth, age at 
menopause, atypical hyperplasia, LCIS, height and BMI. These risk factors were 
assumed to be multiplicative, and when superimposed on the risk derived from FH, 
give the final risk estimation from the Tyrer-Cuzick model.  
The Tyrer-Cuzick model was validated in a study using data from 1,933 
women who had attended for evaluation of their FH of breast cancer, over a mean 
follow up time of 5.27 years. The AUROC for the Tyrer-Cuzick model was found to be 
0.762, with an E/O ratio of 1.09, outperforming both the Claus and Gail model (170). 
Additionally, as it is a relatively newer model, the baseline risk estimates of breast 
cancer used are thought to be more accurate than that of the older risk models (171). 
With regard to BRCA mutations, a German study found Tyrer-Cuzick to successfully 
predict the total number of mutations in their cohort. However, it tended to over 
predict mutation rate in lower risk families (202). Several publications have found the 
Tyrer-Cuzick model to be outperformed by BOADICEA and BRCAPRO (203, 204). 
There has also been evidence to suggest that the model may be poor at 
discriminating between high and low risk women, and may over predict risk in some 
groups (205).  Whilst it is theoretically beneficial to include both personal and genetic 
risk factors for breast cancer risk prediction, in clinical practise, the addition of 
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multiple variables has the potential to lead to problems; should the necessary 
information (such as that of previous breast biopsies) be unavailable to the clinician, 
the result may be a less reliable due to missing information, resulting in an artificially 
low, or high risk estimation (170).  
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1.4.6. Manchester Scoring System (MSS) 
There appears to be a trade-off between the complexity and time-consuming nature 
of computer-based models vs. the over-simplicity of manual models. To address this, 
Evans et al. sought to develop a model for BRCA1/2 carrier prediction that was simple 
and efficient enough for use in busy clinical practice. At the same time, they aimed 
to avoid the short comings of other manual models, such as only taking into account 
a limited number of affected relatives (206). By analysis of the pedigree information, 
and mutation analysis of 422 families in North West England, they develop the 
Manchester Scoring System (MSS). This is an empirical scoring system, incorporating 
age-stratified FH of breast, male breast, ovarian, pancreatic and prostate cancer. 
Separate scoring was developed for BRCA1 and BRCA2 (Table 7). A score of >10 was 
stated to correlate to a 10% risk of finding a BRCA mutation in the family. Notably, in 
their validation of the original model, Evans et al. calculated AUROC statistics for the 
MSS and other models, and found MSS to outperform each of them, including 
computer model BRCAPRO (206). The MSS had an AUROC of 0.772 for combined 
BRCA1 and BRCA2 scores, compared to 0.596 for BRCAPRO in their validation group.  
 
Table 7. Original MSS. Adapted from Evans et al. 2004 (206). 
Cancer (age at diagnosis) BRCA1 BRCA2 
FBCA (<30) 
FBC (30-39) 
FBC (40-49) 
FBC (50-59) 
FBC (>59) 
MBCB (<60) 
MBC (>59) 
Ovarian cancer (<60) 
Ovarian cancer (>59) 
Pancreatic cancer (any age) 
Prostate cancer (<60) 
Prostate cancer (>59) 
6 
4 
3 
2 
1 
5 (if BRCA2 already tested) 
5 (if BRCA2 already tested) 
8 
5 
0 
0 
0 
5 
4 
3 
2 
1 
8 
5 
5 (if BRCA1 already tested) 
5 (if BRCA1 already tested) 
1 
2 
1 
AFemale Breast Cancer BMale Breast Cancer. Scores are summated for each cancer in a direct lineage; score >10 
is equivalent to a 10% chance of identifying a BRCA1/BRCA2 mutation on testing. 
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With evidence emerging of the impact of pathology information in relation to 
BRCA mutation status, the MSS was updated in 2009, in an attempt to further 
improve the sensitivity and specificity of the scoring system. No changes were made 
to BRCA2 scoring however information on grade, type and HR status of breast cancer, 
as well as ovarian cancer pathology was added to the scoring for BRCA1 (207).  Most 
notably, 4 scoring points were added for BRCA1 if a grade 3 TNBC was present, and 
4 points were to be deducted for BRCA1 if a HER2 positive breast cancer was present 
in the family. Despite these changes only being applicable to BRCA1, they found that 
the AUROC for combined BRCA1/2 score increased from 0.701 to 0.726 at a 10% 
threshold in the study population used to validate the updated model (207). Despite 
this improvement, it is important to note that pathology information for cancer in a 
pedigree may not be readily available to clinicians in cancer genetics services. Indeed, 
even in creation of the model it was stated that specific information on breast 
pathology was only available in 43% of cases (207).  
Independent validation for both versions of the MSS was carried out in a 
German population, with results similar to that of the original validation by Evans et 
al. The combined BRCA1/2 AUROC for the 2004 MSS was 0.77, with an improvement 
to 0.80 in the 2009 version. BRCA1 prediction was found to be significantly improved 
by use of the 2009 version, where pathology information was available. However, on 
further analysis of the German cohort, pancreatic cancer was not found to be 
significantly predictive for either BRCA1 or BRCA2, and the presence of female breast 
cancer >50 was found to be negatively predictive, in contrast to the MSS (208). 
Despite this, the authors concluded that the MSS provided a valuable and easy to use 
tool for identifying possible BRCA mutation families, with similar AUROC values to 
BOADICEA and BRCAPRO in studies of the same cohort (202, 208). In agreement, 
another study found the difference in AUROC statistics between MSS and BRCAPRO 
to be insufficiently different to claim superiority of one over the other (209). 
Interestingly, a study was carried out to assess threshold for MSS to achieve a 90% 
sensitivity in a Canadian population. They found that a score of 7.58 was necessary 
to achieve 90% sensitivity, much lower than the suggested score of 10 (203). 
Additionally, they found that at the conventional threshold, the MSS (AUROC 0.68) 
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was outperformed by BRCAPRO and BOADICEA (0.76 and 0.74 respectively) in 
combined BRCA1/2 identification. However, it performed better than Tyrer-Cuzick 
(AUROC 0.47). It is worth noting that the study found BOADICEA and BRCAPRO to be 
the most difficult to use, with the data required often difficult for patients to recall, 
whereas the MSS was found to be one of the most convenient to use in practice 
(203).  
Notable drawbacks of the MSS include the potential unavailability of 
pathological parameters, and failure to take into account full pedigree structure. It is 
also not suitable for use in populations with founder mutations. Nonetheless, 
alongside BOADICEA, it is suggested as a recommended scoring system for identifying 
women at risk of BRCA mutations in the NICE guidelines for management of familial 
breast cancer (79). Given its simplicity of use, the MSS is a popular choice in clinical 
practise. The Institute of Cancer Research (ICR) undertook extensive evaluation of 
the criteria which would meet the 10% carrier probability threshold suggested by 
NICE (79) for BRCA mutation testing. Based on this, they produced a modified version 
of the MSS (MMSS) at which a score of 17 or greater warrants testing for BRCA1 and 
BRCA2 mutations (see Table 8) (79, 210).  
 
Table 8. ICR MSS. Scoring system is combined for BRCA1 and BRCA2. 
Manchester Score 
Cancer (age at diagnosis in years) Score 
FBCA (<30) 
FBC (30-29) 
FBC (40-49) 
FBC (50-59) 
FBC (>59) 
MBCB (<60) 
MBC (>59) 
Ovarian cancer (<60) 
Ovarian cancer (>59) 
Pancreatic cancer (any age) 
Prostate cancer (<60) 
Prostate cancer (>59) 
11 
8 
6 
4 
2 
13 
10 
13 
10 
1 
2 
1 
AFemale Breast Cancer. BMale Breast Cancer. 
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1.4.7. National Institute for Health and Care Excellence 
NICE, established in 1999, is a UK organisation which develops evidence-based 
guidance for healthcare. Although health care professionals working in the UK 
National Health Service (NHS) are not legally obliged to follow the guidance provided 
by NICE, they are actively encouraged to do so. This makes NICE recommendations 
an important influence on clinical practice in the NHS. The current NICE guidance on 
classification and management of people with a FH of breast cancer (CG164) was 
published in June 2013 (updated August 2015) (79). The guideline stratifies women 
with a FH of breast cancer, according to their risk, both for women with and without 
a personal history. Dependent on this, they suggest appropriate surveillance regimes 
for these women. Recommendations are offered for primary care workers as to the 
appropriateness of referral to secondary care and specialist genetics services in a 
women presenting with concerns about her breast cancer risk. The clinical evidence 
review used to build the guideline is publicly available via the NICE website (211). To 
address the best method of predicting individual risk of developing breast cancer in 
a woman with a FH they reviewed literature assessing and comparing risk models 
including Gail, Claus, Ford, and BRCAPRO. They conclude that existing computer 
models may underestimate risk through FH, and the degree of correlation between 
risk models is poor. Further review was carried out to address the optimal method of 
calculating carrier probability, comparing the sensitivity and specificity of a range of 
models including BRCAPRO, BOADICEA, Tyrer-Cuzick, IBIS and the MSS.  They found 
consistent evidence that all of the carrier probability prediction models perform 
better than chance, however BOADICEA was the best calibrated model. It is 
unsurprising therefore, that CG164 recommends BOADICEA as an acceptable method 
of carrier probability calculation. In addition to this, the MSS is also recommended, 
perhaps as the clinical evidence review acknowledges it may be more practical for 
use by clinicians (211). The threshold for mutation testing is set at greater than 10% 
risk of being a carrier. Aside from carrier probability, BOADICEA can provide a 10-
year, or lifetime risk estimation for developing breast cancer, unlike MSS. NICE 
stratify women into low/population, moderate and high risk based on percentage 
absolute lifetime risk and percentage 10-year absolute risk from age 40, as 
demonstrated in Table 9. In the previous NICE guideline for familial breast cancer 
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(CG041) (212), criteria equivalent to these risk categories were given, based on data 
from Claus et al. and the Collaborative Group on Hormonal Factors in Breast Cancer 
(150, 167). These criteria, demonstrated in Table 10, are still present in the updated 
guideline CG164, and are used in clinical practise for risk stratification, as well as 
having been used in research in this format by Evans et al. (213).  
 
 
 
 
 
Table 9. Breast cancer risk category by lifetime risk and risk between ages 40-50. (Adapted 
from NICE guideline CG164 (79)) 
 Breast cancer risk category 
 
Low risk (population 
risk) 
Moderate risk High riskA 
Lifetime risk (from 
age 20) 
≤17% 
>17% but 
<30% 
≥30% 
Risk between ages 
40-50 
<3% 3-8% >8% 
AIncluding BRCA1 and BRCA2 mutation carriers and those with other conditions/mutations known to 
predispose to breast cancer. 
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Table 10. Criteria for categorisation into moderate or high risk category by FH alone 
according to NICE CG164 (79). 
NICE moderate risk criteria - One FDR diagnosed with breast cancer at younger than age 40 
years  
or  
- Two first-degree or SDRs diagnosed with breast cancer at an 
average age of older than 50 years  
or  
- Three first-degree or SDRs diagnosed with breast cancer at an 
average age of older than 60 years 
NICE high risk criteria At least the following female breast cancers only in the family:  
- Two first-degree or SDRs diagnosed with breast cancer at 
younger than an average age of 50 years (at least one must be a 
FDR)  
or  
- Three first-degree or SDRs diagnosed with breast cancer at 
younger than an average age of 60 years (at least one must be a 
FDR )  
or  
- Four relatives diagnosed with breast cancer at any age (at least 
one must be a FDR)  
or 
Families containing one relative with ovarian cancer at any age 
and, on the same side of the family:  
- One FDR (including the relative with ovarian cancer) or SDR 
diagnosed with breast cancer at younger than age 50 years.  
or  
- Two first-degree or SDRs diagnosed with breast cancer at 
younger than an average age of 60 years.  
or 
 - Another ovarian cancer at any age.   
 or 
Families affected by bilateral cancer (each breast cancer has the 
same count value as one relative):  
- One FDR with cancer diagnosed in both breasts at younger than 
an average age 50 years.  
or  
- One first-degree or SDR diagnosed with bilateral cancer and 
one first or SDR diagnosed with breast cancer at younger than 
an average age 60 years.  
or 
Families containing male breast cancer at any age and, on the 
same side of the family, at least:  
- One first-degree or SDR diagnosed with breast cancer at 
younger than age 50 years.  
or  
- Two first-degree or SDRs diagnosed with breast cancer at 
younger than an average age of 60 years. 
56 
 
 
 
 
NICE recommend additional screening for women at moderate and high risk, 
as seen in Table 11, in the form of mammographic surveillance or MRI. This additional 
screening is of particular relevance for younger women who are not yet of the age to 
be enrolled in the NBSP. A study of 62 breast cancers in screened and 1,108 non-
screening women <50 years was carried out to compare survival outcomes The 
screened women had a FH of cancer and were screened at 12-18 month intervals. It 
demonstrated that cancers picked up on screening were significantly more likely to 
be smaller and significantly less likely to be invasive or to have metastasized to lymph 
nodes, despite similarity in cancer grade between the two groups. As a result, there 
was a significantly lower proportion of recurrences and breast cancer deaths in the 
screened population (p=0.008) (214), suggesting a benefit in screening younger 
women with a FH of cancer. A similar but much larger study of 6,710 screened and  
106,971 unscreened women <50 years, also reported benefit of mammograms, 
reporting significantly lower 10-year mortality rates (p=0.022), and in addition, 
smaller tumours of a more favourable grade, which were less likely to have 
metastasised to lymph nodes (215). 
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Table 11. Recommended screening and intervention by risk category according to NICE 
CG164 (79). 
The interventions here pertain to women with no personal history of cancer not yet eligible for inclusion in the NBSP and those 
with no mutation and at risk of or known BRCA mutation. Other recommendations are made in NICE CG164 for women with a 
personal history, of the age group eligible for the NHS breast screening programme and with other conditions/mutations 
conferring an increased risk of breast cancer. ANICE recommends that BRCA carrier probability be assessed using BOADICEA or 
MSS. 
 
Despite there being no formal FH screening for all women with a FH of breast 
cancer, Evans et al. concluded it is possible that up to 5-6% of women age 46-49 years 
in a UK cohort may be eligible for additional screening according to the algorithm 
provided by NICE (213). It is not, however, clear if the same proportion would be 
eligible if the suggested alternative risk model, BOADICEA, were used to determine 
10-year risk. Despite this, the proportion of women who would benefit from 
additional screening before the age of 50 has the potential to be significant. Referral 
for risk estimation depends on women seeking advice regarding their risk, or on 
general practitioners suggesting referral for patients whom they know have a FH. Of 
these women, identifying those who are indeed at increased risk is important. Any 
additional screening should have optimal sensitivity and specificity, to detect as many 
Screening/Intervention Moderate Risk High Risk (including BRCA mutation carriers) 
Mammographic 
surveillance 
Offer annually to women: 
- aged 40–49 years  
 
Consider annually for 
women: 
-aged 50-59 years 
Offer annually to women: 
- Aged 40–59 years at high risk of breast cancer but with a 30% 
or lower probability of being a BRCA or TP53 carrier 
- Aged 40–59 years who have not had genetic testing but have 
a greater than 30% probability of being a  BRCA carrierA 
- Aged 40–69 years with a known BRCA1 or BRCA2 mutation 
 
Offer as part of the population screening programme to 
women: 
- Aged 70 years and over with a known BRCA1 or BRCA2 
mutation 
 
Consider annually for women: 
- Aged 30–39 years at high risk of breast cancer but with a 30% 
or lower probability of being a BRCA carrierA 
- Aged 30–39 years who have not had genetic testing but have 
a greater than 30% probability of being a BRCA carrierA 
- Aged 30–39 years with a known BRCA1 or BRCA2 mutation 
MRI surveillance Do not offer at any age Offer annually to women: 
- Aged 30–49 years who have not had genetic testing but have 
a greater than 30% probability of being a BRCA carrierA 
- Aged 30–49 years with a known BRCA1 or BRCA2 mutation 
Risk-reducing 
mastectomy 
Do not offer  - Should be raised as a risk-reducing strategy option with all 
women at high risk 
- Women considering this should have specialist genetic 
counselling 
Risk-reducing 
oophorectomy 
Do not offer - Information should be provided as a potential risk-reducing 
strategy to women at high risk 
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cancers, as early as possible, whilst remaining cost effective. Accurate risk 
stratification not only allows patients to be offered beneficial screening, but allows 
them to make informed decisions about interventions such as risk-reducing surgery, 
should they be eligible. However, Evans et al. found the sensitivity of the NICE 
algorithm for moderate risk women to be 10.8% (95% CI, 3.5-23.4%), and for high risk 
2.7% (0.3-11.5%). Specificity was 97.1% (96.6-97.6%) for moderate risk and 99.3% 
(99.1-99.5%) for high risk. The positive predictive value (PPV) for NICE moderate risk 
was 3.1%, and high risk 3.3% (213). Together, of the 37 cancers identified in the study, 
only 5 were accounted for in the moderate or high risk category. The poor sensitivity 
in this particular cohort (n=4,360) would suggest a need for re-evaluation of the NICE 
algorithm. Indeed, the study found that sensitivity increased to 54.1% if third degree 
relatives with breast cancer were included in FH, which NICE does not currently take 
into consideration (213). However, it is worth noting firstly, that the confidence 
intervals for sensitivity analysis in this project are wide, potentially due to the fact 
that just 14.8% of the cohort (649/4,360) had a family history of breast cancer in at 
least one SDR, and 9.4% (410/4,360) had a family history of at least one FDR. This 
reflects the fact that the cohort used in this study were selected from women invited 
for routine screening, rather than using a cohort enriched for women with a family 
history of breast cancer. It therefore perhaps doesn’t provide the most relevant 
statistical estimates of the NICE guidelines. Nevertheless, the cost-effectiveness of 
additional screening for women deemed at sufficiently increased risk is important - 
avoiding over-screening of women should be balanced with achieving an acceptable 
level of sensitivity.  
Of course, NICE CG164 is a guideline, and clinicians in specialist genetic 
centres will use their own clinical judgement, taking other factors into consideration 
when assessing a patient’s individual risk of breast cancer. Nonetheless, the 
sensitivities calculated by Evans et al. are perhaps lower than would be expected for 
an assessment tool which is used nation-wide. For this reason, further research into 
the efficacy of the NICE algorithm in a separate cohort is useful, particularly as there 
was such a narrow age range used in the previously mentioned study.  
 
59 
 
 
 
 
 
1.5. Basis of this Research  
It is clear from reviewing the literature that there is significant demand for a risk 
model for familial breast cancer which is both accurate, and simple to use in a clinical 
setting. Ultimately, this should  inform clinical management of these patients, 
including screening. With any screening program, its sensitivity and specificity are 
important to ensure its cost-effectiveness.  To our knowledge, when this study 
commenced, there had be no research attempting to validate the effectiveness of 
the NICE guidelines, used UK wide, in a cohort of women who have attended clinical 
genetics regarding their risk. In Tayside, there are the means to retrospectively 
analyse a large group of women who have attended clinical genetics and determine 
their NICE risk category and outcome over a period of time.   This is a pilot study 
aiming to assess the effectiveness of NICE familial breast cancer guidelines in a 
Tayside cohort, and demonstrate methodology which could be expanded to other 
centres.
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2. Aims and Objectives 
2.1 Aims 
The aims of this study are: 
 To investigate how effective the NICE risk guidelines for familial breast cancer 
are at identifying women at an increased risk of breast cancer. 
 To investigate the relative and absolute risk in a Tayside cohort of developing 
breast cancer depending on NICE risk category. 
 To identify which elements of FH appear to be related to risk of invasive 
breast cancer. 
 To investigate whether NICE guidelines identify women who will benefit from 
increased screening before entering into the NBSP i.e. those who develop 
breast cancer prior to age 50. 
2.2. Objectives 
To achieve the above aims, the following objectives will be carried out: 
 A cohort of patient who have attended clinical genetics regarding risk of 
breast cancer will be identified and assigned a NICE risk category. Women 
who subsequently developed breast cancer will be identified. 
 Based on the collected information, risk of breast cancer for women in each 
NICE risk category will be calculated.  
 Statistical analysis will be performed to assess if any particular element of FH 
is significantly related to breast cancer risk.  
 Age specific statistical analysis will be carried out to assess if women in higher 
NICE risk categories are in fact at significantly increased risk of breast cancer 
prior to age 50, at the beginning of the NBSP. 
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3. Methods 
3.1. Approvals and data collection 
3.1.1. Approvals 
NHS Tayside Caldicott approval was granted to extract data pertaining to up to 1,500 
women who attended the clinical genetics department from 2000-2010. This was to 
assess their risk of breast cancer according to NICE guidelines, and identify women 
who then developed breast cancer. In addition, permission was given to identify 
women within Tayside, but outwith the cohort, who developed breast cancer under 
age 50. Please see appendix 1 for a copy of this approval (Caldicott reference number 
CSAppLL2349). Ethics committee approval was not necessary for this study as there 
was no patient contact.  
3.1.2. Inclusion/Exclusion Criteria 
This was a retrospective, longitudinal cohort study consisting of patients referred for 
genetic counselling regarding FH of breast cancer from 2000-2010. Inclusion criteria 
included being a female age less than 50 at age of initial consultation, seen between 
2000-2010, with no personal history of breast and/or ovarian cancer, and sufficient 
FH information available pertaining to the time of initial consultation. Patients were 
excluded if there was not sufficient recorded FH information or they did not attend 
their appointment.  
3.1.3. Clinical Data Collection and Handling 
Patients who met inclusion criteria were identified, and their FH information was 
collected from clinical genetics electronic and paper records at Ninewells Hospital 
and Medical School, NHS Tayside. The data was extracted from a combination of FH 
questionnaires, clinical pedigrees, clinical notes and official correspondence from or 
to the clinical genetics department. A list of clinical variables collected is provided in 
Appendix 2. Where possible, cancers reported within the family were confirmed by 
information in the clinical notes from the Information Services Division Scotland. 
After initial risk assessment according to NICE guidelines, women who were BRCA 
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mutation carriers were identified, again through electronic records in clinical 
genetics.  
 Women within the cohort who went on to develop breast cancer were 
identified through biopsy results from the Labcentre database within the pathology 
department at Ninewells hospital. The subtype of breast cancer was recorded, as well 
as date of biopsy diagnosis through the Integrated Clinical Environment data (ICE).  
The Labcentre database was also used to identify all women who were 
diagnosed with breast cancer from 2000-2016, within NHS Tayside, who were under 
the age of 50 at the time of diagnosis. The CHI numbers for these patients were then 
used to interrogate the Ninewells clinical genetics database, to identify which of 
them had been seen in clinical genetics at any time. This information was used to 
establish the proportion of women developing breast cancer <50 years from 2000-
2016 being detected by the FH screening programme.  
 All patient identifiable information was stored within the Ninewells Hospital 
computer network in NHS Tayside. To allow use of the data outwith this setting, it 
was pseudoanonymised by assignment of a study identification number, and stored 
within a password protected file, on a password protected laptop. Corresponding CHI 
and Study ID remained stored in the clinical genetics storage drive within the NHS 
Tayside network, separate from the pseudoanonymised information.  
3.2. Assigning NICE risk category  
All women were risk categorised de novo into low, moderate and high risk based on 
their FH information as outlined in the NICE guidelines on familial breast cancer (79). 
They were further assigned a sub-category based on the criteria presented in Table 
10 (section 1.4.7.). A woman with bilateral breast cancer counted as two individual 
breast cancer diagnoses, as suggested by NICE. Where a women had a FH of ovarian 
or male breast cancer and was therefore possibly eligible for more than one high risk 
category, category 13 was prioritised over category 12 which was prioritised over 
category 11. So, for example, a woman with a FH of bilateral breast cancer and male 
breast cancer would be categorised into category 13. Although clinically, NICE 
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guidance would be used alongside the clinician’s judgement, for the purposes of 
research, the guidelines were interpreted in a literal sense.  
3.3. Manchester Score Calculations 
A Modified Manchester Score (MMS) was calculated for each patient using the ICR 
MMSS (210). This was chosen as a scoring system that is used by clinicians in Tayside 
and that doesn’t require extensive information about familial cancers. This can be 
found in Table 8 (section 1.4.6.). For example, a patient with one relative diagnosed 
with ovarian cancer <60 years old and two female relatives diagnosed with breast 
cancer between 50-59 years old would have a MMS of 13+4+4=21. The cut-off used 
clinically for suggested BRCA testing with the ICR MMSS is 17. The MMS also has the 
benefit of women who are related to a patient through a male relative being moved 
up one degree of relation – therefore unaffected intervening males are accounted 
for. Full information on how the MMS is applied can be found at www.icr.ac.uk (216).  
3.4. BRCA mutation carriers 
BRCA mutations present within the cohort were also identified as described in 
section 3.1.3. Where a BRCA mutation carrier was identified for whom their FH would 
have placed them in a moderate/low risk group, their risk was reassigned as high risk 
to best reflect how they would be managed clinically. In addition, women from a 
family with a known BRCA mutation who themselves tested negative were 
reassigned as low risk. 
3.5. Invasive breast cancers and in situ carcinoma  
Women who developed neoplastic breast disease were identified as described in 
section 3.1.3. There were women who were diagnosed with invasive breast cancer 
as well as in situ neoplastic disease. Limited analysis was performed on the in situ 
disease. DCIS and LCIS are widely regarded as cancer precursor lesions, however the 
natural course of these lesions is poorly understood (217). Although women 
identified with these lesions are usually offered surgical and systemic treatment, the 
risk factors determining progression to invasive breast cancer, and the benefit of 
treatment on mortality outcomes is uncertain (218). Only 20-50% of DCIS, which 
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accounts for the majority of in situ lesions will ever progress to invasive disease (219). 
If the aim of screening is to reduce mortality outcomes due to breast cancer, the 
significance of in situ disease is difficult to determine. Due to this uncertainty, very 
limited analysis was performed regarding in situ disease. The focus of this study was 
primarily on risk of invasive breast cancer.  
3.6. Statistical Analysis 
RR, OR, PPV, negative predictive value (NPV) and incidence were calculated using 
standard methods (220). The low risk group was used as the reference group. SPSS 
statistics software (221) was used for all other analyses of the data gathered in this 
study and was also used to generate charts and figures. For analyses generating a 
significance value (p-value), the conventional cut off of p=<0.05 was used to 
determine significance.  
3.6.1. Percentage 10-year absolute risk calculation 
A % 10-year absolute risk for women within the cohort at each NICE risk category, 
and also for BRCA mutation carriers was calculated. This was performed for risk 
between age 40-49 years and 50-59 years inclusive. The number of years follow up 
between those age ranges for all women in the cohort was summated (referred to as 
woman years of follow up). The % incidence of breast cancer per woman year of 
follow up, either between 40-49 or 50-59 was then calculated, and multiplied by 10 
to give the approximate 10-year risk for that age range. % 5-year absolute risk would 
have been desirable as underlying population breast cancer risk will increase even in 
this short time period, however this was limited by cohort size and the number of 
cancers which occurred. 
3.6.2. Chi-square test, Fischer’s exact test, independent T-test and one-way 
analysis of variance  
Categorical variables, such as development of cancer (yes or no) and affected mother 
(yes or no) were compared. Where there were sufficient numbers in the analysis, the 
Pearson Chi-square test was used, reporting asymptotic p-value (2-sided). Otherwise 
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a Fischer’s exact test was used (p-value (2-sided)). The categorical variables analysed 
against development of cancer are shown in Table 12.  
For the comparison of a continuous variable and a binomial categorical 
variable, and independent T-test was used. This was subject to Levene’s test of 
variance to ensure normal distribution of data. Where there was a significant 
difference in Levene’s test (i.e. p=<0.05), the reported p-value (2-sided) for the 
independent T-test does not assume equal variance of the continuous data. An 
example is the analysis of mean age of relative at diagnosis (continuous) and 
development of breast cancer (yes or no). The continuous variables analysed are 
shown in Table 12. These variables, along with the categorical variables were 
selected as broad descriptors of the cancer FH, representing similar family structures 
described the NICE guidance. 
Where the means of a continuous variable were to be analysed for 
significance across a categorical variable with more than two groups (in this case, the 
three NICE risk categories), a one-way analysis of variance (ANOVA) was performed.  
 
Table 12. Categorical and continuous variables selected for statistical analysis 
Categorical variables analysed in Chi-
square analysis 
Continuous variables analysed in 
Independent T-test analysis 
1 affected FDR or SDR 
≥ 2 affected FDRs or SDRs 
≥ 3 affected FDRs or SDRs 
≥ 4 affected FDRs or SDRs 
Mother affected with breast cancer 
Sister affected with breast cancer 
Average age of relatives at diagnosis <40 
Average age of relatives at diagnosis <50 
Average age of relatives at diagnosis <60 
Incidence of ovarian cancer in family 
Incidence of bilateral breast cancer in 
family 
Incidence of male breast cancer in family 
Number of FDRs and SDRs affected in total 
Number of FDRs affected 
Average age of FDRs at diagnosis 
Number of SDRs affected 
Average age of SDRs at diagnosis 
Average age of all relatives at diagnosis 
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3.6.3. Kaplan-Meier Survival Analysis  
Kaplan-Meier (KM) Survival Analysis was used to assess breast cancer development 
across different NICE risk categories and age ranges including total, <39 years, 40-49 
years and 50-59 years of age. Time was measured in number of years follow up within 
that age range, and patients were censored at their completed time of follow up, or 
at breast cancer diagnosis. Separate analyses were performed to compare each NICE 
risk category. The high risk group were analysed both including and excluding BRCA 
carriers from the analysis as they are at known very high risk. KM survival curves were 
generated for selected sets of results.  
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3.7. Sample size calculation 
It was important to address whether the study was adequately powered to assess 
the NICE guidelines ability to identify women at increased risk before age 50. To 
address this, a retrospective sample size calculation was performed. The sample size 
calculation was performed using methodology described by Jones, Carley and 
Harrison (222) for studies reporting categorical data i.e. diagnosis of invasive breast 
cancer. The following assumptions are made: 
 The null hypothesis is that NICE guidelines do not effectively distinguish 
women at population, moderate (3-8%) and high (>8%) risk of breast cancer 
between the ages of 40-49.  
 Type 1 error is to be avoided at the conventional level of 0.05 (pα). 
 Type 2 error is to be avoided at the conventional level of 0.8 (pβ). 
 The clinically important difference to be detected is the difference in % 
absolute risk from age 40-49 years, proposed by NICE, between the risk 
categories. 
The following risk levels were used: 
 Population risk was calculated using female invasive breast cancer rates per 
100,000 reported for the year 2014 for the south east of Scotland. This data 
is available for download from http://www.isdscotland.org/ (223). The rate 
per 100,000 women per year for ages 40-44 and 45-49 was 114.4 and 201.6 
respectively. This equates to % per woman per year risk of 0.114% for each 
year between age 40-44 and 0.2016% from age 45-49. Therefore, for one 
women the cumulative % risk from age 40-44 is 0.114 x 5 = 0.572%, and from 
45-49 is 0.2016 x 5 = 1.008%. The % absolute risk between age 40-49 for a 
woman in the population of south east Scotland is therefore 0.572 + 1.008% 
= 1.580%. The population risk between ages 40-49 years used in the sample 
size calculation was therefore 1.580%.  
 NICE states that a moderate risk woman has an absolute risk of 3-8% between 
ages 40-49. 3% was used as the risk for the sample size calculation so that the 
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sample size needed to detect the smallest possible difference could be 
calculated.  
 NICE guidance suggests that high risk woman have an absolute risk of ≥8% 
between ages 40-49. Therefore, 8% was used as the risk for the sample size 
calculation. Again, this was to ensure that the sample size calculated was 
adequate to detect the smallest possible risk difference between the groups.  
 
Initially the standardised difference between the proportions of expected breast 
cancers is calculated, as follows: 
 
Standardised difference= p1-p2/√(P (1- P) )                
p1 = risk of breast cancer in higher risk group 
p2 = risk of breast cancer in lower risk group 
P= (p1+ p2)/2 
 
The authors of the methodology then suggest that the standardized risk is 
used to work out the required sample size using a nomogram developed by Gore and 
Altman (224). This can be seen in Figure 2. A line is drawn from the calculated 
standard difference across to the designated pβ – in this case 0.8 – and the required 
sample size required at a pα level of 0.05 can be deduced. 
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When the study commenced it was unknown what the number of available patients 
would be, therefore not possible to ascertain whether the study would be 
appropriately powered until completion. The calculation was therefore performed 
retrospectively to determine the sample size required to definitively validate the 
NICE guidelines ability to identify women at low/population, moderate or high risk of 
breast cancer. The result of this are as follows.  
 
 
 
 
Figure 2. Nomogram developed by Gore and Altman for sample size calculation (224) Image 
from an article by Jones, Carley and Harrison (222) 
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3.7.1. Sample size required to detect clinically significant difference between 
population and moderate risk group 
Standardised difference= p1-p2/√(P (1- P) )                
p1 = minimum risk of breast cancer between age 40-49 years at NICE moderate risk 
threshold = 3% or 0.03 
p2 = population risk of breast cancer between age 40-49 years = 1.580% or 0.0158 
P= (p1+ p2)/2 
𝑃 =
(0.03 + 0.0158)
2
= 0.0229 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.03 − 0.0158
√0.0229(1 − 0.0229)
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.0142
√0.0224
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.0142
0.14967
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 0.095 
 
Using the nomogram developed by Gore and Altman (224) (see Figure 2, section 3.7), 
a standardized difference of 0.095 with a pβ of 0.8 and pα of 0.05 requires a 
population sample size of 4,000 subjects to give adequate power to the study. 4,000 
patients with follow up between ages 40-49 would therefore be required to assess 
whether or not NICE guidelines identify women with at least a 3% risk of breast 
cancer between ages 40-49.  There were 425 low, and 413 moderate risk (totalling 
838) women with follow up between the ages of 40-49 in the study cohort, meaning 
this study is likely to be significantly underpowered to detect this clinical difference.   
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3.7.2. Sample size required to detect clinically significant difference between 
population and high risk group 
 
Standardised difference= p1-p2/√(P (1- P) )                
p1 = minimum risk of breast cancer between age 40-49 years at NICE high risk 
threshold = 8% or 0.08 
p2 = population risk of breast cancer between age 40-49 years = 1.580% or 0.0158 
P= (p1+ p2)/2 
𝑃 =
(0.08 + 0.0158)
2
= 0.0958 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.08 − 0.0158
√0.0958(1 − 0.0958)
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.0642
√0.0866
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.0642
0.29428
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 0.218 
 
Using the nomogram developed, a standardized difference of 0.218 with a pβ of 0.8 
and pα of 0.05, requires a population sample size of approximately 800 subjects to 
give adequate power to the study. 800 patients, with follow up between ages 40-49 
would therefore be required to assess whether or not NICE guidelines identify 
women with at least an 8% risk of breast cancer, between ages 40-49. There are 425 
low, and 294 high risk (totalling 719) women with follow up between the ages of 40-
49 in this cohort, meaning this study is likely to be slightly underpowered to detect 
this clinical difference. 
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3.7.3. Sample size required to detect clinically significant difference between 
moderate and high risk group 
 
Standardised difference= p1-p2/√(P (1- P) )                
p1 = minimum risk of breast cancer between age 40-49 years at NICE moderate risk 
threshold = 3% or 0.03 
p2 = minimum risk of breast cancer between age 40-49 years at NICE high risk 
threshold = 8% or 0.08 
P= (p1+ p2)/2 
𝑃 =
(0.08 + 0.03)
2
= 0.055 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.08 − 0.03
√0.055(1 − 0.055)
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.05
√0.0520
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
0.05
0.22804
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 0.219 
 
Using the nomogram, a standardized difference of 0.219 with a pβ of 0.8 and pα of 
0.05, requires a population sample size of approximately 800 subjects to give 
adequate power to the study. 800 patients with follow up between ages 40-49 would 
therefore be required to assess whether or not NICE guidelines distinguish women at 
3%, and women at 8% risk of breast cancer between ages 40-49. There are 413 
moderate and 294 high risk (totalling 707) women with follow up between the ages 
of 40-49 in this cohort, meaning this study is likely to be slightly underpowered to 
detect this clinical difference.
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4.0 Results 
4.1. Descriptive Statistics 
4.1.1. Cohort Characteristics  
In total, 2,009 patient records were screened for eligibility in the study. 1,566 of these 
met the criteria of being a female under the age of 50, unaffected with breast cancer, 
and referred to clinical genetics regarding FH of breast cancer from 2000-2010. After 
this, 115 patient records were excluded as they did not attend their appointment. A 
further 38 were excluded as not enough information was present - FH information 
was regarded as suitable for use when acceptably detailed for at least 1st and 2nd 
degree relatives. Another 4 were excluded as they had been previously affected with 
ovarian cancer. Therefore, in total, 1,409 patients were eligible for inclusion in the 
study. The age at presentation to clinical genetics ranged from 16-49 years. The mean 
age was 36.75 (standard deviation (SD) ±7.855) years and the median was 38 years. 
All patients were referred to clinical genetics with a FH of breast cancer and/or 
ovarian cancer but without a personal history. The total number of years follow up 
time for all patients was 15,414 patient years. The mean number of years follow up 
was 10.935 (±3.3311) years with a median of 10.960 years.  
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4.1.2. Family history structures and cancer history 
The variability in FH structure recorded from clinical notes is recorded in Table 13.  
 
 
Table 13. Information regarding number of relatives within families in the cohort 
 Mean 
Range 
Minimum Maximum 
Sisters 1.01 0 8 
Daughters 0.54 0 5 
Maternal aunts 1.40 0 9 
Paternal aunts 1.04 0 10 
Maternal half-
sisters 
0.03 0 5 
Paternal half-
sisters 
0.02 0 5 
Nieces 0.07 0 7 
 
 
Table 14 gives an overview of the number and percentage of the cohort who had 
reported a history of breast cancer in various family members. The most common 
relative reported to have been affected was the mother (60.6%) followed by the 
maternal aunt (24.6%). 21.8% of the cohort had no history of breast cancer in a FDR, 
and 47.5% had no history of breast cancer in a SDR. Whilst 47.1% presented with only 
1 affected relative, 48.8% presented with 2 or more relatives affected with breast 
cancer. 3.9% reported no FH of breast cancer, presenting instead with a FH of ovarian 
cancer. 10.8% of the cohort had a FH of ovarian cancer, and 1.8% had a history of 
breast cancer in a male relative. More detailed information regarding the frequency 
of responses can be found in Table 15. 
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Table 14. An overview of the reported cancer incidence in relatives of those within the 
cohort 
 
Incidence in relative amongst 
cohort (N=1409) 
N % of cohort 
Breast cancer in Mother 854 60.6 
Breast cancer in Sister 279 19.8 
Breast cancer in Daughter 2 0.1 
Breast cancer in Maternal aunt 346 24.6 
Breast cancer in Paternal aunt 153 10.9 
Breast cancer in Maternal grandmother 274 19.4 
Breast cancer in Paternal grandmother 113 8.0 
Breast cancer in Maternal half-sister 5 0.4 
Breast cancer in Paternal half-sister 5 0.4 
Breast cancer in Niece 1 0.1 
Breast cancer in Male relative 26 1.8 
Ovarian cancer in any relative 152 10.8 
Bilateral breast cancer in 1st or 2nd degree relative 110 7.8 
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Table 15. Number of specific relatives diagnosed with cancer 
 Frequency % of cohort Mean Median 
Range 
Minimum Maximum 
Number of breast cancers among FDRs 
& SDRs 
0 
1 
2 
3 
4 
5 
6 
7 
 
55 
664 
471 
175 
33 
7 
2 
2 
 
3.9 
47.1 
33.4 
12.4 
2.3 
0.5 
0.1 
0.1 
1.649 1.000 
0 
 
7 
Number of breast cancers among FDRs 
0 
1 
2 
3 
 
307 
972 
127 
3 
 
21.8 
69.0 
9.0 
0.2 
0.88 1.00 0 3 
Mother affected with breast cancer 
Yes 
Bilateral 
No 
 
790 
64 
555 
 
56.1 
4.5 
39.4 
- - - - 
Number of breast cancers among sisters 
0 
1 
2 
3 
 
1130 
252 
24 
3 
 
80.2 
17.9 
1.7 
0.2 
0.22 0 0 3 
Number of breast cancers among 
daughters 
0 
1 
 
1407 
2 
 
99.9 
0.1 
- - - - 
Number of breast cancers among SDRs 
0 
1 
2 
3 
4 
5 
6 
7 
 
669 
484 
186 
59 
7 
1 
2 
1 
 
47.5 
34.4 
13.2 
4.2 
0.5 
0.1 
0.1 
0.1 
0.77 1.00 0 7 
Number of breast cancers among 
maternal aunts 
0 
1 
2 
3 
4 
 
 
1062 
255 
80 
11 
1 
 
 
75.4 
18.1 
5.7 
0.8 
0.1 
0.32 0.00 0.00 4 
Number of breast cancers among 
paternal aunts 
0 
1 
2 
3 
4 
7 
 
1256 
109 
31 
9 
3 
1 
 
89.1 
7.7 
2.2 
0.6 
0.2 
0.1 
0.15 0 0 7 
Maternal grandmother affected with 
breast cancer 
No 
Yes 
Bilateral 
 
 
1135 
258 
13 
 
 
80.6 
18.3 
1.1 
- - - - 
Paternal grandmother affected with 
breast cancer 
No 
Yes 
Bilateral 
 
 
1296 
112 
1 
 
 
92.0 
7.9 
0.1 
- - - - 
Number of family members affected 
with ovarian cancer 
0 
1 
2 
3 
4 
 
 
1257 
124 
23 
2 
3 
 
 
89.2 
8.8 
1.6 
0.1 
0.2 
0.13 0 0 4 
Total number of relatives affected with 
bilateral breast cancer 
0 
1 
2 
 
 
1299 
107 
3 
 
 
92.2 
7.6 
0.2 
0.08 0 0 2 
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Not shown in Table 15 is the number of women who reported a sister or aunt 
with bilateral breast cancer. 7.8% of the cohort reported bilateral breast cancer in at 
least one 1st or 2nd degree relative. There were 11 cases of bilateral breast cancer in 
a sister. 28 women reported at least 1 maternal aunt with bilateral breast cancer, 
and 14 women reported a paternal aunt with bilateral breast cancer. There were no 
reports of bilateral breast cancers occurring in the daughter, half-sister or niece of 
any of the women in the study. Of the 26 male breast cancers reported, 7 occurred 
in a father, 1 in a brother, 6 in a maternal uncle, 3 in a paternal uncle, 2 in a maternal 
grandfather and 2 in a paternal grandfather. 5 of the male breast cancers occurred 
in a more distant relative.  
Information regarding the ages of diagnosis of the female breast and 
ovarian cancers, for the whole cohort, is detailed in Table 16. The age at bilateral 
breast cancer diagnosis reflects the mean age at diagnosis of the two cancers.  
 
 
Table 16. Average ages of cancer diagnosis within family members of the entire cohort 
 Mean (±SD) Median 
Range 
Minimum Maximum 
Age of total FDRs and SDRs at 
breast cancer diagnosis 
50.308 (±10.817) 50 19.50 97.00 
Age of ovarian cancer diagnosis 55.376 (±13.740) 53.75 22.00 87.00 
Age of bilateral breast cancer 
diagnosis 
52.864 (±10.596) 51.750 32.0 79.0 
Age of FDR(s) at breast cancer 
diagnosis 
48.810 (±10.991) 48.00 21.00 87.00 
Age mother at breast cancer 
diagnosis 
51.321 (±11.098) 50.75 21.00 87.00 
Age sister(s) at breast cancer 
diagnosis 
41.6261 (±7.324) 42.00 23.00 63.00 
Age daughter(s) at breast cancer 
diagnosis 
27.500 (±0.707) 27.500 27.00 28.00 
Age of SDR(s) at breast cancer 
diagnosis 
55.509 (±12.640) 55.00 23.00 97.00 
Age of maternal aunt(s) at breast 
cancer diagnosis 
52.5614 
(±11.230) 
51.00 25.00 82.00 
Age of paternal aunt(s) at breast 
cancer diagnosis 
56.029 (±10.740) 55.00 32.00 89.00 
Age of maternal grandmother at 
breast cancer diagnosis 
58.620 (±14.539) 58.00 29.00 92.00 
Age of paternal grandmother at 
breast cancer diagnosis 
59.2611 
(±14.219) 
59.00 35.00 97.00 
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4.1.3. NICE risk categories 
After assigning NICE risk categories based on FH, 506 (35.9%) were low risk, 523 
(37.1%) were moderate risk, and 380 (27.0%) were high risk according to NICE 
guidance. There were adjustments made to this made based on the results of BRCA 
testing, which were collected following initial NICE risk assignment (see section 4.1.5. 
for details). The final numbers in each group were therefore 505 (35.8%) low risk, 
522 (37%) moderate risk and 382 (27.1%) high risk (including 12 BRCA1 and 10 BRCA2 
carriers). The corresponding mean age at presentation in these groups was 37.32 
(SD±7.741), 36.60 (±7.868) and 36.19 (±7.957). One-way ANOVA demonstrated no 
significant difference at age of presentation between the three groups (p=0.092). The 
breakdown of the FH subtypes which contribute to each risk category, before 
adjustments for BRCA mutation status, can be found in Table 17 (those in the low risk 
group did not meet any of the criteria shown). Of those in the moderate risk category, 
the majority (58.3%) had a FH of two FDRs or SDRs diagnosed with breast cancer, at 
an average age of older than 50. The most common reason for being assigned a high 
risk was having two FDRs or SDRs diagnosed with breast cancer, at an average age of 
younger than 50, with at least one affected FDR (32.1% of all high risk patients). It is 
worth noting that not all patients with a FH of ovarian cancer or male breast cancer 
are automatically assigned a high risk category if they do not meet the additional 
criteria outlined.  
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Table 17. NICE risk categories and specific criteria assigned to the cohort (before BRCA 
mutation results) 
 Frequency % of cohort 
Moderate Risk 
 
One FDR diagnosed with breast cancer at younger than age 40 years  
  
Two first-degree or SDRs diagnosed with breast cancer at an average age 
of older than 50 years  
 
Three first-degree or SDRs diagnosed with breast cancer at an average age 
of older than 60 years 
 
 
172 
 
 
305 
 
 
46 
 
 
 
12.2 
 
 
21.6 
 
 
3.3 
523 37.1 
High Risk 
 
At least the following female breast cancers only in the family:  
 
Two first-degree or SDRs diagnosed with breast cancer at younger than an 
average age of 50 years (at least one must be a FDR)  
 
Three first-degree or SDRs diagnosed with breast cancer at younger than 
an average age of 60 years (at least one must be a FDR)  
 
Four relatives diagnosed with breast cancer at any age (at least one must 
be a FDR)  
 
Families containing one relative with ovarian cancer at any age and, on the 
same side of the family:  
 
One FDR (including the relative with ovarian cancer) or SDR diagnosed 
with breast cancer at younger than age 50 years.  
 
Two first-degree or SDRs diagnosed with breast cancer at younger than an 
average age of 60 years.  
 
Another ovarian cancer at any age.   
 
Families affected by bilateral cancer (each breast cancer has the same count 
value as one relative):  
 
One FDR with cancer diagnosed in both breasts at younger than an 
average age 50 years.  
 
One first-degree or SDR diagnosed with bilateral cancer and one first or 
SDR diagnosed with breast cancer at younger than an average age 60 
years.  
 
Families containing male breast cancer at any age and, on the same side of 
the family, at least:  
 
One first-degree or SDR diagnosed with breast cancer at younger than age 
50 years.  
 
Two first-degree or SDRs diagnosed with breast cancer at younger than an 
average age of 60 years. 
 
 
 
 
 
122 
 
 
 
46 
 
 
 
14 
 
 
 
 
 
41 
 
 
 
33 
 
 
24 
 
 
 
 
28 
 
 
48 
 
 
 
 
 
 
6 
 
 
 
11 
 
 
 
 
 
8.7 
 
 
 
3.3 
 
 
 
1.0 
 
 
 
 
 
2.9 
 
 
 
2.3 
 
 
1.7 
 
 
 
 
2.0 
 
 
3.4 
 
 
 
 
 
 
0.4 
 
 
 
0.8 
380 27.0 
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4.1.4. Modified Manchester Scores 
The mean MMS for the entire cohort was 10.47 (SD±7.402) with a median of 8.00. 
Scores ranged from 0-65. 95.5% of the cohorts’ MMS fell within the range of 0-25. 
Scores meeting the threshold for BRCA testing i.e. ≥17, accounted for 15.6% of the 
cohort, equal to 220 patients.   
 For the low risk group, the mean MMS was 6.57 (±5.01). The median was 6.00 
and scores ranged from 0-46. 95.1% of the scores in the low risk group ranged from 
0-16, and 99.2% ranged from 0-23. Scores ≥17, accounted for 4.9% of the low risk 
group i.e. 25 patients. The scores of 17 and above, including the exceptionally high 
scores, can be accounted for due to 1) the fact that the MMSS moves affected female 
relatives linked through an unaffected male up one degree of relation, something not 
stated in the NICE risk evaluation 2) the relatively high value the MMS assigns to 
ovarian cancer and male breast cancer in patients for which the FH does not 
otherwise meet NICE risk criteria.  
 In the NICE moderate risk group, the mean MMS was 9.03 (±3.76) and the 
median score was 8.00. The scores in this group ranged from 4-31. 95.4% of the MMS 
ranged from 4-16. Scores ≥17 therefore accounted for 24 patients (4.6%) in the 
moderate risk group, equal to 1.7% of the entire cohort.  
For the NICE high risk group, the mean MMS was 17.61 (±8.68), with a median 
score of 16.0. Scores ranged from 6-65, with 93.5% of the scores ≥10. Scores ≥17, i.e. 
the threshold for offering BRCA testing according to the MMSS, made up 44.6% of 
the high risk group. This equates to 169 high risk patients, i.e. 12.0% of the entire 
cohort. The boxplot of these scores can be seen in Figure 3, which also demonstrates 
the significant outliers.  
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Figure 3. Boxplot of MMS by NICE risk category, with significant outliers shown. 
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4.1.5. BRCA mutation testing and results 
62 patients in the cohort had been tested for a BRCA mutation. 34 of these patients 
had a family member who had tested positive previously. 33 had a MMS ≥17. One of 
the patients who was tested had neither a score ≥17 nor a family member who was 
BRCA positive. Of those tested, 22 patients in total were positive for a mutation – 12 
patients had a mutation in BRCA1 and 10 patients had a mutation in BRCA2. The 
mean MMS for BRCA carriers was 23.50 (SD±12.87). 15 of the 22 had an MMS of 17 
or above.  
As a result of acquiring data on BRCA testing, some patients changed risk 
category, as those with a BRCA mutation are automatically high risk. Some patients’ 
risk category was also lowered if they tested negative for a known familial BRCA 
mutation, in order to reflect how the patient would be regarded clinically. The final 
NICE risk category assignments, using both FH, and BRCA test results, can be seen in 
Table 18. The finalised figures, incorporating BRCA test result, were used for further 
analysis.  
 
 
Table 18. Original and final risk categorisation 
 
FH alone FH and BRCA test result 
N % of cohort N % of cohort 
Low risk 506 35.9 505 35.8 
Moderate 
risk 
523 37.1 522 37.0 
High risk 380 27.0 382 27.1 
Total 1409 100 1409 100 
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Modified Manchester Score and BRCA mutations 
Independent T-test analysis was not appropriate, as the MMS did not meet the 
assumption of being normally distributed that is required for this test to be 
appropriate. Fischer’s exact test was performed to determine whether the cut off of 
a MMS of 17 for BRCA testing suggested by Institute of Cancer Research predicted 
mutation in the cohort. The results of this analysis can be seen in Table 19. For having 
any BRCA mutation and for having either a BRCA1 or BRCA2 mutation, a MMS of ≥17 
was significantly predictive. In addition, the sensitivity and specificity, as well as the 
AUROC for a MMS ≥17 and mutation status is demonstrated.  
Table 19. Fischer’s exact test, sensitivity, specificity and AUROC for MMS ≥17 and carrying a BRCA 
mutation 
 MMS ≥17 (N)  
 
Yes No 
P-value  
(Fischer’s exact test) 
BRCA1 
mutation 
carrier 
 
Non-mutation 
carrier 
 
9 
 
211 
 
3 
 
1186 
<0.001 
BRCA2 
mutation 
carrier 
 
Non-mutation 
carrier 
 
6 
 
214 
 
4 
 
1185 
0.002 
BRCA1 or 
BRCA2 
mutation 
carrier 
 
Non-mutation 
carrier 
 
15 
 
205 
 
7 
 
1182 
<0.001 
 
 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
AUROC  
(95% CI) 
AUROC  
p-value 
BRCA1 
75.00 
(42.84-93.31) 
84.90 
(82.89-86.71) 
0.799 
(0.657-0.942) 
<0.001 
BRCA2 
60.00 
(27.37-86.31) 
84.71 
(82.68-86.53) 
0.724 
(0.542-0.905) 
0.015 
BRCA1 or 
BRCA2 
68.18 
(45.12-85.27) 
85.22 
(83.22-87.02) 
0.767 
(0.652-0.882) 
<0.001 
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4.1.6. Number of years follow up by age range and risk category 
The number of women years of follow up by age bracket and NICE risk category is 
shown in Table 20 and represents the figures used for later incidence and risk 
calculations. BRCA carriers are shown separately.  
 
 
 
Table 20. Number of women years of follow up for each age range and NICE risk category. 
 <39 years 
40-49 
years 
50-59 
years 
>60 years Total 
Low risk 1,871 2,430 1,239 91 5,631 
Moderate risk 2,131 2,384 1,135 69 5,737 
High 
risk 
Non-
BRCA 
carriers 
1,414 1,609 757 52 3,813 
BRCA 
carriers 
139 75 19 0 233 
Total 5,555 6,498 3,150 212 15,414 
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4.1.7. Cancer development in the cohort 
In Situ Carcinoma Development 
10 women in the cohort developed in situ carcinoma. There were 9 cases of DCIS and 
1 case of LCIS. None of the women were BRCA mutation carriers. Age of diagnosis 
ranged from 38-60 years. The mean age of diagnosis was 49.5 years (SD±7.807), and 
median age was 51 years. 4 occurred in women in the high risk group, 4 in the 
moderate risk group and 2 in the low risk group. There was no significant difference 
in the likelihood of developing in situ disease between the low and moderate 
(Fischer’s exact p=0.687), low and high (p=0.411), or moderate and high (p=0.728) 
risk groups. A boxplot of the age at diagnosis can be seen in Figure 4. The difference 
in age of diagnosis between NICE risk groups was not significant on one-way ANOVA 
(p=0.211). However, the numbers in each group are small and the analysis is likely to 
be significantly underpowered. 
 
 
Figure 4. Ages of in situ carcinoma diagnosis by NICE risk group 
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Invasive Cancer Development 
Of the 1,409 women in the cohort, 30 developed an invasive cancer in the period 
between attending clinical genetics and May 2016. These patients first presented to 
clinic genetics at a mean age of 40.5 years (SD±5.76), with a median age of 41, ranging 
from age 29-49. The mean age of breast cancer development in the cohort was age 
48.9 (±6.72), median 49.5, and ranged from age 32-59 years. 3 (10%) of the cancers 
occurred in a BRCA mutation carrier – these occurred at ages 40, 41 and 53. The mean 
time from first contact with clinical genetics to the development of invasive cancer 
was 8.01 years (±3.39), and ranged from 1.25-14.97 years. In total, the women who 
developed invasive breast cancer had cumulative number of years follow up of 360.3 
years, mean 12.01 (±2.91), and range 6.6-16.40.  
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4.1.8. Cohort summary 
Figure 5 shows a consort diagram summarising the data collection process and basic 
descriptive characteristics of the cohort.  
  
Figure 5. Consort diagram overviewing data collection and final cohort 
Eligible patients (n = 1,566) 
Inclusion criteria: 
 Female, <50 years at first presentation 
 Unaffected by breast cancer 
 Referred to Tayside genetics for breast cancer risk 
assessment from 2000-2010 
Excluded (n = 157) 
Did not attend appointment 
(n = 115) 
Inadequate FH information  
(n = 38) 
Previous ovarian cancer 
(n = 4) 
 
Complete cohort (n = 1,409) 
Risk categorized according to NICE guidance based on family 
history 
Risk adjusted based on BRCA test result where appropriate 
 
Low risk 
n = 505 (35.9%) 
 
Moderate risk 
n = 522 (37.1%) 
High risk 
Including 12 BRCA1 and 
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n = 382 (27.1%) 
Invasive cancer which developed in the cohort 
identified through Tayside pathology database 
 
Low risk 
4 invasive breast 
cancers 
 
Moderate risk 
13 invasive breast 
cancers 
High risk 
13 invasive breast 
cancer 
(of which 3 occurred in 
BRCA carriers 
R
is
k 
ca
te
go
ri
sa
ti
o
n
 
D
at
a 
co
lle
ct
io
n
 
C
an
ce
r 
d
e
ve
lo
p
m
e
n
t 
88 
 
 
 
4.2. Risk Analysis 
4.2.1. Mean age of cancer development by NICE risk category 
Of the 30 cancers which developed, 4 occurred in the low risk group, 13 occurred in 
the moderate risk group, and a further 13 occurred in the high risk group. Mean age 
of cancer diagnosis for each group is described in Table 21, and is plotted in Figure 6. 
Age of cancer diagnosis appears to decrease with increasing risk category. This 
however did not reach statistical significance on one-way ANOVA (p=0.578).  
 
Table 21. Age of invasive cancer diagnosis statistics by NICE category (years) 
 Mean (±SD) Median Range 
Low Risk 50.8 (±3.5) 50.5 47-55 
Moderate Risk 49.8 (±5.6) 51.0 39-59 
High Risk 47.5 (±8.4) 47.0 32-59 
 
 
Figure 6. Boxplot of age of invasive cancer diagnosis by NICE risk category 
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4.2.2. Independent T-test analysis 
Independent T-test analysis was performed to compare continuous variables with 
invasive breast cancer development, overall and across different age groups, both 
including and excluding BRCA mutation carriers. The full results of the analysis can 
be found in Table 22. It should be noted that the significance values presented are 
uncorrected for multiple testing. 
 
4.2.3. Pearson Chi-square/Fischer’s exact test  
Fischer’s exact test was performed to compare the collected categorical variables 
with invasive breast cancer development overall and across different age groups, 
both including and excluding BRCA mutation carriers. The full results of the analysis 
can be found in Table 23. Again, it should be noted that the significance values 
presented are uncorrected for multiple testing. 
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Table 22. Results of independent t-test analysis of continuous variables with breast cancer 
development 
 Variable 
Excluding BRCA 
carriers 
Including BRCA 
carriers 
P-value  
(2-tailed) 
P-value  
(2-tailed) 
Overall cancer 
diagnoses 
(N=30) 
Number of FDRs and SDRs affected in 
total 
 
Number of FDRs affected 
 
Average age of FDRs at diagnosis 
 
Number of SDRs affected 
 
Average age of SDRs at diagnosis 
 
Average age of all relatives at diagnosis 
0.004 
 
0.60 
 
0.088 
 
0.240 
 
0.644 
 
0.088 
0.003 
 
0.024 
 
0.269 
 
0.112 
 
0.618 
 
0.436 
Cancer diagnoses 
age ≤39 years 
(N=3) 
Number of FDRs and SDRs affected in 
total 
 
Number of FDRs affected 
 
Average age of FDRs at diagnosis 
 
Number of SDRs affected 
 
Average age of SDRs at diagnosis 
 
Average age of all relatives at diagnosis 
0.189 
 
0.498 
 
0.343 
 
0.086 
 
0.337 
 
0.565 
0.192 
 
0.508 
 
0.347 
 
0.090 
 
0.326 
 
0.557 
Cancer diagnoses 
age 40-49 years 
(N=12) 
Number of FDRs and SDRs affected in 
total 
 
Number of FDRs affected 
 
Average age of FDRs at diagnosis 
 
Number of SDRs affected 
 
Average age of SDRs at diagnosis 
 
Average age of all relatives at diagnosis 
0.111 
 
0.203 
 
0.006 
 
0.144 
 
0.729 
 
0.097 
0.096 
 
0.436 
 
0.089 
 
0.057 
 
0.384 
 
0.565 
Cancer diagnoses 
age 50-59 years 
(N=15) 
Number of FDRs and SDRs affected in 
total 
 
Number of FDRs affected 
 
Average age of FDRs at diagnosis 
 
Number of SDRs affected 
 
Average age of SDRs at diagnosis 
 
Average age of all relatives at diagnosis 
0.038 
 
0.086 
 
0.649 
 
0.779 
 
0.807 
 
0.706 
0.036 
 
0.077 
 
0.681 
 
0.668 
 
0.675 
 
0.744 
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Table 23. Results of Pearson Chi-square/Fischer’s exact test of categorical variables with 
breast cancer development 
 Variable 
Excluding BRCA 
carriers 
Including BRCA 
carriers 
P-value  
(2-tailed) 
P-value  
(2-tailed) 
Overall cancer 
diagnoses 
(N=30) 
1 affected FDR or SDR 
≥ 2 affected FDRs or SDRs 
≥ 3 affected FDRs or SDRs 
≥ 4 affected FDRs or SDRs 
Mother affected with breast cancer 
Sister affected with breast cancer 
Average age of relatives at diagnosis <40 
Average age of relatives at diagnosis <50 
Average age of relatives at diagnosis <60 
Incidence of ovarian cancer in family 
Incidence of bilateral breast cancer in family 
Incidence of male breast cancer in family 
1.000 
0.003 
0.053 
0.205 
1.000 
0.465 
0.856 
0.083 
0.817 
0.514 
0.459 
0.077 
1.000 
0.003 
0.039 
0.228 
0.851 
0.643 
0.996 
0.275 
0.656 
0.764 
0.504 
0.104 
Cancer diagnoses 
age ≤39 years 
(N=3) 
1 affected FDR or SDR 
≥ 2 affected FDRs or SDRs 
≥ 3 affected FDRs or SDRs 
≥ 4 affected FDRs or SDRs 
Mother affected with breast cancer 
Sister affected with breast cancer 
Average age of relatives at diagnosis <40 
Average age of relatives at diagnosis <50 
Average age of relatives at diagnosis <60 
Incidence of ovarian cancer in family 
Incidence of bilateral breast cancer in family 
Incidence of male breast cancer in family 
-a 
0.116 
0.392 
1.000 
0.565 
0.488 
0.889 
0.253 
1.000 
1.000 
0.214 
0.051 
-a 
0.117 
0.398 
1.000 
0.565 
0.484 
0.886 
0.151 
0.487 
0.710 
0.217 
0.054 
Cancer diagnoses 
age 40-49 years 
(N=12) 
1 affected FDR or SDR 
≥ 2 affected FDRs or SDRs 
≥ 3 affected FDRs or SDRs 
≥ 4 affected FDRs or SDRs 
Mother affected with breast cancer 
Sister affected with breast cancer 
Average age of relatives at diagnosis <40 
Average age of relatives at diagnosis <50 
Average age of relatives at diagnosis <60 
Incidence of ovarian cancer in family 
Incidence of bilateral breast cancer in family 
Incidence of male breast cancer in family 
1.000 
0.059 
0.186 
1.000 
0.099 
0.226 
0.547 
0.117 
1.000 
1.000 
0.175 
1.000 
1.000 
0.084 
0.101 
1.000 
0.141 
0.139 
0.999 
0.397 
1.000 
0.378 
0.237 
1.000 
Cancer diagnoses 
age 50-59 years 
(N=15) 
1 affected FDR or SDR 
≥ 2 affected FDRs or SDRs 
≥ 3 affected FDRs or SDRs 
≥ 4 affected FDRs or SDRs 
Mother affected with breast cancer 
Sister affected with breast cancer 
Average age of relatives at diagnosis <40 
Average age of relatives at diagnosis <50 
Average age of relatives at diagnosis <60 
Incidence of ovarian cancer in family 
Incidence of bilateral breast cancer in family 
Incidence of male breast cancer in family 
1.000 
0.108 
0.248 
0.070 
0.422 
0.044 
0.981 
0.796 
1.000 
0.385 
0.617 
0.211 
1.000 
0.069 
0.268 
0.079 
0.602 
0.094 
0.994 
1.000 
1.000 
0.393 
0.622 
0.239 
aUncalculatable due to too few numbers
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4.2.4. Modified Manchester Score 
There is a trend towards higher MMS for women who developed invasive breast 
cancer compared to women who did not, both overall and at difference age ranges. 
However, area under the receiver operating curve (ROC) analysis assessing MMS with 
a cut-point of 17 and risk of developing breast cancer did not reach significance. This 
suggests no predictive ability of MMS for breast cancer at any age range. The mean 
MMS for each risk category and p-values for the AUROC analysis can be seen in Table 
24.  
 
 
Table 24. Mean MMS and AUROC for invasive breast cancer overall and by age range. 
 
Mean MMS  
(±SD) 
 
Invasive breast cancer 
Excluding BRCA 
mutation carriers 
Yes No AUROC 
P-value  
 
Overall 
11.37  
(±5.712) 
10.25 
(±7.121) 
0.519 0.734 
Age <39 years 
14.67 
(±5.033) 
10.26 
(±7.098) 
0.593 0.578 
Age 40-49 years 
10.70 
(±5.293) 
10.26 
(±7.111) 
0.526 0.773 
Age 50-59 years 
11.14 
(±6.249) 
10.25 
(±7.121) 
0.498 0.978 
Including BRCA 
mutation carriers 
 
 
  
Overall 
11.77 
(±5.746) 
10.45 
(±7.429) 
0.522 0.674 
Age <39 years 
14.67  
(±5.033) 
10.47 
(±7.401) 
0.589 0.595 
Age 40-49 years 
11.75 
(±5.786) 
10.46 
(±7.414) 
0.548 0.570 
Age 50-59 years 
11.20  
(±6.026) 
10.45 
(±7.429) 
0.489 0.884 
 
  
93 
 
 
 
4.2.5. Frequency and percentage 10-year absolute risk of breast cancer 
The frequency of cancer diagnosis in the cohort by NICE risk category and age range 
can be seen in Table 25. BRCA mutation carriers are shown both separately and 
included in the high risk group. The % 10-year absolute risk, based on women years 
of follow up in the cohort are shown for age ranges 40-49 and 50-59 years. Across all 
age ranges, the fewest cancer diagnoses occurred in the low risk group and this 
corresponded with the smallest % 10-year absolute risk. The highest absolute risk 
between the ages of 40-49 was in the high risk group, both including and excluding 
BRCA carriers, though BRCA carriers had the highest absolute risk overall in this age 
range. In the 50-59 years group, the moderate risk group had the highest % absolute 
risk, at 7.05%.  
 
 
Table 25. Cancer diagnosis by age range and NICE category. % 10-year risk calculated based 
on number of women years of follow up, shown in Table 21. 
 BRCA carriers separate BRCA carriers included 
 N 
Number of invasive cancers  
(% 10-year absolute risk (95% CI)) 
N 
Number of invasive cancers 
(% 10-year absolute risk (95%CI)) 
  Age range (years)  Age range (years) 
  Overall <39 40-49 50-59  Overall <39 40-49 50-59 
Low Risk 505 4 0 
2 
(0.82%  
(0.72-0.94)) 
2 
(1.61%  
(1.42-1.83)) 
505 4 0 
2 
(0.82%  
(0.72-
0.94)) 
2 
(1.61%  
(1.42-
1.83)) 
Moderate 
Risk 
522 13 1 
4 
(1.68%  
(1.53-1.83)) 
8 
(7.05%  
(6.78-7.31)) 
522 13 1 
4 
(1.68%  
(1.53-
1.83)) 
8 
(7.05%  
(6.78-
7.31)) 
High Risk 360 10 2 
4 
(2.49%  
(2.28-2.70)) 
4 
(5.28%  
(4.93-5.64)) 
382 13 2 
6 
(3.56%  
(3.34-
3.80)) 
5 
(6.44%  
(6.10-
6.78)) 
BRCA 
carriers 
22 3 0 
2 
(26.67%  
(17.98-
37.63)) 
1 
(52.63%  
(31.71-
72.67)) 
Total 1409 30 3 12 15 1409 30 3 12 15 
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4.2.6. Relative risks and odds ratios for NICE risk categories 
The RR and OR for the moderate and high risk groups, with comparison to the low 
risk group are shown in Table 26. BRCA carriers are shown both as separate and 
included in the high risk group. Also shown is the RR and OR associated with meeting 
any of the NICE criteria, i.e. moderate or high risk. Other than being a BRCA carrier, 
the highest RR and OR for developing invasive cancer are in the high risk group, both 
including and excluding BRCA mutation carriers. 
 
 
 
Table 26. RR and OR for NICE risk categories 
 Relative risk  
(95% CI) 
Odds ratio  
(95% CI) 
Moderate Risk 3.14  
(1.03-9.58) 
3.20  
(1.04-9.88) 
High Risk  
(including BRCA carriers) 
4.30  
(1.41-13.07) 
4.410 
 (1.43-13.64) 
High Risk  
(excluding BRCA carriers) 
3.51  
(1.11-11.10) 
3.58  
(1.11-11.50) 
BRCA carriers 17.22  
(1.10-72.29) 
19.78  
(4.13-94.63) 
Moderate or high risk 3.63  
(1.27-10.35) 
3.71  
(1.29-10.69) 
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4.2.7. Sensitivity, specificity, positive predictive value and negative predictive value 
of NICE risk categories 
The sensitivity, specificity, PPV and NPV of the risk categories are shown in Table 27. 
These were calculated for moderate and high risk separately as compared to low risk, 
and in addition with the moderate and high risk categories grouped together. The 
sensitivity of being in any increased risk group was 86.67% however the specificity 
was much poorer at 36.33%.  
 
 
 
Table 27. Sensitivity, specificity, PPV and NPV for NICE risk categories as compared with the 
low risk group. 
 
  
 
Sensitivity (%)  
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI)  
Moderate 
76.47  
(49.8-92.17) 
49.6  
(46.5-52.7) 
2.49  
(1.39-4.33) 
99.2 
(97.8-99.7) 
High 
76.47  
(49.76-92.17) 
57.59 
(54.22-68.90) 
3.40  
(1.90-5.90) 
99.21  
(97.84-99.75) 
Moderate 
& High 
86.67  
(68.36-95.64) 
36.33  
(33.80-38.94) 
2.88  
(1.93-4.25) 
99.21  
(97.84-99.75) 
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4.2.8. Area under the receiver operating curve for NICE risk categories 
AUROC was analysed to determine the accuracy of NICE risk categories at 
determining the likelihood of developing breast cancer, at different age ranges, for 
different NICE risk categories, as compared to women in the NICE low risk category. 
The results can be seen in Table 28. Being in the moderate or high risk group 
combined, across total follow up time, predicted significantly better than chance the 
risk of developing breast cancer (p=0.031), when BRCA carriers are included in the 
analysis. This significance was lost on exclusion of BRCA mutation carriers. Being in 
the high risk group, including BRCA mutation carriers, also predicted significantly 
better than chance the risk of developing breast cancer across total follow up time 
(p=0.016). This significance was again, lost on exclusion of BRCA mutation carriers. 
The receiver operating curves (ROC) for the two significant results are shown in 
Figure 7 and Figure 8. 
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Table 28. AUROC for varying age ranges and NICE risk categories. 
 BRCA carriers excluded BRCA carriers included 
 AUROC  
(95% CI) 
P-value 
AUROC  
(95% CI) 
P-value 
Moderate or 
high risk 
    
Overall 
0.609  
(0.514-704) 
0.052 
0.615 
(0.526-0.704) 
0.031 
<39 years 
0.681  
(0.472-890) 
0.277 
0.680 
(0.469-0.890) 
0.282 
40-49 years 
0.582 
(0.418-0.746) 
0.371 
0.597 
(0.452-0.742) 
0.246 
50-59 years 
0.612 
(0.481-0.742) 
0.150 
0.615 
(0.490-0.740) 
0.125 
Moderate risk     
Overall 
0.630 
(0.506-0.753) 
0.066 
0.630 
(0.507-0.754) 
0.065 
<39 years 
0.746 
(0.457-1.000) 
0.395 
0.746 
(0.458-1.000) 
0.394 
40-49 years 
0.579 
(0.357-0.802) 
0.502 
0.580 
(0.358-0.802) 
0.499 
50-59 years 
0.648 
(0.493-0.802) 
0.108 
0.648 
(0.494-0.802) 
0.107 
High risk     
Overall 0.649 
(0.510-0.789) 
0.055 
0.670 
(0.549-0.791) 
0.016 
<39 years 0.791 
(0.621-0.960) 
0.155 
0.785 
(0.612-0.959) 
0.163 
40-49 years 0.625 
(0.405-0.844) 
0.292 
0.662 
(0.484-0.840) 
0.115 
50-59 years 0.626 
(0.406-0.845) 
0.289 
0.645 
(0.449-0.842) 
0.186 
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Figure 7. ROC for invasive cancer diagnosis over total patient follow up time, comparing the 
combined NICE moderate and high risk group (including BRCA carriers) to the NICE low risk 
group (AUROC=0.615 (0.526-0.704), p=0.031) 
Figure 8. ROC for invasive cancer diagnosis over total patient follow up time, comparing 
the NICE high risk group (BRCA carriers included) to the NICE low risk group 
(AUROC=0.670 
(0.549-0.791) (p=0.016) 
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4.2.9. Kaplan-Meier analysis  
The reported p-values are the Log Rank (Mantel-Cox) p-value from KM analysis.  
Low and moderate risk group 
Across the entire period of follow up time, there were 13 invasive breast cancers in 
the moderate risk group, and 4 in the low risk group. KM survival analysis 
demonstrated a significant difference in breast cancer rates across this time period 
between the low and moderate risk group (p=0.048). The KM survival curve is shown 
in Figure 9.  
There was only 1 case of invasive breast cancer at <39 years in the moderate 
risk group. There were no cases of breast cancer <39 in the low risk group. The KM 
analysis was not significant (p=0.341).  
Between the ages of 40-49, there were 4 invasive cancers in the moderate 
and 2 in the low risk group. There was no significant difference in the cancer rates 
across this age period between the low and moderate risk group (p=0.431). 
 From age 50-59 years, there were 8 invasive cancers in the moderate risk 
group and 2 in the low risk group. KM analysis demonstrated a significant difference 
in rates of breast cancer between the low and moderate risk group across this time 
period (p=0.037). The survival curve is shown in Figure 10.  
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Figure 9. KM analysis of invasive breast cancer in the low and moderate NICE risk categories 
across total patient follow up time. Log-Rank p=0.048. 
Figure 10. KM analysis of invasive breast cancer in the low and moderate NICE risk 
categories between ages 50-59. Log-Rank p=0.037 
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Low and high risk group (BRCA carriers included within the high risk group) 
Across total patient follow up time, 13 invasive cancers occurred in the high risk 
group, and 4 in the low risk group. KM analysis demonstrated a statistically significant 
difference in rates of invasive cancer between the two groups (p=0.003). The survival 
curve can be seen in Figure 11.  
There were 2 cases of invasive breast cancer at <39 years in the high risk 
group. There were no cases of breast cancer <39 in the low risk group. The KM 
analysis was not significant (p=0.091).   
Between 40-49 years of age, there were 6 cases of invasive breast cancer in 
the high risk group, and 2 cases of breast cancer in the low risk group. KM analysis 
showed a significant difference in breast cancer rates between the low and high risk 
groups, between ages 40-49 (p=0.036). The survival curve can be seen in Figure 12.  
From 50-59 years of age, there were 2 invasive cancers in the low risk group 
and 5 invasive cancers in the high risk group. On KM analysis, there was no significant 
difference in rates of invasive breast cancer development during this age range 
(p=0.149).  
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Figure 11. KM analysis of invasive breast cancer in the low and high NICE risk categories 
(BRCA carriers included) across total patient follow up time. Log-Rank p=0.003. 
Figure 12. KM analysis of invasive breast cancer in the low and high NICE risk categories 
(BRCA carriers included) between ages 40-49 years. Log-Rank p=0.036. 
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Low and high risk group (BRCA carriers excluded from high risk group) 
Excluding BRCA mutation carriers from the analysis, across total patient follow up 
time, there were 10 invasive cancers in the high risk group, and 4 invasive cancers in 
the low risk group. On analysis of rates of invasive breast cancer between the two 
groups, there was a significant difference across total patient follow up time 
(p=0.019). The KM survival curve can be seen in Figure 13.  
 At <39 years of age, there were 2 invasive breast cancers in the high risk group 
and 0 in the low risk group. The difference in invasive breast cancer rates over this 
time period between the two groups did not reach statistical significance (p=0.085). 
 Between the ages of 40-49, there were 4 invasive cancers in the high risk 
group, and 2 in the low risk group. The KM analysis demonstrated no significant 
difference in the rates of breast cancer between the low and high risk group between 
age 40-49, when BRCA carriers were excluded from the analysis (p=0.136).  
 There were 4 invasive breast cancers in the high risk group, and 2 in the low 
risk group between the ages of 50-59. KM analysis did not show a significant 
difference in rates of breast cancer during this age range between the high risk 
(excluded BRCA carriers) and low risk group (p=0.145).  
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Figure 13. KM analysis of invasive breast cancer in the low and high NICE risk categories 
(BRCA carriers excluded) across total patient follow up time. Log-Rank p=0.019. 
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Moderate and high risk group (BRCA carriers included) 
Across total patient follow up time, there were 13 invasive breast cancers in both the 
high and moderate risk group. KM analysis demonstrated no significant difference in 
invasive breast cancer rates across total patient follow up time between the 
moderate and high risk groups (p=0.274) The KM survival curve can be seen in Figure 
14.  
 Aged <39 years there were 2 invasive cancers in the high risk group, and 1 in 
the moderate risk group. There was however, no statistically significant difference in 
the breast cancer rates across this time period between these two group on KM 
analysis (p=0.328).  
 There were 6 invasive breast cancers in the high risk group, and 4 in the 
moderate risk group diagnosed between the ages of 40-49. KM analysis 
demonstrated no significant difference in invasive breast cancer diagnosis during this 
time period between the moderate and high risk group (p=0.183).  
 From the ages of 50-59, there were 5 invasive cancers in the high risk group 
and 8 in the low risk group. There was no statistically significant difference in breast 
cancer rates between ages 50-59 comparing these two groups on KM analysis 
(p=0.581).  
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Figure 14. KM analysis of invasive breast cancer in the moderate and high NICE risk categories 
(BRCA carriers included) across total patient follow up time. Log-Rank p=0.274. 
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Moderate and high risk group (BRCA carriers excluded) 
Excluding BRCA mutation carriers there were 10 invasive breast cancers in the high 
risk group, and 13 invasive breast cancers in the moderate risk group, throughout 
total patient follow up time. Comparing rates of invasive breast cancer diagnosis 
using KM analysis, demonstrates no significant difference between the moderate and 
high risk groups across total patient follow up time (p=0.644). The survival curve 
showing the two groups can be seen in Figure 15.  
 At age <39 years, there were 2 cancers in high risk group, and 1 in the 
moderate risk group. There was no statistically significant difference in breast cancer 
rates across this time period between the two groups (p=0.299) 
 From the ages of 40-49 there were 4 invasive breast cancers in the high risk 
and 4 in the moderate risk group. KM analysis demonstrated no significant difference 
between these two groups breast cancer rates from age 40-49 (p=0.499).  
 Between ages 50-59 years there were 4 and 8 invasive breast cancers in the 
high and moderate risk groups respectively. Again, there was no significant 
difference in breast cancer rates between these two group from the age of 50-59 
using KM analysis (p=0.598).  
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Figure 15. KM analysis of invasive breast cancer in the moderate and high NICE risk categories 
(BRCA carriers excluded) across total patient follow up time. Log-Rank p=0.644. 
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Low and combined moderate and high risk group (BRCA carriers included) 
An analysis was performed to examine whether there was a significant difference in 
rates of invasive breast cancer, between the low risk group, and the groups with any 
increase in risk of breast cancer (i.e. combined moderate and high risk). Across total 
patient follow up time, there were 26 cancers which developed in the combined 
moderate/high risk group, and 4 in the low risk group. KM analysis demonstrated a 
significant difference in breast cancer rates across total follow up time (p=0.011). The 
KM survival curve is shown in Figure 16.   
There were no breast cancers in the low risk group at age <39 years and 3 
breast cancers in women with any increase in risk according to NICE. However, there 
was no statistically significant difference in breast cancer rates using KM analysis 
between the two groups at age <39 years (p=0.216).  
 Between the ages of 40-49, there were 2 breast cancers in the low risk group 
and 10 in women of any increased NICE risk category. However, KM analysis showed 
no significant difference in rates of breast cancer across this time period (p=0.134).  
 There were 2 invasive breast cancers in the low risk group between the ages 
of 50-59 years and 13 invasive breast cancers in women of any increased NICE risk 
category over the same age range. There was found to be a borderline significant 
difference in breast cancer rates comparing these groups from age 50-59, using KM 
analysis (p=0.050). The survival curve can be seen in Figure 17.  
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Figure 16. KM analysis of invasive breast cancer in the low and moderate or high NICE risk 
categories (BRCA carriers included) across total patient follow up time. Log-Rank p=0.011 
Figure 17. KM analysis of invasive breast cancer in the low and moderate or high NICE risk 
categories (BRCA carriers included) from age 50-59. Log-Rank p=0.050. 
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Low and combined moderate and high risk group (BRCA carriers excluded) 
Another analysis was performed combining the moderate and high risk groups but 
with BRCA carriers excluded. Across total patient follow up time, there were 4 and 
23 invasive cancer diagnoses in the low and moderate/high risk groups respectively. 
On KM analysis, this difference in rates of invasive breast cancer was found to be 
significantly different (p=0.024). The KM survival curve can be seen in Figure 18.  
 There were 3 cases of breast cancer in the moderate/high risk group at age 
<39, and none in the low risk group. However, this difference did not reach statistical 
significance using KM analysis (p=0.217).  
From the ages of 40-49 years, there were 8 invasive breast cancer diagnoses 
in the moderate/high risk group, and 2 in the low risk group. Again, KM analysis did 
not reveal a statistically significant difference in rates of invasive breast cancer 
comparing the groups across the 40-49 age range (p=0.241).  
Between the ages of 50-59, there were 12 invasive cancer diagnoses in the 
moderate/high risk group, and 2 in the low risk group. On KM analysis comparing 
rates of breast cancer diagnoses during this time period, there was found to be a 
modest statistically significant difference between the low and moderate/high risk 
groups (p=0.049). The KM survival curve is shown in Figure 19.  
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Figure 18. KM analysis of invasive breast cancer in the low and moderate or high NICE risk 
categories (BRCA carriers excluded) across total patient follow up time. Log-Rank p=0.024 
Figure 19. KM analysis of invasive breast cancer in the low and moderate or high NICE risk 
categories (BRCA carriers excluded) from age 50-59 years. Log-Rank p=0.049. 
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4.2.10. Summary of Kaplan-Meier analysis for invasive breast cancer 
Table 29 shows a summary of the results of KM analysis comparing rates of invasive 
breast cancer diagnoses between different NICE risk categories across different age 
ranges. P-values shown are KM Log-Rank (Mantel-Cox) p-values. Significant results 
are highlighted in bold. Figure 20 and Figure 21 show Kaplan-Meier survival curves 
across total follow up time for low, moderate and high risk groups both including and 
excluding BRCA carriers.  
 
Table 29. Summary of KM survival results comparing rates of invasive breast cancer 
between different NICE risk categories. 
NICE risk 
groups being 
compared 
KM Log-Rank (p-value) 
Period of follow up 
 
Total follow 
up time 
Age ≤39 years 
Age 40-49 
years 
Age 50-59 
years 
Low & 
moderate 
0.048 0.341 0.431 0.037 
Low & high  0.003 0.091 0.036 0.149 
Low & high 
(BRCA carriers 
excluded) 
0.019 0.085 0.136 0.145 
Moderate & 
high 
0.274 0.328 0.183 0.581 
Moderate & 
high (BRCA 
carriers 
excluded) 
0.644 0.299 0.499 0.598 
Low & 
moderate/high 
0.011 0.216 0.134 0.050 
Low & 
moderate/high 
(BRCA carriers 
excluded) 
0.024 0.217 0.241 0.049 
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Figure 20. KM survival curve showing invasive breast cancer rates for the low, moderate 
and high NICE risk groups across total patient follow up time (BRCA carriers included) 
Figure 21. KM survival curve showing invasive breast cancer rates for the low, moderate 
and high NICE risk groups across total patient follow up time (BRCA carriers excluded) 
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4.2.11. Risk Summary 
Table 30 shows summary information of the frequency and % 10-year absolute risk of invasive breast cancer, KM analysis and RR for each NICE risk group  
Table 30. Summary data for NICE risk categories A) BRCA mutation carriers analysed separately B) BRCA mutation carriers analysed within high risk group 
A) Number of women 
Number of invasive cancers 
(% 10-year absolute risk (95% CI)) 
KM Log-Ranka  
p-value 
Overall RRa 
(95% CI) 
  Overall <39 40-49 50-59 Overall <39 40-49 50-59  
Low 505 4 0 
2 
(0.82%  
(0.72-0.94)) 
2 
(1.61%  
(1.42-1.83)) 
- - - - - 
Moderate 522 13 1 
4 
(1.68%  
(1.53-1.83)) 
8 
(7.05%  
(6.78-7.31)) 
0.048 0.341 0.431 0.037 
3.14 
(1.03-9.58) 
High 360 10 2 
4 
(2.49%  
(2.28-2.70)) 
4 
(5.28%  
(4.93-5.64)) 
0.019 0.085 0.136 0.145 
3.51 
(1.11-11.10) 
BRCA carrier 22 3 0 
2 
(26.67%  
(17.98-37.63)) 
1 
(52.63%  
(31.71-72.67)) 
- - - - 
17.22 
(1.10-72.29) 
Total 1409 30 3 12 15      
 
B) Number of women 
Number of invasive cancers 
(% 10-year absolute risk (95% CI)) 
KM Log-Ranka  
p-value 
Overall RRa 
(95% CI) 
  Overall <39 40-49 50-59 Overall <39 40-49 50-59  
Low 505 4 0 
2 
(0.82%  
(0.72-0.94)) 
2 
(1.61%  
(1.42-1.83)) 
- - - - - 
Moderate 522 13 1 
4 
(1.68%  
(1.53-1.83)) 
8 
(7.05%  
(6.78-7.31)) 
0.048 0.341 0.431 0.037 
3.14 
(1.03-9.58) 
High 382 13 2 
6 
(3.56%  
(3.34-3.80)) 
5 
(6.44%  
(6.10-6.78)) 
0.003 0.091 0.036 0.149 
4.30 
(1.41-13.07) 
Total 1409 30 3 12 15      
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4.2.12. Comparison with all women in the Tayside population who developed 
breast cancer age <50 years 
Proportion of women assessed in clinical genetics who developed breast cancer 
From 2000-2016, there were a total of 1,074 cases of female breast cancer diagnosed 
under the age of 50 in Tayside. This includes 15 of the 30 cancers identified from 
women in the original cohort. 267 of the women were seen in genetics at some time. 
However, only 47 were seen in clinical genetics prior to their breast cancer diagnosis, 
regarding breast cancer family history (4 were seen regarding another genetic 
condition). 220 were seen after their breast cancer diagnosis. This leaves 807 women 
in Tayside who developed breast cancer under 50, from 2000-2016, and have to date 
never received any genetic counselling. In total, there were 1,027 women who 
developed breast cancer at age less than 50 years from 2000-2016 who had not 
previously been seen in genetics therefore had likely not received any additional 
screening. This information is summarised in Table 31. The proportion of women in 
Tayside with breast cancer under the age of 50 for the given time period, who were 
previously assessed by the clinical genetics department is therefore 4.38% (95% CI, 
3.31-5.78%).  
 
Table 31. Breakdown of women who were/were not seen in clinical genetics who 
developed breast cancer under the age of 50 in Tayside from 2000-2010 
Assessed in clinical 
genetics 
Prior to breast 
cancer 
diagnosis 
Low risk 
Moderate risk 
High risk 
BRCA carrier 
15 
7 
21 
4 
267 
Total  47 
After breast cancer diagnosis 220 
Never assessed in clinical genetics 807 
Total 1,074 
 
 
117 
 
 
 
Age at diagnosis comparison 
The mean age at diagnosis of the women seen in clinical genetics, prior to their breast 
cancer diagnosis, was 42.46 years (SD±6.112). The figure for women not seen prior 
to their breast cancer diagnosis was 42.85 years (±5.139). On Independent T-test 
analysis, there was no significant difference between the ages at breast cancer 
diagnosis between the two groups (p=0.598). The boxplot for age at diagnosis is 
shown in Figure 22.  
 
 
 
 
 
Figure 16. Boxplot comparing age at breast cancer diagnosis between women seen in 
clinical genetics prior to diagnosis and women not seen prior (p=0.598) 
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5.0. Discussion 
5.1. Cohort characteristics 
The initial data collection identified 1,409 patients for inclusion in the main analysis 
of this research, with a total of 15,414 patient years of follow up. The mean number 
of years follow up per woman was 10.935 years (SD±3.3311). Women within the 
cohort had presented to clinical genetics at an average age of 36.75 (±7.855) years, 
and women who presented over the age of 50 were not included. The family 
structures and cancer history of patients included varied, however the most common 
relative reported to be affected with breast cancer was the patient’s mother (60.6%). 
The mean number of relatives reported to be affected with breast cancer was 1.649, 
however some families had up to 7 affected FDRs or SDRs. The average age of a 
relative at breast cancer diagnosis was 50.308 (±10.817) years. Overall, it is likely that 
the data reflects a standard patient who would be attending clinical genetics 
regarding a FH of breast cancer, and 15, 414 patient years of follow up provides a 
considerable quantity of data for analysis.  
5.2. NICE risk category  
5.2.1. NICE risk category assignment 
505 (35.84%) of the women were assigned a low risk category, 522 (37.04%) 
moderate risk, and 382 (27.11%) high risk, suggesting a reasonable distribution of 
women in each group. There was no significant variability in the age of presentation 
between the groups (p=0.092), therefore reducing the likelihood that the follow up 
time at certain age ranges was significantly different. It is worth noting that, all-
together, 64.1% of women who attended clinical genetics about their breast cancer 
risks were eligible to be assigned to a category of increased risk. The majority of 
women referred are therefore appropriate for additional screening. Most of the 
women in the moderate risk group were assigned that risk due to a FH of 2 FDRs or 
SDRs diagnosed with breast cancer at an average age of older than 50 years (58.3%). 
For the high risk women, the most common reason was a FH of 2 FDRs or SDRs, 
diagnosed with breast cancer at an average age of younger than 50 years (32.1%). 
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This suggests that the age of relatives at diagnosis is a key determinant of which risk 
category women are assigned according to NICE guidance, especially given that the 
mean number of relatives affected in the cohort was 1.649.  
The family histories used to categorise patients were correct according to 
clinical records, and most had been confirmed by the relevant cancer registry. Studies 
on the reliability of FH reporting have demonstrated that self-reported familial 
cancer history tends to be accurate, with over-reporting a rare event (225, 226). 
Therefore, there is reasonable confidence that the family histories used to categorise 
women are accurate, and the results here reflect the risks in this cohort.  
5.2.2. Potential discrepancies in NICE risk criteria 
Whilst assigning NICE risk categories, some potential pitfalls in the criteria were 
identified. The relevance of this clinically is unclear given that, for the purposes of 
this study, the NICE guidelines were interpreted in a literal sense. For example, other 
than women with four or more affected family members, the guidance refers to only 
FDRs and SDRs affected with breast cancer, and doesn’t account for more distant 
relatives. It could be argued that a relative more distant than a SDR, shares too little 
of their genetic material with the patient to be relevant to polygenic mode of 
inheritance. However, it is important to consider intervening male relatives. The 
estimated incidence of male breast cancer is <1 per 100,000 men per year, and even 
amongst male BRCA carriers the lifetime risk of breast cancer is around 1-5% for 
BRCA1 and 5-10% for BRCA2 (227). Therefore, if there is a familial predisposition to 
breast cancer segregating in a family, when linked by 1 or more successive males it 
may not be phenotypically expressed in close relatives of the female patient. For 
women at a moderate risk due to presumed polygenic effects, this may be less 
relevant, as it would be assumed that a polygenic risk of breast cancer would be 
diluted within a few generations. The MMSS takes into account intervening male 
relatives when scoring for a >10% likelihood of a BRCA mutation in the family, by 
moving female relatives connected by a male up one degree of relation. It therefore 
bypasses this issue. However, this is not expressly stated in the NICE guidelines.  
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In addition, there were some cases of women who had a FH of breast and 
ovarian cancer, however there were not enough breast cancers, or they were not 
diagnosed young enough to meet the high risk criteria. These women, for the 
purposes of the study, had to be assigned to the low risk group. The same applied for 
women with a FH of male breast cancer. The female breast cancers required to meet 
high risk criteria for those with a FH of ovarian or male breast cancer must have been 
in an FDR or SDR. Male breast cancer and ovarian cancer, in the context of a FH of 
female breast cancer, may be associated with a BRCA mutation. Therefore, it would 
make sense that the breast cancers would have occurred at a younger age. However, 
this cannot be determined with absolute certainty. In addition, if a BRCA mutation 
were segregating through male relatives, there may be more than 1 unaffected male 
BRCA carrier connecting two female carriers – therefore the closest female breast 
cancer may be more distant than a SDR.  
The theoretical pitfalls described above explain why some women in the low 
risk group had a very high MMS despite being low risk according to NICE. 
Hypothetically, if a women was low risk according to NICE, it is possible that a MMS 
would not be calculated for them at all. This means that, in theory, women who met 
the >10% mutation risk threshold may be missed. In reality, clinical judgement will 
determine what to do when faced with anomalies such as these. The impact of these 
considerations on clinical management is therefore uncertain in the context of this 
research. These issues leave room for varied interpretation of guidance amongst 
different clinicians, and between different centres in the NHS. Patients in different 
areas may therefore receive different care, despite having a similar FH. Whilst 
clinicians should always be interpreting guidance with their own knowledge in mind, 
it would be desirable to have guidance which avoids elements of uncertainty and of 
which there can be universal interpretation. 
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5.3. The Modified Manchester Score tends to increase with NICE risk 
category and predicts BRCA mutations in the cohort 
MMS was calculated for each patient in the cohort and compared between NICE risk 
categories. The mean MMS for the low, moderate and high risk groups was 6.57 
(SD±5.01), 9.03 (±3.76) and 17.61 (±8.68) respectively. Despite this there were still 
some significant outliers in the low and moderate risk group due to factors discussed 
in section 5.2.2. 15.6% of the cohort (220 patients) had a MMS ≥17 however only 62 
patients in the cohort had in fact been tested for a BRCA mutation. Of interest, only 
33 of these patients themselves had a MMS of 17 or above. Of the remaining patients 
who had been tested, all but one had a known BRCA mutation segregating in the 
family. 22 of the 62 tested were BRCA mutation positive.  
 Analysis was performed to assess whether the cut-off MMS of 17 predicted a 
BRCA mutation. This result of Fischer’s exact test (BRCA1 (p=<0.001), BRCA2 
(p=0.002) or either mutation (p=<0.001)), and AUROC analysis ((BRCA1 (p=<0.001), 
BRCA2 (p=0.015) or either mutation (p=<0.001)), were significant. This suggests 
benefit of the ICR MMSS (210) in helping identify women who would benefit from 
mutation testing. This is despite a relatively small sample size and the fact that 7 of 
the 22 BRCA carriers had a MMS less than 17. The MMS was generally more specific 
than it was sensitive. However without the mutation status of all the women with a 
score of 17 or greater this cannot be quantified with certainty, therefore it is difficult 
to interpret much from these results. Despite this, the MMS would appear to have 
some clinical utility. It would be beneficial to assess this in a larger group of women 
tested for a BRCA mutation, given the limited number of known mutation carriers in 
this study.  
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5.4. Independent T-test and Pearson Chi-square/Fischer’s exact analysis 
find few predictors of breast cancer development in family history 
To tease out which elements of a patient’s FH may correlate significantly with their 
overall and age specific risk of breast cancer, analysis was performed to assess 
different FH factors. Risk of cancer across all follow up time, was found to significantly 
correlate with the number of FDRs and SDRs in total affected in the family, both 
including (p=0.004) and excluding (p=0.003) BRCA carriers from analysis. The number 
of FDRs affected was found to be significant when including BRCA carriers in analysis 
(p=0.024), but not when excluding them. Having ≥2 affected FDRs or SDRs was 
significantly associated with overall breast cancer risk when BRCA carriers were 
excluded or included (p=0.003 for both). However, there was no correlation with any 
of the other variables assessed, including the age of relatives at diagnosis (and 
specific age cut-offs), or FH of ovarian cancer, bilateral breast cancer or male breast 
cancer. This would suggest that, overall, having 2 or more FDRs or SDRs affected is a 
predictor of developing breast cancer, but that in this cohort, age of relatives at 
diagnosis, or any other factor did not seem to affect the risk.  
 For cancer diagnoses under the age of 39 years, none of the variables 
assessed were determined to be significant both excluding and including BRCA 
mutation carriers. However, in the whole cohort, only 3 women developed breast 
cancer at age <39 years. It is therefore difficult to interpret the relevance of these 
results. Breast cancer at age <39 years is uncommon, affecting just 92/100,000 
women in the UK population (1). Therefore, even in a population such as this which 
is enriched for women at an increased risk of breast cancer, a much larger cohort size 
would be required to detect enough women for sensible statistical analysis.  
 Decreasing average age at diagnosis of FDRs significantly correlated with 
breast cancer development between the ages of 40-49 years, when BRCA carriers 
were excluded from analysis. Otherwise, none of the variables correlated 
significantly with breast cancer in this age range, including number of FDR/SDRs. 
Conversely, the only predictor of breast cancer between age 50-59 years appeared 
to be the total number of FDRs and SDRs affected (BRCA excluded p=0.038, BRCA 
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included p=0.036), however there was no significant cut-off above which a certain 
number of affected relatives became significant.  
 It is surprising that decreasing age of relatives at diagnosis significantly 
correlates with breast cancer between ages 40-49 when excluding, but not including 
BRCA mutation carriers. Since families with BRCA mutations demonstrate young 
onset breast cancers, the significance would be presumed to increase by including 
them in the analysis. This may be due to a lack of young onset breast cancers in the 
female FDR or SDRs of BRCA carriers, given that it may also present with male breast 
cancers and ovarian cancers. Again, since the MMS takes into account intervening 
males, women may be selected for BRCA testing despite a relative lack of affected 
close female relatives. Alternatively, and perhaps more likely, this may be a spurious 
result given the relatively small number of BRCA carriers within the cohort. 
Supporting this theory, ovarian, bilateral and male breast cancer did not reach 
significance when BRCA carriers were included despite being well established 
features of families with BRCA mutations.  
 It is possible that younger age of relatives at diagnosis may be more relevant 
for individuals who will go on to develop breast cancer at <50 years of age, rather 
than the total number of affected relatives. The total number of relatives even when 
diagnosed at older ages may be more relevant in predicting the risk of breast cancer 
over the age of 50, as the data here would suggest. Given that there were relatively 
small numbers of cancers in each age group, the most relevant results to interpret 
are likely to be the results pertaining to the whole cohort, over all age ranges. These 
results suggest that the total number of FDRs and SDRs diagnosed is the strongest 
predictor of developing breast cancer, with ≥2 relatives diagnosed linked to a 
significant risk. Overall, age of relatives at diagnosis doesn’t appear to be relevant, 
other than perhaps in the 40-49 age group. Even then, cut offs of an average age of 
diagnosis at <40 years (BRCA excluded p=0.856, BRCA included p=0.996) or <50 years 
(BRCA excluded p=0.083, BRCA included p=0.275) seemed to make no difference to 
breast cancer risk. This is in disagreement with previous literature; an analysis of 
family history and breast cancer risk from the Nurses’ Health Study (151) found no 
significant difference in cancer risk for women with a mother (p=0.06) or sister 
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(p=0.43) affected with breast cancer under the age of 50, compared to over the age 
of 50. However, when analysed cumulatively, women with either a mother or sister 
(i.e. any female FDR) diagnosed under the age of 50, had a significantly higher risk of 
breast cancer than women with a FDR diagnosed over 50 (RR=1.70 and 1.30 
respectively, p=0.016). The authors concluded that this was a useful way to stratify 
risk. However, the associated breast cancer risk for the women in the cohort was not 
age stratified, therefore whether the risk applies to young onset breast cancers is 
unclear.  
 As described in section 5.2.1, the most common reasons for being assigned 
to either the NICE moderate or high risk category can be differentiated by the 
average age of diagnosis of FDRs or SDRs. The cut-off is 50 years of age. In this cohort, 
a cut-off of <50 years average age at diagnosis did not appear to be significantly 
correlated with risk of breast cancer at any age range. This suggests that a cut-off of 
less than, or greater than age 50 at average breast cancer diagnosis, has limited use 
in distinguishing moderate from high risk women, despite being a differentiator for 
the most common presenting family histories.  
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5.5. Overall mean age of cancer development is not significantly different 
between risk groups 
The mean age of women at breast cancer diagnosis for each risk group was calculated 
and analysed using one-way ANOVA. Although there was a clear trend towards 
younger age at diagnosis with increasing risk category, as demonstrated in Figure 6 
(section 4.2.1.), this did not reach significance (p=0.578). This trend may be expected 
if breast cancers are picked up earlier due to inclusion in early screening. In addition, 
this is not necessarily the best analysis of age at cancer diagnosis between the 
groups, as it is a static test. It does not take into account the age of each patient at 
initial consultation or their overall follow up time. This is important since women who 
had previously been diagnosed with young onset breast cancer were not included in 
the study. Therefore, partly as a product of the study design, there are few breast 
cancer diagnoses under the age of 40. A time-dependent analysis is therefore more 
beneficial.  
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5.6. Cancer risk for each NICE category in this cohort does not meet the 
absolute percentage 10-year risk suggested by guidelines 
As shown in Table 25 (section 4.2.5.), there were 4 cancers in the low risk group, 13 
in the moderate risk group, and 13 in the high risk group, of which 3 were accounted 
for by BRCA mutation carriers. 15 of the cancers occurred between 50-59 years, 12 
between 40-49 years and 3 cancers occurred at age <39 years. There were no cancers 
recorded at age 60 or above, however this is expected due to the younger age of 
women included in the study (<50 years) and the maximum follow up period of 16 
years.  
 Using the number of women years of follow up calculated for each category 
between different age ranges (Table 20, section 4.1.6.), % absolute risk per woman 
year of follow up within the age ranges 40-49 and 50-59, was used to determine the 
approximate 10-year % absolute risk in that time period. This was to establish 
whether or not, in this cohort of women, the % 10-year absolute risk was 
approximately equal to that which NICE suggests their risk should equate to. NICE 
states that the % absolute risk between the age of 40-49 should equate to <3%, 3-
8%, and >8% for the low, moderate and high risk groups respectively. It is at these 
risk levels which they deem the relevant additional screening to be appropriate.  
In this cohort, the % 10-year absolute risk from age 40-49 for each category 
was 0.82% (95% CI, 0.72-0.94%) for the low risk group, 1.68% (1.53-1.83%) for the 
moderate risk group and 3.56% (3.34-3.80%) for the high risk group (when BRCA 
mutation carriers were excluded this risk was 2.49% (2.28-2.70%)). The risk of breast 
cancer in the cohort between the ages of 40-49, increased with increasing NICE risk 
category, suggesting some ability of the guidelines to differentiate risk groups. 
However, the risks and 95% CIs are substantially less than what NICE suggests is the 
appropriate cut off for additional screening. This would suggest that between the 
ages of 40-49, NICE guidance overestimates the risk of breast cancer associated with 
specific FH criteria.  
Between the ages of 50-59 years, the absolute % 10-year risk for low, 
moderate and high risk women was 1.61% (95% CI, 1.42-1.83%), 7.05% (6.78-7.31%) 
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and 6.44% (6.10-6.78%) respectively (5.28% (4.93-5.64%) for high risk excluding BRCA 
carriers). Cumulatively, during the 20-year period from age 40-59, the high risk group 
was at the greatest % absolute risk in this cohort. However, it is interesting to note 
that for the age range of 50-59 the highest % risk occurs in the moderate risk group, 
as it reaches 7.05%. This is the highest risk for any single % 10-year age range. In 
addition, despite the risk being in the ages 50-59 range, rather than the 40-49 year 
age range as it should be, it is the only % absolute 10-year risk which crosses its level 
of clinical significance suggested by NICE (i.e. 3-8% for the moderate risk group).  
The fact that the absolute risk for the moderate group appears greater than 
the high risk group between ages 50-59 is interesting. It is unlikely that the 
explanation is that women with a moderate risk FH are at a greater risk of breast 
cancer overall, given that the cumulative absolute risk from 40-59 is greater in the 
high risk group. A perhaps more likely explanation, is that it reflects women in the 
high risk group being diagnosed with cancer earlier, before the age of 50, and that 
the main proportion of risk for the moderate group occurs after the age of 50. 
Additionally, based on the data from this cohort, it would appear that there is a 3-8% 
risk for moderate risk women between 50-59, rather than 40-49 years. Women at 
moderate risk of breast cancer can be considered for annual screening from age 50-
59 as part of the NICE guidelines, however they are offered it between ages 40-49. 
Based on this study’s results, it would appear to be more beneficial for these women 
to be offered annual screening between ages 50-59 rather than just considered for 
it. The usefulness of screening moderate risk women at age <50 years is questionable 
given that in this cohort their absolute risk doesn’t reach screening threshold.  NICE 
guidance is formulated taking into account a cost model based on an ’incremental 
cost-effectiveness ratio’ (ICER), which assesses cost, against quality of life years 
gained through an intervention. An ICER of <£20,000 is deemed cost effective, 
though there is no absolute cut off (228). Assuming that the familial breast cancer 
guidelines were formulated under this model, the fact that the absolute 10-year risk 
of breast cancer is overestimated, would suggest that the guidelines may not be cost 
effective.  
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5.7. Relative risks, odds ratios, sensitivity and specificity for each category 
5.7.1. The relative risk and odds ratio for developing breast cancer increases with 
increasing NICE risk category 
The RR and OR for each NICE category, as well as the combined moderate and high 
risk groups are shown in Table 26 (section 4.2.6.). This was with comparison to the 
low risk group. The RR and OR for breast cancer development tended to increase 
with increasing NICE risk category. The highest risk, unsurprisingly, was for BRCA 
carriers with a RR of 17.22 (95% CI, 1.10-72.29) and an OR of 19.78 (4.13-94.63). The 
next greatest risk was for the high risk group including BRCA mutation carriers, (RR 
4.30 (1.41-13.07), OR 4.410 (1.43-13.64)). As would be expected, this risk dropped 
when BRCA carriers were excluded from the high risk group (RR 3.51 (1.11-11.10), 
OR 3.58 (1.11-11.50)), however still remained greater than that of the moderate risk 
group (RR 3.14 (1.03-9.58), OR 3.20 (1.04-9.88)). It is worth noting the wide 
confidence intervals for these figures, due to the relatively small number of breast 
cancers that developed in the cohort, however the lower limit of the confidence 
interval is never less than or equal to 1.00.  
5.7.2. The sensitivity of NICE risk categories is reasonable but the specificity is poor 
The criteria for the moderate, high, or combined moderate/high risk group, had 
reasonably good sensitivity for invasive breast cancer development across the total 
period of follow up time (76.47% (95% CI, 49.8-92.17%), 76.47% (49.76-92.17%) and 
86.67% (68.36-95.64%) respectively).  In addition, the NPV was above 99% for the 
moderate, high or combined group, with narrow confidence intervals (see Table 27, 
section 4.2.7.), however this is expected given that the number of events was small. 
Specificity was 49.6% (95% CI, 46.5-52.7%) for moderate, 57.59% (54.22-6.89%) for 
high and dropped to 36.33% (33.80-38.94%) for either risk group. Likewise, the PPV 
for each group was never above 4%.  
Although these values are not age specific, it is worth noting that the 
sensitivity was 86.67% for the combined risk group, as additional screening is offered 
from at least 40 for both. This means that theoretically, a considerable portion of 
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breast cancer which may occur in the cohort should be picked up through screening, 
although moderate risk women over the age of 50 do not necessarily have to be 
screened annually, and may return to the NBSP. Only 3 of the 30 cancers in the cohort 
occurred prior to age 40 (none of which were in the low risk group), and 2 occurred 
in the low risk group between ages 40-49. Therefore, in theory, 25 of 30 cancers 
(83.33%) which developed in the cohort had the potential to be picked up either by 
early screening due to increased NICE risk category, or through the NBSP. However, 
this seems to come at a considerable trade off with specificity. To be cost-effective, 
it is beneficial for screening programmes to be both as sensitive and specific as they 
can be. The sensitivity appears to be reasonably good, and a modest trade-off for 
specificity is generally acceptable if the benefits of screening are substantial. 
However, it is worth considering whether or not a specificity of maximally 57.59% in 
this cohort is cost-effective, especially given the small number of events. AUROC 
analysis, discussed below, provides a more informative measure of the effectiveness 
of the criteria at discriminating risk groups, combining sensitivity and specificity.  
5.7.3. Using area under the receiver operating curve, NICE guidelines did not 
perform significantly better than chance for identifying women who would 
develop breast cancer when BRCA carriers are excluded 
AUROC analysis was used to assess the performance of the risk categories overall, 
and at different age ranges, compared to the low risk group. The results are shown 
in Table 28 (section 4.2.8.).  
The high risk category performed significantly better as a breast cancer 
prediction model over all time periods (p=0.016), as did the combined moderate and 
high risk category (p=0.031), although the AUROC was only 0.670 and 0.615 
respectively. However, the significance of the results was lost on exclusion of BRCA 
carriers. There was no significant difference in performance for specific age 
categories (<39 years, 40-49 years, 50-59 years). The moderate risk category did not 
perform significantly better than the low risk group at predicting breast cancer at any 
specific time period or overall.  
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 Although the sensitivity was high for all increased risk categories, it would 
appear that the poor specificity in the moderate risk group limits its usefulness as a 
risk predictor. From the analysis of the RRs and ORs for each group, we can see that 
there is a definite trend towards increasing risk with risk category. However, the 
AUROC analysis would suggest that the risk is not significantly greater, with enough 
specificity in the moderate risk group for it to be an overall beneficial discriminator.  
The loss of significance when excluding BRCA carriers from the high and 
combined risk group, also suggests that the performance of the risk categorisation 
criteria is dependent on the highest risk patients i.e. BRCA carriers. Excluding them 
from analysis, the model fails to effectively identify at-risk women. However, it is 
worth noting that the analysis, again, does not take into account the number of years 
follow up each woman in the cohort received, and that numbers in each subcategory 
were relatively small. Nonetheless, they will contribute to the overall assessment of 
the effectiveness of the guidelines. The most interesting analysis of risk, is the rate 
of breast cancer diagnosis across different age ranges, rather than the number which 
developed overall; it reflects the information most relevant to the question of when 
women at increased risk should be screened.  
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5.8. Kaplan-Meier Survival Analysis 
5.8.1. The rate of breast cancer development is significantly greater in the 
moderate risk group than the low risk group, overall, and between age 50-59 years 
KM analysis allows determination of the difference in follow-up time specific rates of 
diagnosis between groups, which can then be analysed by different age categories. 
When comparing the low and moderate risk group, overall, there was a significant 
difference in rates of breast cancer development between the moderate and low risk 
group (p=0.048). On analysis of specific age ranges, there was a significantly higher 
rate of breast cancer in the moderate risk group between the ages of 50-59 
(p=0.037). However, from ages 40-49 and <39 years, there was no significant 
difference in rates between the two groups. This would suggest that women in the 
moderate risk group are at increased risk of breast cancer, but that the increased risk 
only becomes significant after the age of 50 years.  
5.8.2. The rate of breast cancer development is significantly greater in the high risk 
group compared to the low risk group, overall, and between ages 40-49 years 
when BRCA carriers are included 
The high risk group was analysed, both including and excluding BRCA carriers from 
the analysis. Across total follow up time, the high risk group demonstrated 
significantly increased rates of breast cancer development compared to the low risk 
group, including or excluding BRCA mutation carriers (p=0.003 and p=0.019 
respectively). At <39 years, the difference in breast cancer rates between the high 
risk (including and excluding BRCA carriers) and low risk group was not significantly 
different, however there were very few cancers at this age. Likewise, from age 50-59 
years the breast cancer rates for the high risk group were not significantly greater 
than the low risk group both including (p=0.149) and excluding (p=0.145) BRCA 
carriers.  
The most interesting results on KM analysis in the high risk group were 
between 40-49 years. Including BRCA mutation carriers, the difference in breast 
cancer rates over this 10-year period was significant (p=0.036). However, when BRCA 
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carriers were excluded from the analysis, the value was no longer significant, at 
p=0.136. This would suggest that, other than for people with a BRCA mutation, the 
breast cancer rate prior to age 50 is not significantly different for women with a NICE 
high risk FH than for women with a NICE low risk FH. Likewise, the rate doesn’t appear 
to be greater for them after age 50. Given that additional screening will be offered 
to these women, it is crucial to know whether or not the difference is significant.  
5.8.3. There is no significant difference in breast cancer rates between the 
moderate and high risk group 
KM analysis was also performed to assess the difference in breast cancer rates 
between the moderate and high risk group. Including or excluding BRCA carriers, 
there was no significant difference in rates of breast cancer diagnosis overall, or at 
any specific age range. It would appear that the NICE guidelines poorly differentiate 
between women at a moderate and women at a high risk of breast cancer. However, 
when these two categories are combined and breast cancer rates compared with the 
low risk group, we can see significant differences; including BRCA carriers and over 
total follow up time, the difference in rates is significant (p=0.011), and the same 
holds true when BRCA carriers are excluded (p=0.024). Therefore, although the 
differentiation between moderate and high risk is poor, overall, the NICE guidelines 
are able to differentiate between women at low risk and women at some increased 
risk of breast cancer. Analysing the combined moderate and high risk group also 
shows borderline significantly different breast cancer rates compared to the low risk 
groups between ages 50-59 years (including BRCA carriers p=0.050, excluding BRCA 
carriers p=0.049). There was no significant rate difference at <39 years or 40-49 
years. Again, this is crucial as additional screening is offered to all in the combined 
risk group from age 40, despite no significant increase in risk detected in this study.  
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5.9. NICE guidelines identify women at some increased risk of breast 
cancer, mainly after the age of 50 years 
The results of KM analysis provide an interesting insight into the effectiveness of NICE 
guidelines at identifying women at increased risk of breast cancer, and take into 
account the number of years of follow up each patient has within the given time 
period being analysed. They are summarised in Table 29 (section 4.2.10.) and shown 
again in Table 32 (below) for reference. They demonstrate that overall, the guidance 
differentiates low risk women from those who are at some increased risk of breast 
cancer. However, the difference in breast cancer rates between moderate and high 
risk women is not significant at all, suggesting poor differentiation (although 
individual analysis would suggest that high risk women are at a slightly greater risk 
than moderate risk women). What we can see however, is that the risk for women in 
either the moderate or high risk groups, excluding BRCA carriers, is significant from 
the age of 50 onwards and not significant prior to this. Even on analysis of the high 
risk group, the rate difference was only significant from 40-49 years when BRCA 
carriers were included in analysis, and was lost when they were excluded. This would 
indicate that BRCA carriers account for a major part of the breast cancer risk prior to 
age 50 years. Given that screening is offered to all moderate and high risk women 
from age 40 onwards, this is an important finding. In addition, it is important to note 
that the genuine risk increase for the moderate group occurs after the age of 50. At 
this age, they can be considered for annual screening instead of the NBSP, rather than 
being offered it as a standard recommendation.  
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Table 32. KM survival analysis data summary 
NICE risk groups 
being compared 
KM Log-Rank (p-value) 
Period of follow up 
 
Total follow up 
time 
Age ≤39 years 
Age 40-49 
years 
Age 50-59 
years 
Low & moderate 0.048 0.341 0.431 0.037 
Low & high  0.003 0.091 0.036 0.149 
Low & high 
(BRCA carriers 
excluded) 
0.019 0.085 0.136 0.145 
Moderate & high 0.274 0.328 0.183 0.581 
Moderate & high 
(BRCA carriers 
excluded) 
0.644 0.299 0.499 0.598 
Low & 
moderate/high 
0.011 0.216 0.134 0.050 
Low & 
moderate/high 
(BRCA carriers 
excluded) 
0.024 0.217 0.241 0.049 
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5.10. NICE guidelines overestimate the risk of breast cancer below the age 
of 50 years 
In the meta-analysis by Pharoah et al. absolute risks were not determined, however, 
looking at RR, there were mixed results amongst studies regarding the risk to young 
women dependant on their FH (149). Some studies in the meta-analysis indicated a 
greater risk to young women when a relative was affected at a younger age, however 
whether or not this risk would meet an acceptable level to justify screening in the 
NHS is unclear.  The results of this research suggest the risk of breast cancer below 
age 50, according to NICE risk category, appears to be less than suggested. The % 10-
year absolute risk did not meet screening threshold aged <50 years, suggesting that 
there is likely to be unnecessary screening occurring in these women.  
The only group in whom there was evidence of a significantly increased risk 
of breast cancer prior to age 50 were the BRCA mutation carriers. This is unsurprising 
given the well-established, greatly increased risk of breast cancer posed to them. 
Early screening in BRCA carriers would appear to be justified. In addition, the 
absolute risk to BRCA carriers after the age of 50 appears to increase in this cohort, 
contrary to findings from other studies (190). However, it is worth noting that the 
total number of years follow up available for known BRCA carriers after the age of 50 
was only 19 years, compared to 75 years follow up between ages 40-49. Therefore, 
it cannot be ruled out that this spurious finding.  
Conversely, there is no evidence emerging from this work to suggest that 
screening under the age of 50 in non-mutation carriers is beneficial. Below age 50, 
there is no significant difference between the low risk group and the moderate, high 
or combined risk group. Only after the age of 50 does a risk difference emerge. 
Therefore, there would appear to be limited benefit in screening these women 
according to currently suggested guidelines.  
The risk to BRCA carriers was significant despite there being a considerable 
proportion of women meeting the testing threshold that were not tested. There were 
also women who came from families with BRCA mutations who had not been tested, 
who had to be regarded as high risk nonetheless. Genetic testing is a patient’s choice, 
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and therefore this cannot be avoided either in a study such as this, or in the clinical 
setting. Nevertheless, had more BRCA carriers been identified in the cohort, it would 
still be expected that their risk prior to age 50 was significant. If more women had 
been tested and identified as having a mutation, they would have been analysed 
separately from the high risk group. The anticipated results of this would be that the 
overall risk in the high risk group would decrease on removal of more BRCA carriers. 
Therefore, the risks to NICE high risk, non-carrier women calculated in this study 
would be even less significant. Although this is theoretical, it is logical to assume that 
the results would remain unaffected.  
The criteria appear to significantly overestimate the risk to women under the 
age of 50, and in addition, leave room for varied interpretation. It is unclear how the 
criteria corresponding to the absolute risks were determined by NICE, and the 
evidence presented here suggests that it should be reviewed. The fact that there is 
room for interpretation in the guidance is an issue in itself as it will inevitably result 
in a form of ‘postcode lottery’ for patients, in which their treatment may vary 
depending on which genetics department they are seen in. The overestimation may 
result in unnecessary screening of a large number of women, whose absolute risk of 
breast cancer is not equal to that of the suggested screening threshold. The 
discrepancies found in this study are significant, with the 95% CI of the absolute 10-
year risks failing to cross the risk thresholds set by NICE. NHS standards state that for 
a screening programme to be suitable, the benefits gained by individuals should 
outweigh harms such as overtreatment, and that it should be economically balanced 
(229). These needs should be met to ensure appropriate resource division of NHS 
funding. In this case, with no significant risk above that of the low risk group 
identified in non-BRCA carriers aged less than 50, both of these requirements are 
unlikely to be met. The benefit of putting these patients through annual 
mammograms from age 40 should be questioned, especially considering both the 
radiation exposure and the likely anxiety induced by attending screening. The criteria 
being used to categorise women, and the cost-effectiveness of the current screening 
programme should be questioned. 
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5.11. Implications for current family history screening guidelines 
The results presented here would imply that the NICE FH criteria used to assess 
breast cancer risk should be revised. It was interesting to note that in this cohort, 
average age of breast cancer diagnosis amongst family members did not seem to 
affect breast cancer risk despite being a discriminator used in the NICE guidance. At 
present, the current system of categorisation doesn’t identify individuals at 
significantly increased risk over population with reliable specificity. No difference 
could be found in breast cancer rates between the moderate and high risk women 
excluding BRCA carriers, however when the groups are combined, the breast cancer 
rate is significantly greater than the low risk group between the ages of 50-59 years. 
Therefore, perhaps it would be beneficial to consider women without a BRCA 
mutation who meet moderate or high risk criteria as one group. Increased screening 
for these women would seem to be of benefit after the age of 50, and could perhaps 
remain more frequent than the 3-yearly screening offered as part of the NBSP. BRCA 
carriers on the other hand seem to both be identifiable using the MMSS and benefit 
from screening at a younger age.  
 Of course, more work with an adequate cohort size would be required to 
generate substantial evidence before the consideration of any kind of policy change. 
However, it is possible that the kind of approach outlined above would be 
considerably more cost-effective than current practise, should the results of this pilot 
study be replicated. Better yet, if the guidance could be modified to improve 
specificity at <50 years, truly high risk women could be identified. Inevitably, 
screening programmes are never perfect and some young onset breast cancers will 
be missed for a variety of reasons. However, it is important to consider the cost to 
society of funding a screening programme with a PPV of just 2.88 % (95% CI, 1.93-
4.25%).  
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5.12. The family history screening programme picks up a small percentage 
of young onset breast cancers in Tayside 
After identifying that there were 1,075 cases of female breast cancer diagnosed at 
<50 years in Tayside, it was determined that just 52 (4.34%) of these patient had been 
assessed in clinical genetics prior to their cancer diagnosis. In addition, the mean ages 
between the two groups of patients were very similar (42.46 for the assessed group 
and 42.85 for the unassessed group), suggesting that the women not seen by clinical 
genetics weren’t developing breast cancer significantly later than those who were. 
Since the aim of the screening programme is to identify women who will develop 
young onset breast cancer, this perhaps seems like a small pick-up rate, and is an 
interesting observation. However, the reason for this is not clear from these results, 
and could be due to a number of factors. Although it is likely that breast cancers 
occurring at a very young age have a significant genetic component, this study did 
not determine whether or not the women who were not assessed in genetics prior 
to diagnosis had a FH of breast cancer. Even if they did, they may not have been 
aware of the potential risk, never made their general practitioner aware or may have 
simply not wished to be referred to genetics. Alternatively, if there was no FH, it may 
be that there were strong hormonal, environmental and lifestyle risk factors 
predisposing these women to disease.  
These results leave a very open question of why so many young onset breast 
cancers are not being picked up by screening; are there simply no identifiable factors 
present which could indicate increased risk, or are these women simply not seeking, 
or being offered referral concerning their risk? In addition, at present there has been 
no assessment made of possible survival benefit of having been seen by a clinical 
geneticist. Having identified these two groups of patients, it would be useful to see 
whether or not patients who receive screening gain a survival benefit as a result of 
earlier diagnosis. 
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5.13. A larger cohort may be necessary to accurately assess absolute risk of 
breast cancer for women in each NICE risk group  
Retrospective sample size calculation confirmed that this study was marginally 
underpowered to compare the low vs. high and moderate vs. high risk group, and 
significantly underpowered to compare the low vs. moderate risk groups. It is 
necessary to factor this in when interpreting results. To detect a clinical difference, 
4000 women at either low or moderate risk of breast cancer, with clinical follow up 
between the ages of 40-49 would be required, which is unlikely to have been feasible 
in Tayside in the time frame for this research. This analysis will help inform any 
conclusions that are to be drawn from the study’s results.  
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5.14. Strengths and limitations of this study 
5.14.1. Limitations 
This study was performed retrospectively, which is not the ideal way of performing 
such a cohort study. Women were selected for having no personal history of cancer, 
and the FH information used was that which they reported at their first appointment 
with clinical genetics. There was no indication at the time of FH gathering for the 
study which patients went on to develop cancer. Therefore, the risk of recall bias 
should not necessarily be a significant factor. It is possible that when there is a FH of 
breast cancer, the patient’s anxiety may be heightened, however, over-reporting of 
cancer history is thought to be rare (225). The family histories used were a snapshot 
in time at initial assessment – changes in FH across time were not taken into account. 
Due to this, there may be some women for whom the risk category changed over the 
course of follow up. This could have been taken into account more easily using a 
prospective study design, which recruited patients and followed them up at given 
intervals. However, it is also important to acknowledge that the initial risk 
assessment will have been made with the relevant FH at the time, and this study 
assesses how the guidelines perform based on that assessment.  
The fact that there was not always adequate information from clinical notes, 
somewhat limited the potential sample size of the study. If the study had been 
designed in a prospective way this could have been largely avoided by specific FH 
protocols. However, this may not be an accurate reflection of what happens in clinic. 
Time limitations meant it would not have been possible to accumulate a period of 
follow up time prospectively which was substantial enough to address the study 
aims.   
It was necessary to interpret the NICE guidelines in a literal sense, meaning 
that clinical judgement which would most likely impact the risk categorisation of 
women was lost. As a result, some women may have been assigned risk categories 
which they otherwise would not have been in. However, it was necessary to use a 
standardised approach, and this flaw somewhat reflects some of the previously 
discussed interpretation issues which are present in the guidelines. In addition, it was 
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unfortunate that there was no in depth analysis of the in situ carcinoma development 
in the study for reasons outlined in section 3.5. In the UK, in situ carcinoma is usually 
treated and therefore it would not be possible to assess which would develop into 
invasive cancers. To do this would be considered unethical. Nevertheless, the 
screening programme aims to prevent deaths from invasive cancer, therefore in situ 
cancer rates are not necessarily the primary research question. 
Breast cancer rates were analysed using three broad groups - <39 years, 40-
49 years and 50-59 years, and no breast cancers developed over the age of 60. This 
means that the risks calculated reflect a rather broad age range. There are likely to 
be differences in risk across 5-year age brackets such as 40-44 and 45-49, which may 
have been beneficial to assess. However, it was necessary to consider the sample size 
and the number of years follow up available between each age bracket. 10-year risk 
assessment was necessary to provide a more statistically viable analysis. With a larger 
cohort size, it may be possible to look at narrower age range.  
Probably the biggest limitation of this study was that it was found to be 
significantly underpowered. The results therefore must be interpreted with caution. 
In addition, the power calculation was performed using population risk figures, as the 
low risk group are said to be at ‘population risk’. However, it is very possible that 
women in the low risk group are at an inherently higher risk of breast cancer 
nonetheless, since having any relative affected with breast cancer has been shown 
to increase risk by up to 2-fold, though not necessarily at a younger age (149).This 
would mean that the difference being detected between the low and moderate risk 
group, is in fact smaller than population and moderate risk. Therefore, a larger 
sample size would be required to detect this difference if a cohort who attended 
clinical genetics was used, as in this study. Regardless, as a pilot study it demonstrates 
methodology which could easily be applied to a larger cohort in order to produce 
results which can be relied upon more confidently.  
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5.14.2 Strengths 
Since the study was looking to assess a small % difference in absolute risk of breast 
cancer, particularly between the low and moderate risk women, it was inevitably 
underpowered, as discussed above. Regardless, it does have a total patient follow up 
time of 15, 414 years, a considerable amount. Whilst it would be unscientific to draw 
definitive conclusions, it can be reasonably argued that the sample size is large 
enough to raise serious questions about the effectiveness of the guidelines which 
warrant further investigation. In addition, the 95% CIs determined when calculating 
the absolute % 10-year risk of breast cancer between ages 40-49, did not cross the 
risk thresholds for screening set by NICE.  
Detailed FH information was gathered for each individual. This has built a 
database of FH structures which may prove beneficial in future research. There were 
a significant number of women in each NICE risk group which allowed comparisons 
to made between them. In addition, the groups were assessed to see if there were 
significant differences in the age at presentation which may bias the results, which 
there were not. The analysis also allowed fair comparison of breast cancer rates by 
looking at cancers per woman year of follow of time.   
 Overall, the methodology presented in this study provided a reasonable way 
of analysing the available data and assessing the effectiveness of the guidelines. 
Without the resource of an extended time period, the approach taken balanced the 
best study design and feasibility as adequately as possible. Much of the analysis could 
have benefitted from a larger cohort size, but this research has demonstrated that it 
possible to address the study aims through relatively simple means.  
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5.15. Conclusions 
The risk of breast cancer under the age of 50 seems to be significantly greater for 
those with a BRCA mutation but, crucially, not for other moderate or high risk women 
in the cohort compared to the low risk group. There was no evidence to suggest a 
significantly increased risk of breast cancer in the high risk, non-BRCA mutation 
carriers compared to moderate risk women.  
The results suggest that the combined moderate/high risk group are at an 
increased risk compared to the low risk group, albeit that this risk emerges after the 
age of 50 years, when all women would have already entered into the NBSP. Evidence 
to suggest a benefit of using NICE risk criteria to identify women who should be 
screened prior to age 50, appears to be lacking.  
The current screening picks up cancers in the screened population with good 
sensitivity, however only a small proportion of the total young onset breast cancer in 
the general population is identified, and the specificity of screening is poor.  
This study demonstrates simple methodology which could feasibly be expanded 
to other treatment centres in order to generate a sample size large enough to 
definitively address the research question. If replicated, the results presented here 
could have implications for breast cancer screening and how at-risk women are 
identified.  
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5.16. Future work 
5.16.1 Increased sample size 
The first thing to be addressed from the current study is the sample size. It raises a 
number of interesting questions about the effectiveness of the NICE guidelines, 
therefore it is important that they are investigated with sufficient power. It is likely 
that a sample size of 5000-6000 patient followed up between 40-49 years of age 
would be adequate. Tayside is one of the smaller health boards in Scotland, therefore 
recruitment of a few larger centres would most likely reach a substantial enough 
cohort size. The information gathering stage of this study took approximately 7 
months part-time, so it would be feasible to repeat the same methodology in larger 
centres in a reasonably short time frame. The gold standard for a cohort study such 
as this would be for it to be performed prospectively. The same number of patients 
would be required, but to gather the required amount of follow-up time, spanning 
the required age ranges, would take several years. The FH reporting may be recorded 
more accurately, but the time frame is significantly longer and limits the speed at 
which results which may inform clinical practise are generated. If this study design 
was expanded, and the results replicated, a prospective study would be justified to 
generate a large, reliable database to identify family histories which truly give a 
significant increase in early onset breast cancer risk. To repeat the study would 
require multiple centres, and communication with specialists to come to a 
standardised way of interpreting NICE guidance.  
5.16.2. Survival and cost-benefit analysis 
A very important aspect missing from this study is survival analysis. The point of the 
screening programme is to reduce mortality in women with an increased cancer risk, 
rather than just identify them. Within the original FH cohort, there were simply not 
enough cancer diagnoses to analyse survival. However, with the addition of the 
cancers that were identified in women out-with the FH cohort, or who were seen 
prior to the year 2000, there may be a substantial enough number to carry this out. 
It would be very beneficial to analyse survival outcomes of women who develop 
breast cancer at less than 50 years, between screened and unscreened populations. 
Records of tumour stage at diagnosis could be analysed to see if screened cancers 
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were identified at an earlier stage. The most important analysis however is likely to 
be disease-free and overall survival from breast cancer. Given the large number of 
patients identified in Tayside with breast cancer <50 years, this wasn’t possible within 
the time frame of this study. However, since the patients have been identified, it is 
well within the realms of feasibility for this to be carried out.  
If survival analysis can be performed, it should also by extension be possible 
to perform a cost-benefit analysis of the screening programme. Any screening 
programme needs to have a trade-off between the cost to run it and the overall 
benefit to patients. Preliminary results presented here have suggested that the 
specificity of the screening programme may need to be improved. However, if the 
survival benefit to patients was significant enough, despite its cost, it would give 
more weight to the overall viability of the screening programme. Therefore, cost-
benefit analysis is another very important aspect of assessing the NICE guidelines 
which has been omitted from this study.  
5.16.3. Improving the specificity of the guidance 
The specificity of the guidance in this cohort was poor, therefore it would be 
interesting to do work which aimed to improve this. Given that detailed FH 
information was recorded for each patient, it may be possible to assess the exact 
breast cancer risks associated with differing family histories. This may enable 
remodelling using similar empiric FH structures as NICE, but with improved 
specificity. It would be desirable to maintain a good level of sensitivity, but the overall 
cost-effectiveness of the screening programme is likely to be improved if specificity 
is increased. In addition, being able to do this relying on simple FH parameters such 
as number and age of relatives affected would be more user-friendly for clinicians 
than a model which requires specific pathology or lifestyle information, since this 
isn’t always available. This study collected the dataset that would be required to do 
this, so by extending it to other centres and increasing its size, a large enough sample 
to investigate alternative criteria would be available. 
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7.0. Appendices 
7.1. Appendix 1: Caldicott approval Letter for study 
Information Governance 
Maryfield House South Mains 
Loan 
Dundee 
DD4 7BT 
T. 01382 740074 Ext. 70249 
www.nhstayside.scot.nhs.uk 
Date 09 January 2017 
Your Ref 
Our Ref Caldicott/CSAppLL2349++++ 
Enquiries To Sender 
Extension 70249 
Direct 
Email joseph.donnelly@nhs.net
Dear Ms Littlejohn 
 
 
Caldicott Approval – Assessing current models of risk stratification for familial breast cancer 
 
 
Original Approval 25 September 2015 
Caldicott approval is given for you to extract patient data pertaining to up to 1500 women who 
attended clinical genetics regarding familial breast cancer risk between 2000 and 2010 and to 
assess, according to NICE guidelines, their risk of breast cancer at presentation. The TRACES 
database will then be used to identify women within the cohort who subsequently developed breast 
cancer in order to assess the accuracy of NICE risk prediction. The ICE system and HAMAM 
database will also be accessed in order to assess risk prediction models other than NICE guidelines, 
as described in your application and supporting information. 
 
It is noted that all data will be pseudonymised following initial patient matching. 
 
Extended Approval 10 February 2016 
Lucy Littlejohn, Medical Student, University of Dundee included as additional data user. 
 
Headquarters 
Ninewells Hospital and Medical School, Dundee DD1 9SY 
 
Vice Chairman, Mr Doug Cross OBE  
Chief Executive, Ms Lesley McLay 
Ms Lucy Littlejohn Medical 
Student  
25 Thomson Street 
Dundee 
DD1 4LE 
 
 
Proposal Sponsor: Dr Jonathan Berg, Senior Lecturer and Honorary Consultant in 
Clinical Genetics, NHS Tayside 
Data Users: Dr Jonathan Berg, Senior Lecturer and Honorary Consultant in 
Clinical Genetics, NHS Tayside 
Ms Lucy Littlejohn, Medical Student, University of 
Dundee Subbra Palaniappan, 
Dr Lee Jordan, Consultant Pathologist/Honorary Senior Clinical Lecturer, 
Lead Clinician for the Scottish Pathology Network (SPAN), CMO's Specialty 
Adviser for Histopathology, NHS Tayside 
Dr Sarah Vinnecombe, 
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Extended Approval 16 February 2016 
Lyndsay McGregor, Medical Student, University of Dundee included as additional data user. 
 
Extended Approval 06 April 2016 
To allow access to Labcentre system data under the supervision of Dr Jim Gibbs, Pathology 
Data IT Manager, to extract breast cancer diagnosis where present and date of diagnosis. 
 
Extended Approval 13 January 2017 
Clarification that data relating to all women in Tayside who developed breast cancer under 
50 may be extracted from Labcentre (not only those who attended Clinical Genetics. 
 
Thank you for your co-operation in providing us with the information requested by us in this 
process. Please contact me should any queries arise from the application of this approval. 
 
 
Joe Donnelly 
CHI Administrator  
Information Governance 
 
Copy to: 
Dr Jonathan Berg, Senior Lecturer and Honorary Consultant in Clinical Genetics, NHS 
Tayside Subbra Palaniappan, 
Dr Lee Jordan, Consultant Pathologist/Honorary Senior Clinical Lecturer, Lead 
Clinician for the Scottish Pathology Network (SPAN), CMO's Specialty Adviser for 
Histopathology, NHS Tayside Dr Sarah Vinnecombe 
Lyndsay McGregor, Medical Student, University of Dundee 
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7.2. Appendix 2: Clinical variables collected for each patient 
 
 
 
Patient information 
Name 
Community Health Index number 
Date of referral to clinical genetics 
Age at presentation 
 
History of FDRs (FDR) 
Number of breast cancers among FDRs 
 
Mother affected (yes/no) 
Age mother affected (years) 
 
Sister(s) affected (yes/no) 
Number of breast cancers among sisters  
Age sister(s) affected (years) 
Total number of sisters 
 
Daughter(S) affected (yes/no) 
Number of breast cancers among 
daughter(s)  
Age daughter(s) affected (years) 
Total number of daughters 
 
History in SDRs (SDR) 
Number of breast cancers among SDRs 
 
Maternal aunt(s) affected (yes/no) 
Number of breast cancers among maternal 
aunts  
Age maternal aunt(s) affected (years) 
Total number of maternal aunt 
 
Paternal aunt(s) affected (yes/no) 
Number of breast cancers among paternal 
aunts 
Age paternal aunt (s) affected (years) 
Total number of paternal aunts 
 
Maternal grandmother affected (yes/no) 
Age maternal grandmother affected (years) 
 
Paternal grandmother affected (yes/no) 
Age paternal grandmother affected (years) 
 
 
Maternal half-sister(s) affected (yes/no) 
Number of breast cancers among maternal 
half-sisters  
Age maternal half-sister(s) affected (years) 
Total number of maternal half-sisters 
 
Paternal half-sister(s) affected (yes/no) 
Number of breast cancers among paternal 
half-sisters  
Age paternal half-sister(s) affected (years) 
Total number of paternal half-sisters 
 
Niece(s) affected (yes/no) 
Number of breast cancers among nieces  
Age niece(s) affected (years) 
Total number of nieces 
 
Bilateral breast cancer 
FDR with bilateral breast cancer (yes/no) 
SDR with bilateral breast cancer (yes/no) 
Number of relatives with bilateral breast 
cancer 
Age at first breast cancer (years) 
Age at contralateral breast cancer (years) 
 
Other cancers 
Incidence of ovarian cancer (yes/no) 
Number of relatives with ovarian cancer 
Age of ovarian cancer(s) (years) 
 
Incidence of male breast cancer (yes/no) 
Age of male breast cancer (years) 
 
Number of pancreatic cancers in family 
Number of prostate cancers in family 
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